PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
25825493-2	2015	The inhibitory activity of rapid, reversible COX inhibitors (ibuprofen, naproxen, mefenamic acid, and lumiracoxib) demonstrated a significant increase in potency and time dependence of inhibition against double tryptophan murine COX-2 mutants at the 89/90 and 89/119 positions.	Naproxen	72-80	cytochrome c oxidase II, mitochondrial	Mus musculus	229-234
25711428-0	2015	Characterization of the anti-inflammatory properties of NCX 429, a dual-acting compound releasing nitric oxide and naproxen.	Naproxen	115-123	T cell leukemia, homeobox 2	Mus musculus	56-59
25522350-5	2015	Piroxicam and niflumic acid inhibited UGT1A9 activity (IC50 = 73.8 mum and 0.38 mum, respectively) and naproxen selectively inhibited UGT2B7 activity (IC50 = 53.1 mum), whereas it did not inhibit the other UGTs tested (IC50 > 200 mum).	Naproxen	103-111	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	134-140
25711428-7	2015	Moreover, in in vivo experiments, NCX 429, at the lowest dose tested, was able to significantly inhibit cell influx in response to IL-1beta administration although naproxen was found to be more potent than NCX 429 at reducing PGE2 in inflammatory exudates.	Naproxen	164-172	interleukin 1 beta	Mus musculus	131-139
25681154-11	2015	In naproxen-induced gastric damage, FOR0810 prevented gastric injury, decreased gastric MPO activity and leukocyte adherence, associated with a decrease in TNFalpha and IL-1beta gastric concentrations.	Naproxen	3-11	myeloperoxidase	Mus musculus	88-91
25755876-10	2015	Both naproxen and ATB-346 inhibited the increase of gingival IL-1beta and IL-6 secondary to periodontitis, but IL-10 was unaffected.	Naproxen	5-13	interleukin 6	Rattus norvegicus	74-78
25755876-11	2015	Significant damage and increased MPO contents were only found in the stomachs of the naproxen-treated animals.	Naproxen	85-93	myeloperoxidase	Rattus norvegicus	33-36
25681154-11	2015	In naproxen-induced gastric damage, FOR0810 prevented gastric injury, decreased gastric MPO activity and leukocyte adherence, associated with a decrease in TNFalpha and IL-1beta gastric concentrations.	Naproxen	3-11	tumor necrosis factor	Mus musculus	156-164
25681154-11	2015	In naproxen-induced gastric damage, FOR0810 prevented gastric injury, decreased gastric MPO activity and leukocyte adherence, associated with a decrease in TNFalpha and IL-1beta gastric concentrations.	Naproxen	3-11	interleukin 1 beta	Mus musculus	169-177
25091567-0	2015	Naproxen induces type X collagen expression in human bone-marrow-derived mesenchymal stem cells through the upregulation of 5-lipoxygenase.	Naproxen	0-8	arachidonate 5-lipoxygenase	Homo sapiens	124-138
26040034-6	2015	Cyclooxygenese blockage with naproxen prior to induction of water-restrained stress was accompanied by the decease of iNOS in small and large intestines, with the synchronous rise of cNOS activity in the large intestine as compared with indexes in stress.	Naproxen	29-37	nitric oxide synthase 2	Rattus norvegicus	118-122
25091567-2	2015	We recently found that Naproxen, but not other nonsteroidal anti-inflammatory drugs (NSAIDs) (Ibuprofen, Celebrex, Diclofenac), can induce type X collagen gene (COL10A1) expression in bone-marrow-derived MSCs from healthy and OA donors.	Naproxen	23-31	collagen type X alpha 1 chain	Homo sapiens	161-168
25091567-12	2015	Our results showed that increased basal COL10A1 expression in OA hMSCs was significantly suppressed in the presence of JNK and p38 inhibitors, whereas Naproxen-induced COL10A1 expression was suppressed by 5-lipoxygenase inhibitor.	Naproxen	151-159	arachidonate 5-lipoxygenase	Homo sapiens	205-219
25091567-14	2015	Elevated basal COL10A1 expression in OA hMSCs is probably through the activation of MAPK pathway and Naproxen-induced COL10A1 expression is through the increased 5-lipoxygenase signaling.	Naproxen	101-109	collagen type X alpha 1 chain	Homo sapiens	118-125
25091567-14	2015	Elevated basal COL10A1 expression in OA hMSCs is probably through the activation of MAPK pathway and Naproxen-induced COL10A1 expression is through the increased 5-lipoxygenase signaling.	Naproxen	101-109	arachidonate 5-lipoxygenase	Homo sapiens	162-176
25091567-3	2015	In this study we determined the effect of Naproxen on COL X protein expression and investigated the intracellular signaling pathways that mediate Naproxen-induced COL10A1 expression in normal and OA hMSCs.	Naproxen	146-154	collagen type X alpha 1 chain	Homo sapiens	163-170
25091567-9	2015	Naproxen significantly increased the MAPK phosphorylation in normal and OA hMSCs.	Naproxen	0-8	mitogen-activated protein kinase 1	Homo sapiens	37-41
25091567-11	2015	To investigate the involvement of these pathways in the Naproxen-induced COL10A1 expression, we incubated normal and OA hMSCs with Naproxen with and without inhibitors of ERK (U0126), JNK (BI-78D3), p38 (SB203580), and 5-lipoxygenase (MK-886).	Naproxen	56-64	collagen type X alpha 1 chain	Homo sapiens	73-80
25091567-11	2015	To investigate the involvement of these pathways in the Naproxen-induced COL10A1 expression, we incubated normal and OA hMSCs with Naproxen with and without inhibitors of ERK (U0126), JNK (BI-78D3), p38 (SB203580), and 5-lipoxygenase (MK-886).	Naproxen	56-64	mitogen-activated protein kinase 8	Homo sapiens	184-187
25091567-11	2015	To investigate the involvement of these pathways in the Naproxen-induced COL10A1 expression, we incubated normal and OA hMSCs with Naproxen with and without inhibitors of ERK (U0126), JNK (BI-78D3), p38 (SB203580), and 5-lipoxygenase (MK-886).	Naproxen	56-64	mitogen-activated protein kinase 14	Homo sapiens	199-202
25091567-11	2015	To investigate the involvement of these pathways in the Naproxen-induced COL10A1 expression, we incubated normal and OA hMSCs with Naproxen with and without inhibitors of ERK (U0126), JNK (BI-78D3), p38 (SB203580), and 5-lipoxygenase (MK-886).	Naproxen	56-64	arachidonate 5-lipoxygenase	Homo sapiens	219-233
25091567-12	2015	Our results showed that increased basal COL10A1 expression in OA hMSCs was significantly suppressed in the presence of JNK and p38 inhibitors, whereas Naproxen-induced COL10A1 expression was suppressed by 5-lipoxygenase inhibitor.	Naproxen	151-159	collagen type X alpha 1 chain	Homo sapiens	168-175
24747869-6	2014	However, a significantly greater effect was observed with ATB-346 (H2S-releasing naproxen) and it was also effective at much lower doses, where naproxen was ineffective.	Naproxen	81-89	histocompatibility 2, S region (C4, Slp, Bf, C2)	Mus musculus	67-70
25385584-3	2014	Although ibuprofen, naproxen, and celecoxib all had the potential to compete with the access of aspirin to the substrate binding channel of COX-1 in vitro, exposure of volunteers to a single therapeutic dose of each NSAID followed by 325 mg aspirin revealed a potent drug-drug interaction between ibuprofen and aspirin and between naproxen and aspirin but not between celecoxib and aspirin.	Naproxen	20-28	prostaglandin-endoperoxide synthase 1	Homo sapiens	140-145
24856747-8	2014	Alcohol is known to reduce G6PD activity, and thus it is hypothesized that the administration of naproxen in an alcohol-dependent patient caused methemoglobinemia.	Naproxen	97-105	glucose-6-phosphate dehydrogenase	Homo sapiens	27-31
24597536-2	2014	Here, we investigated the role of three different NSAIDs (naproxen, ibuprofen and oxaprozin) on neutrophil responses to CXCL8 and C5a.	Naproxen	58-66	C-X-C motif chemokine ligand 8	Homo sapiens	120-125
24656855-0	2014	Effective anodic oxidation of naproxen by platinum nanoparticles coated FTO glass.	Naproxen	30-38	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	72-75
24656855-1	2014	This study investigated applications of the electrochemical anodic oxidation process with Pt-FTO and Pt/MWCNTs-FTO glasses as anodes on the treatment of one of the most important emerging contaminants, naproxen.	Naproxen	202-210	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	93-96
24656855-1	2014	This study investigated applications of the electrochemical anodic oxidation process with Pt-FTO and Pt/MWCNTs-FTO glasses as anodes on the treatment of one of the most important emerging contaminants, naproxen.	Naproxen	202-210	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	111-114
24656855-3	2014	XRD patterns of Pt nanoparticles coated on FTO and MWCNTs revealed that MWCNTs can prevent the surface of PtNPs from sintering and thus provide a greater reaction sites density to interact with naproxen, which have also been confirmed by higher degradation and mineralization efficiencies in the Pt/MWCNTs-FTO system.	Naproxen	194-202	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	43-46
24656855-3	2014	XRD patterns of Pt nanoparticles coated on FTO and MWCNTs revealed that MWCNTs can prevent the surface of PtNPs from sintering and thus provide a greater reaction sites density to interact with naproxen, which have also been confirmed by higher degradation and mineralization efficiencies in the Pt/MWCNTs-FTO system.	Naproxen	194-202	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	306-309
24656855-4	2014	Results from the CV analysis showed that the Pt-FTO and Pt/MWCNTs-FTO electrodes possessed dual functions of decreasing activation energy and interactions between hydroxyl radicals to effectively degrade naproxen.	Naproxen	204-212	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	48-51
24656855-4	2014	Results from the CV analysis showed that the Pt-FTO and Pt/MWCNTs-FTO electrodes possessed dual functions of decreasing activation energy and interactions between hydroxyl radicals to effectively degrade naproxen.	Naproxen	204-212	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	66-69
24652770-5	2014	It is revealed that the micelles possess a core-shell-corona structure in which the PPO/Nap, PBLG/DOX, and PEG aggregate to form the core, shell, and corona, respectively.	Naproxen	88-91	protoporphyrinogen oxidase	Homo sapiens	84-87
24753230-0	2014	Structural studies of bovine, equine, and leporine serum albumin complexes with naproxen.	Naproxen	80-88	albumin	Bos taurus	51-64
24753230-5	2014	A comparison of the structurally investigated complexes with the analogous complex of human serum albumin (HSA-NPS) revealed surprising differences in the number and distribution of naproxen binding sites.	Naproxen	182-190	albumin	Bos taurus	92-105
25034046-0	2014	Naproxen affects osteogenesis of human mesenchymal stem cells via regulation of Indian hedgehog signaling molecules.	Naproxen	0-8	Indian hedgehog signaling molecule	Homo sapiens	80-95
25034046-14	2014	Cpn reversed the effect of Npx on the expression of COL10A1, ALP, OPN and COL1A1.	Naproxen	27-30	collagen type X alpha 1 chain	Homo sapiens	52-59
25034046-14	2014	Cpn reversed the effect of Npx on the expression of COL10A1, ALP, OPN and COL1A1.	Naproxen	27-30	alkaline phosphatase, placental	Homo sapiens	61-64
25034046-14	2014	Cpn reversed the effect of Npx on the expression of COL10A1, ALP, OPN and COL1A1.	Naproxen	27-30	secreted phosphoprotein 1	Homo sapiens	66-69
25034046-14	2014	Cpn reversed the effect of Npx on the expression of COL10A1, ALP, OPN and COL1A1.	Naproxen	27-30	collagen type I alpha 1 chain	Homo sapiens	74-80
25006185-11	2014	There was an increased risk for agents with cox-2>cox-1 inhibition (HR, 1.17; 1.10-1.24; P<0.001 and naproxen only: HR, 1.22; 1.12-1.34; P<0.001).	Naproxen	107-115	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	44-49
24597536-2	2014	Here, we investigated the role of three different NSAIDs (naproxen, ibuprofen and oxaprozin) on neutrophil responses to CXCL8 and C5a.	Naproxen	58-66	complement C5a receptor 1	Homo sapiens	130-133
24597536-12	2014	Pre-incubation with naproxen or oxaprozin, but not ibuprofen, inhibited the PI3K/Akt-dependent chemotactic pathways.	Naproxen	20-28	AKT serine/threonine kinase 1	Homo sapiens	81-84
24597536-16	2014	Inhibition by ibuprofen was associated with integrin down-regulation, while naproxen and oxaprozin blocked the PI3K/Akt pathway.	Naproxen	76-84	AKT serine/threonine kinase 1	Homo sapiens	116-119
23368763-0	2014	Evaluation of naproxen and cromolyn activities against cancer cells viability, proliferation, apoptosis, p53 and gene expression of survivin and caspase-3.	Naproxen	14-22	tumor protein p53	Homo sapiens	105-108
24614581-8	2014	Naproxen-HPMC E15 wet-milled samples, showed an IR peak shift suggesting strong bond formation or molecular interaction (i.e. amorphous phase).	Naproxen	0-8	RNA, U105C small nucleolar	Homo sapiens	14-17
24614581-9	2014	In addition, naproxen has a strong interaction with HPMC E15 as determined by MTDSC (i.e. melting point depression).	Naproxen	13-21	RNA, U105C small nucleolar	Homo sapiens	57-60
24697248-2	2014	This risk seems to be related to the COX-2 inhibitory potency and has been found with most NSAIDs except naproxen.	Naproxen	105-113	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	37-42
23368763-0	2014	Evaluation of naproxen and cromolyn activities against cancer cells viability, proliferation, apoptosis, p53 and gene expression of survivin and caspase-3.	Naproxen	14-22	caspase 3	Homo sapiens	145-154
24220607-2	2014	To examine whether inhibition of inflammation is directed by cyclo-oxygenase pathways, we performed animal studies with naproxen, which inhibits prostaglandin-endoperoxide synthases 1 and 2 and is in extensive clinical use.	Naproxen	120-128	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	145-189
24345643-6	2014	Treatments with both PGD2 and a CRTH2 agonist decreased ERK1/2 (Thr202/Tyr204) and Akt (Ser473) phosphorylation, whereas both treatments increased beta-arrestin-1 phosphorylation (Ser412) in the presence of naproxen, which was used to eliminate endogenous prostaglandin production.	Naproxen	207-215	prostaglandin D2 synthase	Homo sapiens	21-25
24345643-6	2014	Treatments with both PGD2 and a CRTH2 agonist decreased ERK1/2 (Thr202/Tyr204) and Akt (Ser473) phosphorylation, whereas both treatments increased beta-arrestin-1 phosphorylation (Ser412) in the presence of naproxen, which was used to eliminate endogenous prostaglandin production.	Naproxen	207-215	prostaglandin D2 receptor 2	Homo sapiens	32-37
24327721-1	2014	Naproxen [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid] is a potent nonsteroidal anti-inflammatory drug that inhibits both COX-1 and COX-2 and is widely used as an over-the-counter medication.	Naproxen	0-8	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	130-135
24327721-1	2014	Naproxen [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid] is a potent nonsteroidal anti-inflammatory drug that inhibits both COX-1 and COX-2 and is widely used as an over-the-counter medication.	Naproxen	0-8	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	140-145
24327721-1	2014	Naproxen [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid] is a potent nonsteroidal anti-inflammatory drug that inhibits both COX-1 and COX-2 and is widely used as an over-the-counter medication.	Naproxen	10-61	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	130-135
24327721-1	2014	Naproxen [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid] is a potent nonsteroidal anti-inflammatory drug that inhibits both COX-1 and COX-2 and is widely used as an over-the-counter medication.	Naproxen	10-61	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	140-145
24327721-6	2014	Computer kinase profiling results suggested that phosphoinositide 3-kinase (PI3K) is a potential target for naproxen.	Naproxen	108-116	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	49-74
24327721-9	2014	Western blot data showed that naproxen decreased phosphorylation of Akt, and subsequently decreased Akt signaling in UM-UC-5 and UM-UC-14 urinary bladder cancer cells.	Naproxen	30-38	AKT serine/threonine kinase 1	Homo sapiens	68-71
24327721-9	2014	Western blot data showed that naproxen decreased phosphorylation of Akt, and subsequently decreased Akt signaling in UM-UC-5 and UM-UC-14 urinary bladder cancer cells.	Naproxen	30-38	AKT serine/threonine kinase 1	Homo sapiens	100-103
24327721-11	2014	Naproxen caused an accumulation of cells at the G1 phase mediated through cyclin-dependent kinase 4, cyclin D1, and p21.	Naproxen	0-8	cyclin dependent kinase 4	Homo sapiens	74-99
24327721-11	2014	Naproxen caused an accumulation of cells at the G1 phase mediated through cyclin-dependent kinase 4, cyclin D1, and p21.	Naproxen	0-8	cyclin D1	Homo sapiens	101-110
24327721-11	2014	Naproxen caused an accumulation of cells at the G1 phase mediated through cyclin-dependent kinase 4, cyclin D1, and p21.	Naproxen	0-8	H3 histone pseudogene 16	Homo sapiens	116-119
24327721-12	2014	Moreover, naproxen induced significant apoptosis, accompanied with increased levels of cleaved caspase-3, caspase-7, and PARP in both cell types.	Naproxen	10-18	caspase 7	Homo sapiens	106-115
24327721-12	2014	Moreover, naproxen induced significant apoptosis, accompanied with increased levels of cleaved caspase-3, caspase-7, and PARP in both cell types.	Naproxen	10-18	collagen type XI alpha 2 chain	Homo sapiens	121-125
24327721-13	2014	Naproxen-induced cell death was mainly because of apoptosis in which a prominent downregulation of Bcl-2 and upregulation of Bax were involved.	Naproxen	0-8	BCL2 apoptosis regulator	Homo sapiens	99-104
24327721-13	2014	Naproxen-induced cell death was mainly because of apoptosis in which a prominent downregulation of Bcl-2 and upregulation of Bax were involved.	Naproxen	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	125-128
24327721-14	2014	Naproxen also caused apoptosis and inhibited Akt phosphorylation in rat urinary bladder cancers induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine.	Naproxen	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	45-48
24376205-1	2014	A group of cyclooxygenase-2 (COX-2)-specific fluorescent cancer biomarkers were synthesized by linking the anti-inflammatory drugs ibuprofen, (S)-naproxen, and celecoxib to the 7-nitrobenzofurazan (NBD) fluorophore.	Naproxen	142-154	prostaglandin-endoperoxide synthase 2	Homo sapiens	11-27
24315932-8	2014	We found that ritonavir administration caused intestinal damage and its co-administration with naproxen or ASA exacerbated the severity of injury and intestinal inflammation, as assessed by measuring haematocrit, MPO, mucosal levels of PGE2 and mRNA levels of iNOS, MCP-1 and VLA-1.	Naproxen	95-103	nitric oxide synthase 2	Homo sapiens	260-264
24315932-8	2014	We found that ritonavir administration caused intestinal damage and its co-administration with naproxen or ASA exacerbated the severity of injury and intestinal inflammation, as assessed by measuring haematocrit, MPO, mucosal levels of PGE2 and mRNA levels of iNOS, MCP-1 and VLA-1.	Naproxen	95-103	C-C motif chemokine ligand 2	Homo sapiens	266-271
24315932-8	2014	We found that ritonavir administration caused intestinal damage and its co-administration with naproxen or ASA exacerbated the severity of injury and intestinal inflammation, as assessed by measuring haematocrit, MPO, mucosal levels of PGE2 and mRNA levels of iNOS, MCP-1 and VLA-1.	Naproxen	95-103	integrin subunit alpha 1	Homo sapiens	276-281
24376205-1	2014	A group of cyclooxygenase-2 (COX-2)-specific fluorescent cancer biomarkers were synthesized by linking the anti-inflammatory drugs ibuprofen, (S)-naproxen, and celecoxib to the 7-nitrobenzofurazan (NBD) fluorophore.	Naproxen	142-154	prostaglandin-endoperoxide synthase 2	Homo sapiens	29-34
24041627-8	2014	The only randomized clinical trial conducted for the prevention and treatment of G-CSF induced bone pain showed the efficacy of naproxen in reducing the incidence, the severity and the duration of bone pain induced by the administration of pegfilgrastim.	Naproxen	128-136	colony stimulating factor 3	Homo sapiens	81-86
24345240-1	2014	This study investigated the roles and optimum conditions of four independent variables [ultraviolet (UV) intensity, Fe(III), NO3 (-), and humic acid (HA) concentration] in the photolytic removal of naproxen (NPX) and ibuprofen (IBP) in water using a response surface method based on the Box-Behnken design.	Naproxen	198-206	NBL1, DAN family BMP antagonist	Homo sapiens	125-128
24021029-19	2014	Consistent with large regulatory studies comparing the efficacy of SumaRT/Nap with naproxen sodium, SumaRT/Nap in this study was statistically superior to naproxen sodium at 2 hours in reducing headache severity during months 2 and 3.	Naproxen	83-98	catenin beta like 1	Homo sapiens	107-110
25007521-6	2014	The activity of iNOS remained much higher than under condition of the naproxen action.	Naproxen	70-78	nitric oxide synthase 2	Rattus norvegicus	16-20
24183439-2	2014	In this work, the effect of micellar environment on the binding of naproxen and diclofenac sodium with bovine serum albumin has been studied.	Naproxen	67-75	albumin	Homo sapiens	110-123
25139652-4	2014	It has been shown that NSAIDs with high COX-1 affinity like ibuprofen and naproxen cause a pharmacodynamic interaction with the inhibition of thromboxane synthesis by acetylsalicylic acid.	Naproxen	74-82	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	40-45
24662962-4	2014	RESULTS: Chromatolysis and amyloid plaques were found along with higher ROS, nitrite and TNF-alpha levels in the hippocampus of colchicine-induced AD rats, and these changes were prevented by naproxen in a dose-dependent manner.	Naproxen	192-200	tumor necrosis factor	Rattus norvegicus	89-98
23883161-6	2013	Naproxen significantly increased clinic and ambulatory systolic/diastolic BP (SBP/DBP) values in patients treated with ramipril (p < 0.01) or valsartan (p < 0.05), but did not affect aliskiren effects.	Naproxen	0-8	selenium binding protein 1	Homo sapiens	78-81
24799999-0	2013	Naproxen Twice Daily Versus as Needed (PRN) Dosing: Efficacy and Tolerability for Treatment of Acute Ankle Sprain, a Randomized Clinical Trial.	Naproxen	0-8	cytosolic iron-sulfur assembly component 3	Homo sapiens	39-42
24055223-5	2013	The naproxen/ibuprofen selectivity ratio was estimated as 6.2 for the MIX and 2.5 for the MIP.	Naproxen	4-12	Mix paired-like homeobox	Homo sapiens	70-73
24255997-9	2013	Some NSAIDs (such as ibuprofen) can interfere with the cardioprotective effects of aspirin by competitively binding to COX-1 enzyme, resulting in increased TXA2 production Naproxen may differ from other NSAIDs in sustaining functionally important degrees of inhibition of platelet cyclooxygenase-1 activity throughout the dosing interval.	Naproxen	172-180	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	119-124
23883161-6	2013	Naproxen significantly increased clinic and ambulatory systolic/diastolic BP (SBP/DBP) values in patients treated with ramipril (p < 0.01) or valsartan (p < 0.05), but did not affect aliskiren effects.	Naproxen	0-8	D-box binding PAR bZIP transcription factor	Homo sapiens	82-85
23884372-0	2013	Impairment of salivary mucin production resulting in declined salivary viscosity during naproxen administration as a potential link to upper alimentary tract mucosal injury.	Naproxen	88-96	LOC100508689	Homo sapiens	23-28
23884372-13	2013	In addition the trend to restorative capacity of rabeprazole on the quantitative impairment of salivary mucin during administration of naproxen may potentially translate into its tangible clinical benefit but it requires further investigation.	Naproxen	135-143	LOC100508689	Homo sapiens	104-109
23784744-0	2013	Naproxen and cromolyn as new glycogen synthase kinase 3beta inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation.	Naproxen	0-8	glycogen synthase kinase 3 beta	Mus musculus	29-59
23784744-1	2013	Naproxen and cromolyn were investigated as new inhibitors of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain their hypoglycemic properties.	Naproxen	0-8	glycogen synthase kinase 3 beta	Mus musculus	61-91
23784744-1	2013	Naproxen and cromolyn were investigated as new inhibitors of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain their hypoglycemic properties.	Naproxen	0-8	glycogen synthase kinase 3 beta	Mus musculus	93-102
23784744-3	2013	Both drugs not only were optimally fitted within a GSK-3beta binding pocket via several attractive interactions with key amino acids but also exhibited potent in vitro enzymatic inhibitory activities of IC50 1.5 and 2.0 microM for naproxen and cromolyn, respectively.	Naproxen	231-239	glycogen synthase kinase 3 beta	Mus musculus	51-60
23784744-6	2013	It can be concluded that naproxen and cromolyn are novel GSK-3beta inhibitors and can help in management of diabetes and obesity.	Naproxen	25-33	glycogen synthase kinase 3 beta	Mus musculus	57-66
23884372-8	2013	RESULTS: The rate of salivary mucin secretion in basal condition declined by 32% during administration of naproxen-placebo (11.3+-1.7 vs. 16.8+-3.3 mg/h).	Naproxen	106-114	LOC100508689	Homo sapiens	30-35
23884372-9	2013	Salivary mucin secretion in pentagastrin-stimulated condition declined significantly (by 34%) during the administration of naproxen-placebo (13.6+-1.5 vs. 20.7+-3.0 mg/h; P<0.05).	Naproxen	123-131	LOC100508689	Homo sapiens	9-14
23884372-11	2013	Coadministration of rabeprazole at least partly restored the naproxen-induced decline of salivary mucin in basal condition (by 8%), and pentagastrin-stimulated conditions (by 30%).	Naproxen	61-69	LOC100508689	Homo sapiens	98-103
23884372-12	2013	CONCLUSIONS: A significant decline of salivary mucin and viscosity during administration of naproxen may at least partly explain a propensity of patients on chronic therapy with NSAIDs to the development of esophageal mucosal injury and complications.	Naproxen	92-100	LOC100508689	Homo sapiens	47-52
23295212-1	2013	The interaction of the enantiomers of the non-steroidal anti-inflammatory drug naproxen (NPX) with human serum albumin (HSA) has been investigated using fluorescence and phosphorescence spectroscopy in the steady-state and time-resolved mode.	Naproxen	79-87	albumin	Homo sapiens	105-124
23541425-8	2013	Correspondingly, for naproxen significantly higher PID% (P <= .021) was seen at 2.5, 3, 4, 5, 6, 7 and 8 h. The frequency of patients obtaining perceptible and meaningful pain relief was about 85% and 48% after AZD1386 and about 53% and 25% after placebo.	Naproxen	21-29	metastasis associated 1 family member 2	Homo sapiens	51-55
23478633-8	2013	Moreover, we showed that NAP itself led to a low but reproducible production of reactive oxygen species (ROS), to protein modifications by lipid peroxidation-derived aldehydes, to p38 phosphorylation and to the slowing-down of DNA replication, while UVA treatment alone showed no effects.	Naproxen	25-28	mitogen-activated protein kinase 14	Homo sapiens	180-183
23478633-9	2013	NAP photosensitization with UVA led to protein S-glutathionylation, oxidation of the proliferating cell nuclear antigen (PCNA), oxidation of cellular tryptophan, phosphorylation of Chk1 and inhibition of DNA replication.	Naproxen	0-3	proliferating cell nuclear antigen	Homo sapiens	85-119
23478633-9	2013	NAP photosensitization with UVA led to protein S-glutathionylation, oxidation of the proliferating cell nuclear antigen (PCNA), oxidation of cellular tryptophan, phosphorylation of Chk1 and inhibition of DNA replication.	Naproxen	0-3	proliferating cell nuclear antigen	Homo sapiens	121-125
23478633-9	2013	NAP photosensitization with UVA led to protein S-glutathionylation, oxidation of the proliferating cell nuclear antigen (PCNA), oxidation of cellular tryptophan, phosphorylation of Chk1 and inhibition of DNA replication.	Naproxen	0-3	checkpoint kinase 1	Homo sapiens	181-185
23478633-11	2013	Nevertheless, inhibition of Chk1, but not of p38, sensitized the cells to the phototoxic effects of NAP.	Naproxen	100-103	checkpoint kinase 1	Homo sapiens	28-32
22946530-0	2013	Computer aided discovery of potential anti-inflammatory (S)-naproxen analogs as COX-2 inhibitors.	Naproxen	56-68	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	80-85
23295212-1	2013	The interaction of the enantiomers of the non-steroidal anti-inflammatory drug naproxen (NPX) with human serum albumin (HSA) has been investigated using fluorescence and phosphorescence spectroscopy in the steady-state and time-resolved mode.	Naproxen	89-92	albumin	Homo sapiens	105-124
23200247-1	2013	The observation that the cyclooxygenase-2 (COX-2) isozyme is over-expressed in multiple types of cancer, relative to that in adjacent non-cancerous tissue, prompted this investigation to prepare a group of hybrid fluorescent conjugates wherein the COX inhibitors ibuprofen, (S)-naproxen, acetyl salicylic acid, a chlororofecoxib analog and celecoxib were coupled via a linker group to an acridone, dansyl or rhodamine B fluorophore.	Naproxen	274-286	prostaglandin-endoperoxide synthase 2	Homo sapiens	25-41
23538186-9	2013	RESULTS: The model estimated an ICER of $59,473 for duloxetine over naproxen.	Naproxen	68-76	cAMP responsive element modulator	Homo sapiens	32-36
23538186-11	2013	In subpopulations at a higher risk of NSAID-related AEs, the ICER over naproxen was $33,105 or lower.	Naproxen	71-79	cAMP responsive element modulator	Homo sapiens	61-65
23136972-3	2013	In this work, we demonstrate that the covalent conjugation of d-amino acids to naproxen (i.e., a NSAID) not only affords supramolecular hydrogelators for the topical gels but also unexpectedly and significantly elevates the selectivity toward COX-2 about 20x at little expense of the activity of naproxen.	Naproxen	79-87	prostaglandin-endoperoxide synthase 2	Homo sapiens	243-248
23200247-1	2013	The observation that the cyclooxygenase-2 (COX-2) isozyme is over-expressed in multiple types of cancer, relative to that in adjacent non-cancerous tissue, prompted this investigation to prepare a group of hybrid fluorescent conjugates wherein the COX inhibitors ibuprofen, (S)-naproxen, acetyl salicylic acid, a chlororofecoxib analog and celecoxib were coupled via a linker group to an acridone, dansyl or rhodamine B fluorophore.	Naproxen	274-286	prostaglandin-endoperoxide synthase 2	Homo sapiens	43-48
22406417-0	2012	The inhibitory action of the antimigraine nonsteroidal anti-inflammatory drug naproxen on P2X3 receptor-mediated responses in rat trigeminal neurons.	Naproxen	78-86	purinergic receptor P2X 3	Homo sapiens	90-94
22705147-5	2012	Treatment with PGD(2) for 24hours in the presence of naproxen (10muM) to inhibit endogenous prostaglandin production increased the percentage of apoptotic OCs in a dose-dependent manner, as did the specific CRTH2 agonist compound DK-PGD(2) but not the DP agonist compound BW 245C.	Naproxen	53-61	prostaglandin D2 receptor 2	Homo sapiens	207-212
22881598-11	2013	Deletion of GPBAR1 altered the morphology of the small intestine and increased sensitivity to injury caused by naproxen.	Naproxen	111-119	G protein-coupled bile acid receptor 1	Mus musculus	12-18
22930354-1	2012	HPLC and emission spectroscopy were used to investigate UVA photosensitization of methylene blue (MB) or naproxen (NAP) towards bovine serum albumin (BSA).	Naproxen	105-113	albumin	Homo sapiens	135-148
22930354-1	2012	HPLC and emission spectroscopy were used to investigate UVA photosensitization of methylene blue (MB) or naproxen (NAP) towards bovine serum albumin (BSA).	Naproxen	115-118	albumin	Homo sapiens	135-148
22833186-10	2012	However, the nonselective NSAID naproxen was associated with a significant decrease in the CRP level, whereas the cyclooxygenase 2-selective NSAID lumiracoxib was associated with a significant increase in the CRP level.	Naproxen	32-40	C-reactive protein	Homo sapiens	91-94
22270486-8	2012	The serum corticosterone (CORT) concentration was increased in rats exposed to HH condition and this elevated CORT concentration was blocked after administration of naproxen in HH condition.	Naproxen	165-173	cortistatin	Rattus norvegicus	26-30
22270486-8	2012	The serum corticosterone (CORT) concentration was increased in rats exposed to HH condition and this elevated CORT concentration was blocked after administration of naproxen in HH condition.	Naproxen	165-173	cortistatin	Rattus norvegicus	110-114
22407924-2	2012	To increase the delivery of naproxen across the blood-brain barrier (BBB), 3 prodrugs (P1, P2 and P3) of naproxen were synthesized through either ester bond or amido bond using the dimethylamino moiety as a brain-targeting ligand.	Naproxen	28-36	perforin 1	Rattus norvegicus	87-100
22407924-2	2012	To increase the delivery of naproxen across the blood-brain barrier (BBB), 3 prodrugs (P1, P2 and P3) of naproxen were synthesized through either ester bond or amido bond using the dimethylamino moiety as a brain-targeting ligand.	Naproxen	105-113	perforin 1	Rattus norvegicus	87-100
22407924-5	2012	After i. v. administration to rats, the brain concentration of total naproxen (summation of released and bound naproxen, TN) of P1, P2 and P3 groups were 28.81, 24.51 and 15.54 times greater than that of the control naproxen group at 5 min, respectively, and the brain AUC0-t were 6.94, 10.06 and 6.70 times greater than that of the control naproxen group.	Naproxen	69-77	perforin 1	Rattus norvegicus	128-141
22407924-5	2012	After i. v. administration to rats, the brain concentration of total naproxen (summation of released and bound naproxen, TN) of P1, P2 and P3 groups were 28.81, 24.51 and 15.54 times greater than that of the control naproxen group at 5 min, respectively, and the brain AUC0-t were 6.94, 10.06 and 6.70 times greater than that of the control naproxen group.	Naproxen	111-119	perforin 1	Rattus norvegicus	128-141
22407924-5	2012	After i. v. administration to rats, the brain concentration of total naproxen (summation of released and bound naproxen, TN) of P1, P2 and P3 groups were 28.81, 24.51 and 15.54 times greater than that of the control naproxen group at 5 min, respectively, and the brain AUC0-t were 6.94, 10.06 and 6.70 times greater than that of the control naproxen group.	Naproxen	111-119	perforin 1	Rattus norvegicus	128-141
22407924-5	2012	After i. v. administration to rats, the brain concentration of total naproxen (summation of released and bound naproxen, TN) of P1, P2 and P3 groups were 28.81, 24.51 and 15.54 times greater than that of the control naproxen group at 5 min, respectively, and the brain AUC0-t were 6.94, 10.06 and 6.70 times greater than that of the control naproxen group.	Naproxen	111-119	perforin 1	Rattus norvegicus	128-141
22221151-21	2012	Sumatriptan acts on the 5-HT(1B) and 5-HT(1D) receptors, whereas naproxen inhibits the COX-1 and COX-2 enzymes.	Naproxen	65-73	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	87-92
22344408-10	2012	In conclusion, NCX 466 has shown a significantly higher efficacy than naproxen in reducing lung inflammation and preventing collagen accumulation.	Naproxen	70-78	T cell leukemia, homeobox 2	Mus musculus	15-18
22406417-3	2012	In this study, we tested whether naproxen, a common antimigraine medicine, could affect the function of P2X3 receptors in the presence or absence of the algogen nerve growth factor (NGF), the level of which is elevated in patients with chronic migraine.	Naproxen	33-41	purinergic receptor P2X 3	Homo sapiens	104-108
22406417-7	2012	The inhibitory action of 1 mM naproxen was enhanced after NGF pretreatment, suggesting that P2X3 receptors in sensitized neurons are more susceptible to inhibition by high doses of this nonsteroidal anti-inflammatory drug (NSAID).	Naproxen	30-38	purinergic receptor P2X 3	Rattus norvegicus	92-96
22406417-8	2012	Using patch clamp recordings from HEK293 cells expressing P2X3 receptors, we tested the direct action of naproxen on P2X3 receptor-mediated membrane currents.	Naproxen	105-113	purinergic receptor P2X 3	Homo sapiens	117-121
22406417-10	2012	Kinetic analysis suggests that naproxen inhibited P2X3 receptors via facilitation of fast desensitization, which determines current decay in the continuous presence of the agonist.	Naproxen	31-39	purinergic receptor P2X 3	Homo sapiens	50-54
22274589-4	2012	The analyses of Natural Bond Orbital and interaction energy using the B3LYP and MP2 (fc) methods suggested that the solubilization mechanism of microemulsion for naproxen mainly might be the formation of complex between the hydrogen atom of hydroxyl in Tween 80 and the oxygen atom of carbonyl group in naproxen, as is in accordance with the result from (1)H NMR experiments.	Naproxen	162-170	proline rich protein HaeIII subfamily 1	Mus musculus	80-83
22221151-21	2012	Sumatriptan acts on the 5-HT(1B) and 5-HT(1D) receptors, whereas naproxen inhibits the COX-1 and COX-2 enzymes.	Naproxen	65-73	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	97-102
22178666-2	2012	The deprotonated naproxen acts as monodentate ligand coordinated to Co(II) ion through a carboxylato oxygen.	Naproxen	17-25	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	68-74
22328075-5	2012	The result of this study indicates that the incorporation of the 4-(methylsulfonyl)aniline pharamacophore into naproxen, indomethacine, diclofenac and mefanamic acid maintained their anti-inflammatory activity and may increase selectivity towards the COX-2 enzyme which will be confirmed in the future by assessing COX-2: COX-1 inhibitory ratios using a whole blood assay.	Naproxen	111-119	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	251-256
22328075-5	2012	The result of this study indicates that the incorporation of the 4-(methylsulfonyl)aniline pharamacophore into naproxen, indomethacine, diclofenac and mefanamic acid maintained their anti-inflammatory activity and may increase selectivity towards the COX-2 enzyme which will be confirmed in the future by assessing COX-2: COX-1 inhibitory ratios using a whole blood assay.	Naproxen	111-119	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	315-320
22328075-5	2012	The result of this study indicates that the incorporation of the 4-(methylsulfonyl)aniline pharamacophore into naproxen, indomethacine, diclofenac and mefanamic acid maintained their anti-inflammatory activity and may increase selectivity towards the COX-2 enzyme which will be confirmed in the future by assessing COX-2: COX-1 inhibitory ratios using a whole blood assay.	Naproxen	111-119	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	322-327
20861716-8	2012	The naproxen-alone group showed significant elevations in CRP, alanine transaminase, and aspartate transaminase when compared with the other groups.	Naproxen	4-12	C-reactive protein	Homo sapiens	58-61
22072415-8	2011	These findings represent the stereoselective inhibitory potencies of flurbiprofen, ibuprofen and naproxen on hOAT1, and the (S)-enantiomers are greater.	Naproxen	97-105	solute carrier family 22 member 6	Homo sapiens	109-114
21564085-11	2011	FXR activation by GW4064 rescued mice from intestinal injury caused by naproxen.	Naproxen	71-79	nuclear receptor subfamily 1, group H, member 4	Mus musculus	0-3
22030324-7	2012	Spinal administration of naproxen, a nonselective COX-inhibitor, significantly attenuated RVM CCK-induced hindpaw tactile hypersensitivity.	Naproxen	25-33	cholecystokinin	Rattus norvegicus	94-97
22937138-7	2012	To understand how other NSAIDs bind to AKR1C3, we have determined ten crystal structures of AKR1C3 complexes that cover three different classes of NSAID, N-phenylanthranilic acids (meclofenamic acid, mefenamic acid), arylpropionic acids (flurbiprofen, ibuprofen, naproxen), and indomethacin analogues (indomethacin, sulindac, zomepirac).	Naproxen	263-271	aldo-keto reductase family 1 member C3	Homo sapiens	92-98
22072415-0	2011	Stereoselective inhibitory effect of flurbiprofen, ibuprofen and naproxen on human organic anion transporters hOAT1 and hOAT3.	Naproxen	65-73	solute carrier family 22 member 6	Homo sapiens	110-115
22072415-0	2011	Stereoselective inhibitory effect of flurbiprofen, ibuprofen and naproxen on human organic anion transporters hOAT1 and hOAT3.	Naproxen	65-73	solute carrier family 22 member 8	Homo sapiens	120-125
22072415-2	2011	In this study, uptake experiments were performed using Xenopus laevis oocytes to assess stereoselectivity in the inhibitory characteristics of flurbiprofen, ibuprofen and naproxen against hOAT1 and hOAT3.	Naproxen	171-179	solute carrier family 22 member 6	Homo sapiens	188-193
22072415-2	2011	In this study, uptake experiments were performed using Xenopus laevis oocytes to assess stereoselectivity in the inhibitory characteristics of flurbiprofen, ibuprofen and naproxen against hOAT1 and hOAT3.	Naproxen	171-179	solute carrier family 22 member 8	Homo sapiens	198-203
21781963-6	2011	In contrast, non-RhoA-inhibiting NSAID naproxen does not have such an effect.	Naproxen	39-47	ras homolog family member A	Homo sapiens	17-21
21764859-0	2011	Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/beta-catenin/cyclin D1 signaling pathway in rats.	Naproxen	45-53	catenin beta 1	Rattus norvegicus	121-133
21764859-0	2011	Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/beta-catenin/cyclin D1 signaling pathway in rats.	Naproxen	45-53	cyclin D1	Rattus norvegicus	134-143
21764859-8	2011	Proliferation markers, proliferating cell nuclear antigen, cyclin D1, and beta-catenin in tumors of rats exposed to sulindac, naproxen, atorvastatin, and/or combinations showed a significant suppression.	Naproxen	126-134	proliferating cell nuclear antigen	Rattus norvegicus	23-57
21764859-8	2011	Proliferation markers, proliferating cell nuclear antigen, cyclin D1, and beta-catenin in tumors of rats exposed to sulindac, naproxen, atorvastatin, and/or combinations showed a significant suppression.	Naproxen	126-134	cyclin D1	Rattus norvegicus	59-68
21764859-8	2011	Proliferation markers, proliferating cell nuclear antigen, cyclin D1, and beta-catenin in tumors of rats exposed to sulindac, naproxen, atorvastatin, and/or combinations showed a significant suppression.	Naproxen	126-134	catenin beta 1	Rattus norvegicus	74-86
21764859-0	2011	Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/beta-catenin/cyclin D1 signaling pathway in rats.	Naproxen	45-53	synaptotagmin 1	Rattus norvegicus	117-120
21497079-4	2011	By using MWCNT, the limit of detection was enhanced from 59 to 12 muM in case of Cyclophosphamide and from to 187 to 82 muM in case of Naproxen.	Naproxen	135-143	latexin	Homo sapiens	120-123
21830840-1	2011	BACKGROUND: Naproxen, ibuprofen and diclofenac are frequently used as comparators in randomized controlled trials (RCTs) on the safety and efficacy of cyclooxygenase (COX)-2 inhibitors.	Naproxen	12-20	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	151-173
21605674-5	2011	Specificity of in vivo [F-18]FDDNP binding was assessed by naproxen pretreatment, which reversibly blocked [F-18]FDDNP binding to Abeta aggregrates.	Naproxen	59-67	amyloid beta precursor protein	Rattus norvegicus	130-135
21601217-4	2011	To improve its lipophilic character, NAP was conjugated through a diethylamine spacer (EDA) to lipoamino acids (LAA), alpha-amino acids containing a long alkyl side chain, to obtain the NAP-EDA-LAA10 and NAP-EDA-LAA14 prodrugs.	Naproxen	37-40	ectodysplasin A	Homo sapiens	87-90
21601217-4	2011	To improve its lipophilic character, NAP was conjugated through a diethylamine spacer (EDA) to lipoamino acids (LAA), alpha-amino acids containing a long alkyl side chain, to obtain the NAP-EDA-LAA10 and NAP-EDA-LAA14 prodrugs.	Naproxen	37-40	ectodysplasin A	Homo sapiens	190-193
21601217-4	2011	To improve its lipophilic character, NAP was conjugated through a diethylamine spacer (EDA) to lipoamino acids (LAA), alpha-amino acids containing a long alkyl side chain, to obtain the NAP-EDA-LAA10 and NAP-EDA-LAA14 prodrugs.	Naproxen	37-40	ectodysplasin A	Homo sapiens	190-193
21601217-4	2011	To improve its lipophilic character, NAP was conjugated through a diethylamine spacer (EDA) to lipoamino acids (LAA), alpha-amino acids containing a long alkyl side chain, to obtain the NAP-EDA-LAA10 and NAP-EDA-LAA14 prodrugs.	Naproxen	186-189	ectodysplasin A	Homo sapiens	87-90
21601217-4	2011	To improve its lipophilic character, NAP was conjugated through a diethylamine spacer (EDA) to lipoamino acids (LAA), alpha-amino acids containing a long alkyl side chain, to obtain the NAP-EDA-LAA10 and NAP-EDA-LAA14 prodrugs.	Naproxen	186-189	ectodysplasin A	Homo sapiens	190-193
21601217-4	2011	To improve its lipophilic character, NAP was conjugated through a diethylamine spacer (EDA) to lipoamino acids (LAA), alpha-amino acids containing a long alkyl side chain, to obtain the NAP-EDA-LAA10 and NAP-EDA-LAA14 prodrugs.	Naproxen	186-189	ectodysplasin A	Homo sapiens	190-193
21504739-0	2011	Naproxen interferes with the assembly of Abeta oligomers implicated in Alzheimer"s disease.	Naproxen	0-8	amyloid beta precursor protein	Homo sapiens	41-46
21504739-2	2011	To investigate the interactions of naproxen with Abeta dimers, which are the smallest cytotoxic aggregated Abeta peptide species, we use united atom implicit solvent model and exhaustive replica exchange molecular dynamics.	Naproxen	35-43	amyloid beta precursor protein	Homo sapiens	107-112
21504739-2	2011	To investigate the interactions of naproxen with Abeta dimers, which are the smallest cytotoxic aggregated Abeta peptide species, we use united atom implicit solvent model and exhaustive replica exchange molecular dynamics.	Naproxen	35-43	amyloid beta precursor protein	Homo sapiens	49-54
21504739-3	2011	We show that naproxen ligands bind to Abeta dimer and penetrate its volume interfering with the interpeptide interactions.	Naproxen	13-21	amyloid beta precursor protein	Homo sapiens	38-43
21504739-4	2011	As a result naproxen induces a destabilizing effect on Abeta dimer.	Naproxen	12-20	amyloid beta precursor protein	Homo sapiens	55-60
20861644-9	2011	PGN- and Pam(3)CSK(4)-induced mast cell IL-6, but not IL-1beta, production was dependent on adenylyl cyclase activity and could be partially inhibited by the cyclooxygenase inhibitor naproxen.	Naproxen	183-191	interleukin 6	Homo sapiens	40-44
21504739-6	2011	The analysis of naproxen binding energetics shows that the location of ligand binding sites in Abeta dimer is dictated by the Abeta amino acid sequence.	Naproxen	16-24	amyloid beta precursor protein	Homo sapiens	95-100
21504739-6	2011	The analysis of naproxen binding energetics shows that the location of ligand binding sites in Abeta dimer is dictated by the Abeta amino acid sequence.	Naproxen	16-24	amyloid beta precursor protein	Homo sapiens	126-131
21612106-8	2011	Indomethacin, naproxen, and other NSAID increase the blood pressure in patients treated with beta-blockers, diuretics, metildopa, ACE-inhibitors and combination of various antihipertensive drugs, but there is no increase of blood pressure in patients treated with calcium blockers.	Naproxen	14-22	angiotensin I converting enzyme	Homo sapiens	130-133
20932884-6	2011	Moreover, naproxen stimulated the decomposition of tryptophan into kynurenate, which inhibits fibroblast growth factor-1 and delays ulcer healing.	Naproxen	10-18	fibroblast growth factor 1	Rattus norvegicus	94-120
21360514-11	2011	CONCLUSION: Sequential administration of 220 mg naproxen twice a day and low-dose aspirin interferes with the irreversible inhibition of platelet cyclooxygenase 1 afforded by aspirin.	Naproxen	48-56	prostaglandin-endoperoxide synthase 1	Homo sapiens	146-162
27942290-0	2010	Recombinant Human Epidermal Growth Factor Alleviates Gastric Antral Ulcer Induced by Naproxen: A Non-steroidal Anti Inflammatory Drug.	Naproxen	85-93	epidermal growth factor	Homo sapiens	18-41
20810665-4	2010	We performed a detailed study of naproxen-COX-2 interactions using site-directed mutagenesis, structure-activity analysis, and x-ray crystallography.	Naproxen	33-41	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	42-47
20810665-8	2010	Crystallization and x-ray analysis yielded structures of COX-2 complexed to naproxen and its methylthio analog at 1.7 and 2.3 A resolution, respectively.	Naproxen	76-84	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	57-62
20810665-9	2010	The combination of mutagenesis, structure analysis, and x-ray crystallography provided comprehensive information on the unique interactions responsible for naproxen binding to COX-2.	Naproxen	156-164	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	176-181
20539104-2	2010	Nonselective NSAIDs inhibit both COX 1 and 2 isoenzymes (eg, ibuprofen and naproxen).	Naproxen	75-83	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	33-44
20215413-4	2010	CYP2C9-mediated metabolism of S-naproxen and S-flurbiprofen was inhibited up to 80% by coincubation with CYP3A4, although K(m) values were unchanged.	Naproxen	30-40	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
20215413-4	2010	CYP2C9-mediated metabolism of S-naproxen and S-flurbiprofen was inhibited up to 80% by coincubation with CYP3A4, although K(m) values were unchanged.	Naproxen	30-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
20674154-6	2010	NO-Aspirin and NO-naproxen reduced NF-kappaB protein levels, and activated caspase-3 enzyme in a dose- and time-dependent manner.	Naproxen	18-26	nuclear factor kappa B subunit 1	Homo sapiens	35-44
20979356-1	2010	Using implicit solvent model and replica exchange molecular dynamics, we examine the propensity of a nonsteroidal anti-inflammatory drug, naproxen, to interfere with Abeta fibril growth.	Naproxen	138-146	amyloid beta precursor protein	Homo sapiens	166-171
20979356-4	2010	Similar to ibuprofen, naproxen destabilizes binding of incoming Abeta peptides to the fibril due to direct competition between the ligands and the peptides for the same binding location on the fibril surface (the edge).	Naproxen	22-30	amyloid beta precursor protein	Homo sapiens	64-69
20979356-5	2010	However, in contrast to ibuprofen, naproxen binding also alters the conformational ensemble of Abeta monomers by promoting beta-structure.	Naproxen	35-43	amyloid beta precursor protein	Homo sapiens	95-100
20979356-7	2010	These findings appear to explain the experimental observations, in which naproxen binds to the Abeta fibril with higher affinity than ibuprofen, yet produces weaker antiaggregation action.	Naproxen	73-81	amyloid beta precursor protein	Homo sapiens	95-100
20864142-6	2010	Naproxen and diclofenac were efficiently removed (93%) in B1 and B2, revealing anaerobic degradation as a probable removal mechanism.	Naproxen	0-8	immunoglobulin kappa variable 7-3 (pseudogene)	Homo sapiens	58-67
27942290-1	2010	BACKGROUND: To study the effect (s) of recombinant human Epidermal Growth Factor (rhEGF) on naproxen induced gastric ulcer in Wistar NIN rats.	Naproxen	92-100	epidermal growth factor	Homo sapiens	57-80
27942290-6	2010	RESULTS: Naproxen per se induced gastric antral ulcers in Wistar NIN rats.	Naproxen	9-17	ninein	Rattus norvegicus	65-68
27942290-11	2010	Compared with control group, naproxen induced group exhibited more gene expression of both Cox-2 and TGF beta while gene expression of Cox-2 and TGF beta in rhEGF group was comparable to control group.	Naproxen	29-37	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	91-96
27942290-11	2010	Compared with control group, naproxen induced group exhibited more gene expression of both Cox-2 and TGF beta while gene expression of Cox-2 and TGF beta in rhEGF group was comparable to control group.	Naproxen	29-37	transforming growth factor, beta 1	Rattus norvegicus	101-109
20144213-11	2010	The addition of naproxen to cultured chondrocytes revealed that FLAP and 5-LOX regulation by HNE required PGE2 production.	Naproxen	16-24	arachidonate 5-lipoxygenase activating protein	Homo sapiens	64-74
20175977-10	2010	TTMP was significantly better for tramadol/acetaminophen and naproxen than placebo (P<0.001 to P=0.015) for walks on Day 1 after a single dose and on Day 3.	Naproxen	61-69	chromosome 3 open reading frame 52	Homo sapiens	0-4
19823098-7	2010	RESULTS: Pancreatic collagen content and alpha-smooth muscle actin expression were higher in the CP group treated with high-dose (40 mg/kg PO) naproxen (P < 0.05).	Naproxen	143-151	actin gamma 2, smooth muscle	Rattus norvegicus	41-66
19850159-8	2010	On the contrary, Septin-8 was similarly expressed in control cells in the presence of less toxic drugs such ibuprofen, naproxen, and meloxicam.	Naproxen	119-127	septin 8	Homo sapiens	17-25
19843975-8	2010	In contrast, indomethacin, ketoprofen, and naproxen led to significant stimulation of OATP2A1-mediated PGE(2) transport by 162.7 +/- 13.9, 77.2 +/- 3.6, and 32.3 +/- 4.9%, respectively.	Naproxen	43-51	solute carrier organic anion transporter family member 2A1	Homo sapiens	86-93
20144213-11	2010	The addition of naproxen to cultured chondrocytes revealed that FLAP and 5-LOX regulation by HNE required PGE2 production.	Naproxen	16-24	lysyl oxidase	Homo sapiens	75-78
19845543-4	2010	Prostaglandin E(2) (PGE(2)) and tumor necrosis factor alpha (TNF-alpha) levels were increased 96 h post-UVB in acutely irradiated animals and both mediators were modified by topical naproxen application-PGE(2) was decreased while TNF-alpha was increased.	Naproxen	182-190	tumor necrosis factor	Mus musculus	32-59
20214635-2	2010	Covalent linkage of naproxen to human serum albumin (HSA) has been shown to target it efficiently to the liver and this may potentially be exploited for liver-selective inhibition of angiogenesis.	Naproxen	20-28	albumin	Homo sapiens	38-51
19845543-4	2010	Prostaglandin E(2) (PGE(2)) and tumor necrosis factor alpha (TNF-alpha) levels were increased 96 h post-UVB in acutely irradiated animals and both mediators were modified by topical naproxen application-PGE(2) was decreased while TNF-alpha was increased.	Naproxen	182-190	tumor necrosis factor	Mus musculus	61-70
19845543-4	2010	Prostaglandin E(2) (PGE(2)) and tumor necrosis factor alpha (TNF-alpha) levels were increased 96 h post-UVB in acutely irradiated animals and both mediators were modified by topical naproxen application-PGE(2) was decreased while TNF-alpha was increased.	Naproxen	182-190	tumor necrosis factor	Mus musculus	230-239
19845543-8	2010	Furthermore, reduction in the incidence of tumor lesions by naproxen may be due to its ability to increase TNF-alpha levels as well as to decrease PGE(2).	Naproxen	60-68	tumor necrosis factor	Mus musculus	107-116
19487247-5	2009	The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized.	Naproxen	256-264	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	45-51
19487247-2	2009	Unlike most UGT1A and UGT2B xenobiotic-metabolizing enzymes, UGT1A4 and UGT2B10 lack the ability to glucuronidate 4-methylumbelliferone (4MU) and 1-naphthol (1NP), both planar phenols, and naproxen (a carboxylic acid).	Naproxen	189-197	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	61-67
19487247-5	2009	The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized.	Naproxen	256-264	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	53-59
19487247-2	2009	Unlike most UGT1A and UGT2B xenobiotic-metabolizing enzymes, UGT1A4 and UGT2B10 lack the ability to glucuronidate 4-methylumbelliferone (4MU) and 1-naphthol (1NP), both planar phenols, and naproxen (a carboxylic acid).	Naproxen	189-197	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	72-79
19487247-5	2009	The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized.	Naproxen	256-264	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	61-67
19487247-5	2009	The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized.	Naproxen	256-264	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	73-79
19487247-5	2009	The conserved N-terminal domain histidine of UGT1A1, UGT1A6, UGT1A9, and UGT2B7 was mutated to proline and leucine 34 of UGT2B10 was substituted with histidine, and the capacity of the wild-type and mutant proteins to glucuronidate 4MU, 1NP, LTG, TFP, and naproxen was characterized.	Naproxen	256-264	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	121-128
19487247-6	2009	Whereas UGT1A1(H39P), UGT1A6(H38P), and UGT1A9(H37P) lacked the ability to metabolize 4MU, 1NP, and naproxen, all glucuronidated LTG.	Naproxen	100-108	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	8-14
19487247-6	2009	Whereas UGT1A1(H39P), UGT1A6(H38P), and UGT1A9(H37P) lacked the ability to metabolize 4MU, 1NP, and naproxen, all glucuronidated LTG.	Naproxen	100-108	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	22-28
19487247-6	2009	Whereas UGT1A1(H39P), UGT1A6(H38P), and UGT1A9(H37P) lacked the ability to metabolize 4MU, 1NP, and naproxen, all glucuronidated LTG.	Naproxen	100-108	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	40-46
19563267-2	2009	The common anti-inflammatory drugs (such as aspirin, ibuprofen and naproxen) all act by blocking the action of both the COX-1 and COX-2 enzymes.	Naproxen	67-75	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	120-125
19563267-2	2009	The common anti-inflammatory drugs (such as aspirin, ibuprofen and naproxen) all act by blocking the action of both the COX-1 and COX-2 enzymes.	Naproxen	67-75	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	130-135
19442216-3	2009	In order to understand the metabolic mechanism of various drugs, two crystal structures of CYP2C9 have been studied, and their structural differences and structure-activity relationships with the drugs of Fluoxetine, Ibuprofen, Naproxen, Suprofen, and Mefenamic acid were investigated.	Naproxen	228-236	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	91-97
19359223-10	2009	The Fos count after systemic LPS was reduced to 99+/-30 following pretreatment with the cyclooxygenase inhibitor Naproxen (10 mg kg(-1); p>0.05 versus vehicle controls) and increased to 242+/-66 following the iNOS-inhibitor Aminoguanidine (15 mg kg(-1); p<0.01).	Naproxen	113-121	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	4-7
19422321-1	2009	Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib.	Naproxen	254-262	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	17-23
19422321-1	2009	Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib.	Naproxen	254-262	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	28-34
19422321-1	2009	Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib.	Naproxen	254-262	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	84-90
19422321-1	2009	Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib.	Naproxen	254-262	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	95-101
18955235-6	2009	Both Naproxen and Lyprinol(R) decreased the levels of the pro-inflammatory cytokines TNF-alpha and IFN-gamma, and increased that of IL-10.	Naproxen	5-13	tumor necrosis factor	Rattus norvegicus	85-94
18955235-6	2009	Both Naproxen and Lyprinol(R) decreased the levels of the pro-inflammatory cytokines TNF-alpha and IFN-gamma, and increased that of IL-10.	Naproxen	5-13	interferon gamma	Rattus norvegicus	99-108
18955235-6	2009	Both Naproxen and Lyprinol(R) decreased the levels of the pro-inflammatory cytokines TNF-alpha and IFN-gamma, and increased that of IL-10.	Naproxen	5-13	interleukin 10	Rattus norvegicus	132-137
19280158-0	2009	Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects.	Naproxen	53-61	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	10-16
19280158-1	2009	The genetically polymorphic CYP2C9 metabolizes many non-steroidal anti-inflammatory agents, including naproxen.	Naproxen	102-110	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	28-34
19280158-2	2009	This study examined the effects of a CYP2C9 genetic polymorphism on the pharmacokinetics of naproxen in Korean subjects.	Naproxen	92-100	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	37-43
19280158-6	2009	The mean plasma concentration-time profiles of naproxen in the CYP2C9*1/*3 and CYP2C9*1/*1 individuals were similar.	Naproxen	47-55	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	63-69
19038416-5	2009	NF-kappaB activity in T24 cells was significantly reduced by all NSAIDs analysed (diclofenac, ketoprofen, naproxen, ibuprophen and dextropropoxyphene), but also by trimethoprim, using environmentally relevant concentrations.	Naproxen	106-114	nuclear factor kappa B subunit 1	Homo sapiens	0-9
19235551-6	2009	The dissolution rate of naproxen from microparticles was enhanced significantly with increasing the ratio of drug: polymer and stirring rate, and sustained by increasing SLS % in crystallization medium.	Naproxen	24-32	aldehyde dehydrogenase 3 family member A2	Homo sapiens	170-173
19345936-5	2009	Herein, we tested a variety of Cox-1/Cox-2 non-selective NSAIDs, namely ibuprofen, tylenol, aspirin and naproxen and report that they blunt IgM and IgG synthesis in stimulated human peripheral blood mononuclear cells (PBMC).	Naproxen	104-112	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	31-36
19345936-5	2009	Herein, we tested a variety of Cox-1/Cox-2 non-selective NSAIDs, namely ibuprofen, tylenol, aspirin and naproxen and report that they blunt IgM and IgG synthesis in stimulated human peripheral blood mononuclear cells (PBMC).	Naproxen	104-112	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	37-42
18377945-6	2008	Comparison of isotherms for the target compounds to those for other conventional micropollutants suggested that naproxen and carbamazepine could be effectively removed by applying the same dosage utilized to remove odorous compounds (geosmin and MIB) at very low concentrations.	Naproxen	112-120	MIB E3 ubiquitin protein ligase 1	Homo sapiens	246-249
18710815-6	2008	Naproxen treatment notably reduces PGE2 production and iNOS expression, reflecting the COX-NOS crosstalk already reported, although it causes an important increment in TNF-alpha synthesis in the epidermis of irradiated mice.	Naproxen	0-8	nitric oxide synthase 2, inducible	Mus musculus	55-59
18710815-6	2008	Naproxen treatment notably reduces PGE2 production and iNOS expression, reflecting the COX-NOS crosstalk already reported, although it causes an important increment in TNF-alpha synthesis in the epidermis of irradiated mice.	Naproxen	0-8	tumor necrosis factor	Mus musculus	168-177
18550689-4	2008	The expression of Nox1, Nox2, Nox4, and p22phox was increased markedly by the nonselective NSAIDs diclofenac or naproxen and moderately by rofecoxib or celecoxib in the aorta and heart of SHR.	Naproxen	112-120	NADPH oxidase 1	Homo sapiens	18-22
18550689-4	2008	The expression of Nox1, Nox2, Nox4, and p22phox was increased markedly by the nonselective NSAIDs diclofenac or naproxen and moderately by rofecoxib or celecoxib in the aorta and heart of SHR.	Naproxen	112-120	cytochrome b-245 beta chain	Homo sapiens	24-28
18550689-4	2008	The expression of Nox1, Nox2, Nox4, and p22phox was increased markedly by the nonselective NSAIDs diclofenac or naproxen and moderately by rofecoxib or celecoxib in the aorta and heart of SHR.	Naproxen	112-120	NADPH oxidase 4	Homo sapiens	30-34
18550689-4	2008	The expression of Nox1, Nox2, Nox4, and p22phox was increased markedly by the nonselective NSAIDs diclofenac or naproxen and moderately by rofecoxib or celecoxib in the aorta and heart of SHR.	Naproxen	112-120	cytochrome b-245 alpha chain	Homo sapiens	40-47
18581209-7	2008	Unexpectedly, the short-term treatment with naproxen induced an important increase of BCRP expression, but this induction was lost after long-term treatment.	Naproxen	44-52	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	86-90
18702823-6	2008	RESULTS: Results showed significant risk reductions for selective COX-2 inhibitors (OR = 0.31, 95% CI = 0.16-0.57), regular aspirin (OR = 0.33, 95% CI = 0.20-0.56), and ibuprofen or naproxen (0.28, 95% CI = 0.15-0.54).	Naproxen	182-190	prostaglandin-endoperoxide synthase 2	Homo sapiens	66-71
18259051-0	2008	Structural basis for the binding of naproxen to human serum albumin in the presence of fatty acids and the GA module.	Naproxen	36-44	albumin	Homo sapiens	54-67
18397691-3	2008	Apart from aspirin, which irreversibly inactivates COX-1, high-dose naproxen causes sustained COX-1 inhibition throughout the dose interval in some individuals.	Naproxen	68-76	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	94-99
18397691-4	2008	The present study examines whether naproxen sodium after a single dose administration and at steady state using "over-the-counter (OTC) doses" produces sufficient COX-1 inhibition.	Naproxen	35-50	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	163-168
18397691-13	2008	For both isoenzymes, COX inhibition correlated with naproxen plasma levels (ex vivo IC50 values of 35.48 micromol/l (COX-1) and 64.62 micromol/l (COX-2)).	Naproxen	52-60	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	117-122
18397691-13	2008	For both isoenzymes, COX inhibition correlated with naproxen plasma levels (ex vivo IC50 values of 35.48 micromol/l (COX-1) and 64.62 micromol/l (COX-2)).	Naproxen	52-60	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	146-151
18397691-15	2008	Although low-dose naproxen may elicit a virtually complete COX-1 inhibition in some individuals, it does not mimic the reliable, sustained and complete COX-1 blockade produced by aspirin.	Naproxen	18-26	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	59-64
18275109-0	2008	Sensitivity enhancement for the analysis of naproxen in tap water by solid-phase extraction coupled in-line to capillary electrophoresis.	Naproxen	44-52	nuclear RNA export factor 1	Homo sapiens	56-59
18275109-1	2008	SPE coupled in-line to CE, as the strategy to enhance the concentration sensitivity in CE, has been used to enrich naproxen in tap water samples.	Naproxen	115-123	nuclear RNA export factor 1	Homo sapiens	127-130
17963739-1	2008	BACKGROUND: To test the hypothesis that naproxen, meloxicam and methylprednisolone down-regulate the plasminogen activator (PA)/plasmin system and gelatinases [matrix metalloproteinase (MMP)-2 and MMP-9] expression during early development of osteoarthritis (OA).	Naproxen	40-48	plasminogen	Homo sapiens	101-108
17963739-1	2008	BACKGROUND: To test the hypothesis that naproxen, meloxicam and methylprednisolone down-regulate the plasminogen activator (PA)/plasmin system and gelatinases [matrix metalloproteinase (MMP)-2 and MMP-9] expression during early development of osteoarthritis (OA).	Naproxen	40-48	matrix metallopeptidase 2	Homo sapiens	160-192
17963739-1	2008	BACKGROUND: To test the hypothesis that naproxen, meloxicam and methylprednisolone down-regulate the plasminogen activator (PA)/plasmin system and gelatinases [matrix metalloproteinase (MMP)-2 and MMP-9] expression during early development of osteoarthritis (OA).	Naproxen	40-48	matrix metallopeptidase 9	Homo sapiens	197-202
17963739-4	2008	RESULTS: Gelatin zymography revealed that naproxen, meloxicam and methylprednisolone could suppress MMP-2 secretion in all tissue cultures and MMP-9 production in meniscal and synovial cultures.	Naproxen	42-50	matrix metallopeptidase 2	Homo sapiens	100-105
17963739-4	2008	RESULTS: Gelatin zymography revealed that naproxen, meloxicam and methylprednisolone could suppress MMP-2 secretion in all tissue cultures and MMP-9 production in meniscal and synovial cultures.	Naproxen	42-50	matrix metallopeptidase 9	Homo sapiens	143-148
17963739-5	2008	ELISA showed that naproxen and meloxicam reduced u-PA secretion in chondral and synovial cultures at 48 h except in naproxen-treated chondral cultures.	Naproxen	18-26	plasminogen activator, urokinase	Homo sapiens	49-53
17686967-1	2007	CYP2C9 catalyzes the demethylation of the biphasic kinetics substrate (S)-naproxen, and the CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants are associated with lower rates of (S)-naproxen demethylation.	Naproxen	70-82	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
17944992-1	2008	BACKGROUND: Anti-inflammatory analgesics, including ibuprofen and naproxen, are known to interfere with the antiplatelet effect of aspirin, presumably as a result of a drug-drug interaction at the level of platelet cyclooxygenase-1 (COX-1).	Naproxen	66-74	prostaglandin-endoperoxide synthase 1	Homo sapiens	215-231
17944992-1	2008	BACKGROUND: Anti-inflammatory analgesics, including ibuprofen and naproxen, are known to interfere with the antiplatelet effect of aspirin, presumably as a result of a drug-drug interaction at the level of platelet cyclooxygenase-1 (COX-1).	Naproxen	66-74	prostaglandin-endoperoxide synthase 1	Homo sapiens	233-238
17686967-1	2007	CYP2C9 catalyzes the demethylation of the biphasic kinetics substrate (S)-naproxen, and the CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants are associated with lower rates of (S)-naproxen demethylation.	Naproxen	70-82	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	92-98
17686967-1	2007	CYP2C9 catalyzes the demethylation of the biphasic kinetics substrate (S)-naproxen, and the CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants are associated with lower rates of (S)-naproxen demethylation.	Naproxen	70-82	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	92-98
17686967-1	2007	CYP2C9 catalyzes the demethylation of the biphasic kinetics substrate (S)-naproxen, and the CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants are associated with lower rates of (S)-naproxen demethylation.	Naproxen	174-186	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
17686967-1	2007	CYP2C9 catalyzes the demethylation of the biphasic kinetics substrate (S)-naproxen, and the CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants are associated with lower rates of (S)-naproxen demethylation.	Naproxen	174-186	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	92-98
17686967-1	2007	CYP2C9 catalyzes the demethylation of the biphasic kinetics substrate (S)-naproxen, and the CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants are associated with lower rates of (S)-naproxen demethylation.	Naproxen	174-186	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	92-98
17553913-5	2007	Naproxen (K(i) = 52 microM), mefenamic acid (K(i) = 39 microM), and tolfenamic acid (K(i) = 50 microM) inhibited TPMT activity in a noncompetitive manner.	Naproxen	0-8	thiopurine S-methyltransferase	Homo sapiens	113-117
17554529-8	2007	Figure Fluorescence polarization displacement titration of dansylsarcosine (3D-structure as insert) bound to human serum albumin (HSA) by naproxene.	Naproxen	138-147	albumin	Homo sapiens	115-128
17652209-4	2007	Using fluorescence to monitor uptake, we demonstrated that SCC-25 cell monolayers transport naproxen with a Michaelis constant (K(m)) and maximum velocity (V(max)) of 164 microg/mL and 0.94 ng/min/microg protein, respectively.	Naproxen	92-100	serpin family B member 3	Homo sapiens	59-62
17652209-9	2007	Thus, SCC-25 cells possess transporters for naproxen.	Naproxen	44-52	serpin family B member 3	Homo sapiens	6-9
17594377-13	2007	According to the results of the only RCT, a 6-week course of the non-selective cyclooxygenase (COX) inhibitor naproxen may lead to slightly better OHQoL in patients with temporomandibular joint (TMJ) arthralgia than the selective COX-2 inhibitor celecoxib.	Naproxen	110-118	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	230-235
17470020-0	2007	Effect of systemically administered naproxen sodium on clinical parameters and myeloperoxidase and elastase-like activity levels in gingival crevicular fluid.	Naproxen	36-51	myeloperoxidase	Homo sapiens	79-94
19075973-6	2007	The common anti-inflammatory drugs (like aspirin, ibuprofen, and naproxen) all act by blocking the action of both the COX-1 and COX-2 enzymes.	Naproxen	65-73	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	118-123
19075973-6	2007	The common anti-inflammatory drugs (like aspirin, ibuprofen, and naproxen) all act by blocking the action of both the COX-1 and COX-2 enzymes.	Naproxen	65-73	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	128-133
17428993-7	2007	In contrast, the non-RhoA-inhibiting NSAID naproxen does not have the axon growth-promoting effects on cultured or lesioned neurons.	Naproxen	43-51	ras homolog family member A	Rattus norvegicus	21-25
17216336-10	2007	In contrast, naproxen nearly completely inhibited COX-1 over the dosing interval.	Naproxen	13-21	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	50-55
17488481-3	2007	In order to evaluate if selective (celecoxib, rofecoxib) and non-selective (aspirin, naproxen) anti-inflammatory compounds could decrease PGI2 production in endothelial cells by inhibiting PGIS, we analyzed the effect of anti-inflammatory compounds on the enzyme activity by ELISA assay after addition of exogenous substrate, on PGIS protein levels by Western blotting and on its subcellular distribution by confocal microscopy.	Naproxen	85-93	prostaglandin I2 synthase	Homo sapiens	189-193
17409433-6	2007	The most efficacious compounds for induction of p75(NTR) and decreased survival, in rank-order, were R-flurbiprofen, ibuprofen, oxaprozin, fenoprofen, naproxen, and ketoprofen.	Naproxen	151-159	TNF receptor superfamily member 1B	Homo sapiens	48-51
17409433-6	2007	The most efficacious compounds for induction of p75(NTR) and decreased survival, in rank-order, were R-flurbiprofen, ibuprofen, oxaprozin, fenoprofen, naproxen, and ketoprofen.	Naproxen	151-159	neurotensin receptor 1	Homo sapiens	52-55
17157900-3	2007	METHODS: Ninety-seven patients who were scheduled for elective PCI were randomized either for naproxen sodium (500 mg bid) (n:39, 75% male, 59+/-10 years) or control (n:58, 76% male, 60+/-10 years).	Naproxen	94-109	BH3 interacting domain death agonist	Homo sapiens	118-121
17005917-7	2007	Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model.	Naproxen	34-42	ATP binding cassette subfamily C member 2	Homo sapiens	87-91
17005917-7	2007	Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model.	Naproxen	34-42	ATP binding cassette subfamily C member 4	Homo sapiens	97-101
17157900-7	2007	After coronary stenting, the rise in CRP levels was significantly higher in controls than those treated with naproxen (DeltaCRP=6.4 mg/L in the controls and 0.43 mg/L in the naproxen group, p<0.0001).	Naproxen	109-117	C-reactive protein	Homo sapiens	37-40
17157900-7	2007	After coronary stenting, the rise in CRP levels was significantly higher in controls than those treated with naproxen (DeltaCRP=6.4 mg/L in the controls and 0.43 mg/L in the naproxen group, p<0.0001).	Naproxen	174-182	C-reactive protein	Homo sapiens	37-40
17157900-10	2007	CONCLUSION: Our data show that naproxen pretreatment leads to significant suppression in PCI related CRP elevation.	Naproxen	31-39	C-reactive protein	Homo sapiens	101-104
17213165-0	2006	Review: Selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs.	Naproxen	82-90	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	18-23
17023006-0	2006	The effects of G-CSF and naproxen sodium on the serum TGF-beta1 level and fracture healing in rat tibias.	Naproxen	25-40	transforming growth factor, beta 1	Rattus norvegicus	54-63
17023006-4	2006	In this study, the effects of the NSAID naproxen sodium, G-CSF, and both of them in combination on the TGF-beta1 serum level in rats with tibia fractures were measured and fracture healing was evaluated by histopathologic and radiologic examination.	Naproxen	40-55	transforming growth factor, beta 1	Rattus norvegicus	103-112
17023006-6	2006	At the end of the first week, TGF-beta1 levels were significantly lower in naproxen-treated rats than those of the other groups excluding control (p = 0.002).	Naproxen	75-83	transforming growth factor, beta 1	Rattus norvegicus	30-39
17023006-11	2006	The results point to the negative effect of naproxen sodium on fracture healing is due to its decreasing effect on the level of TGF-beta1, which may be a new possible mechanism.	Naproxen	44-59	transforming growth factor, beta 1	Rattus norvegicus	128-137
17022718-11	2006	The risk for digestive hemorrhage associated with the CYP2C9 genotype is particularly relevant when using aceclofenac, celecoxib, diclofenac, ibuprofen, indomethacin, lornoxicam, piroxicam, or naproxen.	Naproxen	193-201	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	54-60
17125386-0	2006	Binding of naproxen and amitriptyline to bovine serum albumin: biophysical aspects.	Naproxen	11-19	albumin	Homo sapiens	48-61
17125386-1	2006	Binding of the drugs naproxen (which is an anti-inflammatory) and amitriptyline (which is an anti-depressant) to bovine serum albumin (BSA) has been studied using isothermal titration calorimetry (ITC), in combination with fluorescence and circular dichroism spectroscopies.	Naproxen	21-29	albumin	Homo sapiens	120-133
17080978-0	2006	Review: selective COX-2 inhibitors increase vascular events more than placebo and naproxen, but not more than other NSAIDs.	Naproxen	82-90	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	18-23
16815961-7	2006	Benzbromarone altered naproxen demethylation kinetics from a biphasic profile to that of a hyperbolic form in CYP2C9.1 and CYP2C9.3, resulting in inhibition and activation, respectively.	Naproxen	22-30	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	123-129
16815961-8	2006	In contrast, benz(meth)arone activated naproxen demethylation in both CYP2C9.1 and CYP2C9.3.	Naproxen	39-47	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	70-76
16815961-8	2006	In contrast, benz(meth)arone activated naproxen demethylation in both CYP2C9.1 and CYP2C9.3.	Naproxen	39-47	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	83-89
16632760-5	2006	Naproxen transport was most efficient at neutral pH and was significantly enhanced upon cell treatment with TNF-alpha.	Naproxen	0-8	tumor necrosis factor	Homo sapiens	108-117
16682968-3	2006	The current investigation characterises the inhibition of prostaglandin E2 (PGE(2)) and thromboxane B2 (TXB(2)) by naproxen in vitro and in vivo in rat and human blood.	Naproxen	115-123	UDP glucuronosyltransferase 1 family, polypeptide A2	Rattus norvegicus	100-110
16257278-7	2006	Conversely, only the high OA group showed a significant inhibition of IGF-1 production when PGE2 synthesis was reduced with Naproxen, a non-steroidal antiinflammatory drug (NSAID) that inhibits cyclooxygenases (COX).	Naproxen	124-132	insulin like growth factor 1	Homo sapiens	70-75
17402229-3	2006	In the state of equilibrium the solubilizing properties of aqueous solutions of the products of oxyetyenation of UDOCh acid x nTE were estimated with respect to non-steroidal therapeutic agents such as diclofenac, ibuprofen, ketoprofen, and naproxen.	Naproxen	241-249	patatin like phospholipase domain containing 6	Homo sapiens	126-129
16444599-3	2006	Non-steroidal anti-inflammatory drugs (NSAIDS), piroxicam, aspirin, ibuprofen, naproxen and celecoxib all specifically inhibited tNOX activity of HeLa (human cervical carcinoma) and BT-20 (human mammary carcinoma) cells (IC(50) in the nanomolar range) without effect on ECTO-NOX activities of non-cancer MCF-10A mammary epithelial cells.	Naproxen	79-87	ecto-NOX disulfide-thiol exchanger 2	Homo sapiens	129-133
16444599-3	2006	Non-steroidal anti-inflammatory drugs (NSAIDS), piroxicam, aspirin, ibuprofen, naproxen and celecoxib all specifically inhibited tNOX activity of HeLa (human cervical carcinoma) and BT-20 (human mammary carcinoma) cells (IC(50) in the nanomolar range) without effect on ECTO-NOX activities of non-cancer MCF-10A mammary epithelial cells.	Naproxen	79-87	tripartite motif containing 33	Homo sapiens	270-274
16445867-6	2006	RESULTS: Results showed significant risk reductions for selective COX-2 inhibitors as a group (OR = 0.29, 95% CI = 0.14-0.59), regular aspirin (OR = 0.49, 95% CI = 0.26-0.94), and ibuprofen or naproxen (0.36, 95% CI = 0.18-0.72).	Naproxen	193-201	prostaglandin-endoperoxide synthase 2	Homo sapiens	66-71
16183274-2	2005	We report that some other NSAIDs (diclofenac and naproxen) also inhibit AKR1C3, with the IC(50) values in the low micromolar range.	Naproxen	49-57	aldo-keto reductase family 1 member C3	Homo sapiens	72-78
17154669-3	2006	These patients develop cross-reactions to other, chemically non-related, NSAIDs with strong inhibitory activity towards cyclo-oxygenase (COX)-1 (e.g. indomethacin, naproxen, ketoprofen).	Naproxen	164-172	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	120-143
16168964-2	2005	This report compares two CINODs, NMI-1182 (naproxen-glyceryl dinitrate) and AZD3582 (naproxen-n-butyl nitrate), for their ability to inhibit COX-1 and -2, deliver bioavailable nitric oxide, and release naproxen, using in vitro biochemical and pharmacological methods.	Naproxen	43-51	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	141-153
16081671-2	2005	There was an excellent correlation between IC(50, apparent) values determined using diclofenac and naproxen as CYP2C9 substrates (r2 = 0.82, p < 0.0001), with values being generally higher in the naproxen assay.	Naproxen	99-107	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	111-117
16262557-3	2005	As examples, ketorolac, flurbiprofen, ketoprofen and indomethacin have increased COX-1 selectivity when compared with naproxen and ibuprofen.	Naproxen	118-126	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	81-86
16193661-1	2005	Non-narcotic analgetics sodium diclofenac, indomethacin, naproxen, nimesulid, ketorolac, and celebrex (cytochrome P-450(2)c substrates) produce more pronounced and prolonged analgesic effect in pubertate female rats than in males.	Naproxen	57-65	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	103-119
16083531-4	2005	Non-selective NSAIDs such as ibuprofen and naproxen, which inhibit both COX-1 and COX-2, have proven highly effective and safe in the short-term management of acute pain.	Naproxen	43-51	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	72-77
16083531-4	2005	Non-selective NSAIDs such as ibuprofen and naproxen, which inhibit both COX-1 and COX-2, have proven highly effective and safe in the short-term management of acute pain.	Naproxen	43-51	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	82-87
16187975-0	2005	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.	Naproxen	0-10	beta-1,3-glucuronyltransferase 2	Homo sapiens	97-125
16187975-0	2005	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.	Naproxen	0-10	beta-1,3-glucuronyltransferase 2	Homo sapiens	127-130
16187975-0	2005	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.	Naproxen	24-32	beta-1,3-glucuronyltransferase 2	Homo sapiens	97-125
16187975-8	2005	UGT 1A1, 1A3, 1A6, 1A7, 1A8, 1A9, 1A10 and 2B7 glucuronidated naproxen.	Naproxen	62-70	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-7
16372823-16	2005	COX-2 selectivity of lumiracoxib is associated with a reduced incidence of gastroduodenal erosions compared with naproxen and a lack of effect on both small and large bowel permeability.	Naproxen	113-121	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-5
15962179-9	2005	We found that NSAIDs inhibited both the peroxidation and chlorinating activity of MPO as follows: diclofenac (36 +/- 10, 45 +/- 3%), indomethacin (97 +/- 2, 100 +/- 1%), naproxen (56 +/- 8, 76 +/- 3%), piroxicam (77 +/- 5, 99 +/- 1%), and tenoxicam (90 +/- 2, 100 +/- 1%), respectively (N = 3).	Naproxen	170-178	myeloperoxidase	Rattus norvegicus	82-85
15705740-10	2005	Similarly the inhibitory effects of the cyclo-oxygenase-2 selective inhibitor rofecoxib or the mixed cyclo-oxygenase-1/cyclo-oxygenase-2 inhibitors ibuprofen and naproxen were significant reduced by t-butylOOH.	Naproxen	162-170	prostaglandin-endoperoxide synthase 2	Homo sapiens	40-57
15705740-10	2005	Similarly the inhibitory effects of the cyclo-oxygenase-2 selective inhibitor rofecoxib or the mixed cyclo-oxygenase-1/cyclo-oxygenase-2 inhibitors ibuprofen and naproxen were significant reduced by t-butylOOH.	Naproxen	162-170	prostaglandin-endoperoxide synthase 1	Homo sapiens	101-136
15801029-9	2005	Under these conditions, naproxen treatment induced a higher level of IL-1beta production.	Naproxen	24-32	interleukin 1 beta	Homo sapiens	69-77
15892673-4	2005	Non-selective cyclooxygenase-1 (COX-1) inhibitors used in periodontal research include compounds such as aspirin, flurbiprofen, ibuprofen, naproxen and piroxicam.	Naproxen	139-147	prostaglandin-endoperoxide synthase 1	Homo sapiens	14-30
15892673-4	2005	Non-selective cyclooxygenase-1 (COX-1) inhibitors used in periodontal research include compounds such as aspirin, flurbiprofen, ibuprofen, naproxen and piroxicam.	Naproxen	139-147	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	32-37
15593193-9	2004	In the presence of TGFbeta1 plus 1,25(OH)(2)D(3), naproxen, but not licofelone, induced MMP-1 production and both drugs decreased nitric oxide levels.	Naproxen	50-58	transforming growth factor beta 1	Homo sapiens	19-27
15593193-9	2004	In the presence of TGFbeta1 plus 1,25(OH)(2)D(3), naproxen, but not licofelone, induced MMP-1 production and both drugs decreased nitric oxide levels.	Naproxen	50-58	matrix metallopeptidase 1	Homo sapiens	88-93
15837265-8	2005	Moreover, the rapid recovery of platelet COX-1 activity and function supports the occurrence of a pharmacodynamic interaction between naproxen and aspirin.	Naproxen	134-142	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	41-46
15837265-9	2005	CONCLUSIONS: Naproxen interfered with the inhibitory effect of aspirin on platelet COX-1 activity and function.	Naproxen	13-21	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	83-88
15745101-2	2005	However, its potential restorative impact on gastric mucus and mucin production impairment, resulting from administration of naproxen, remained to be explored.	Naproxen	125-133	LOC100508689	Homo sapiens	63-68
15745101-8	2005	Gastric mucin secretion during naproxen/placebo administration also declined significantly in both basal (by 39%; P < 0.01) and stimulated (by 49%; P = 0.003) conditions.	Naproxen	31-39	LOC100508689	Homo sapiens	8-13
15745101-9	2005	Rabeprazole also significantly restored the naproxen-induced decline of gastric mucin output during pentagastrin-stimulated conditions (by 67%; P = 0.003) and by 40% in basal conditions (P = 0.05).	Naproxen	44-52	LOC100508689	Homo sapiens	80-85
15745101-10	2005	The restorative capacity of rabeprazole on the quantitative impairment of gastric mucus and mucin during administration of naproxen may translate into a clinical benefit of protection of the upper alimentary tract from NSAID-related mucosal injury.	Naproxen	123-131	LOC100508689	Homo sapiens	92-97
16431382-0	2005	Competitive binding of ibuprofen and naproxen to bovine serum albumin : modified form of drug-drug displacement interaction at the binding site.	Naproxen	37-45	albumin	Homo sapiens	56-69
16431382-1	2005	The competitive binding characteristics of ibuprofen and naproxen with respect to binding site on bovine serum albumin (BSA) was studied by equilibrium dialysis method at pH 7.4 and 25 degrees C. We studied the effect of one drug on the free concentration of another in vitro during concurrent administration.	Naproxen	57-65	albumin	Homo sapiens	105-118
15177303-1	2004	The use of the new selective cyclooxygenase-2 (COX-2) inhibitors (such as celecoxib and rofecoxib) for the treatment of pain and inflammation caused by fractures, cementless total joint replacements, soft tissue healing to bone, and spinal fusion surgeries has been controversial due to the convincing data collected from nonspecific NSAIDs such as indomethacin and naproxen regarding their inhibitory effects on bone healing and the similar effects of COX-2 specific NSAIDs in animal models.	Naproxen	366-374	prostaglandin-endoperoxide synthase 2	Homo sapiens	29-45
15327804-9	2004	Dual COX-1 and COX-2 inhibition with naproxen was demonstrated to be effective for the treatment of painful TMJs, as seen by significant improvement in clinical signs and symptoms of TMJ DD with reduction compared to celecoxib and placebo.	Naproxen	37-45	prostaglandin-endoperoxide synthase 2	Homo sapiens	15-20
15177303-1	2004	The use of the new selective cyclooxygenase-2 (COX-2) inhibitors (such as celecoxib and rofecoxib) for the treatment of pain and inflammation caused by fractures, cementless total joint replacements, soft tissue healing to bone, and spinal fusion surgeries has been controversial due to the convincing data collected from nonspecific NSAIDs such as indomethacin and naproxen regarding their inhibitory effects on bone healing and the similar effects of COX-2 specific NSAIDs in animal models.	Naproxen	366-374	prostaglandin-endoperoxide synthase 2	Homo sapiens	47-52
15276689-5	2004	The oral and intrathecally administered tramadol, a mu-opioid and naproxen, a nonselective COX inhibitor produced dose-dependent antinociception, however, rofecoxib, a selective COX-2 inhibitor lacked analgesic efficacy in writhing test.	Naproxen	66-74	cytochrome c oxidase II, mitochondrial	Mus musculus	178-183
15276689-9	2004	The results demonstrated marked synergistic interaction between naproxen and tramadol and such interaction involved opioid as well as non-opioid mechanisms of tramadol and inhibition of COX-1 but not COX-2 by naproxen.	Naproxen	64-72	cytochrome c oxidase I, mitochondrial	Mus musculus	186-191
15276689-9	2004	The results demonstrated marked synergistic interaction between naproxen and tramadol and such interaction involved opioid as well as non-opioid mechanisms of tramadol and inhibition of COX-1 but not COX-2 by naproxen.	Naproxen	209-217	cytochrome c oxidase I, mitochondrial	Mus musculus	186-191
12953342-0	2003	Naproxen 500 mg bid versus acetaminophen 1000 mg qid: effect on swelling and other acute postoperative events after bilateral third molar surgery.	Naproxen	0-8	BH3 interacting domain death agonist	Homo sapiens	16-19
14510637-3	2004	With the detergent genapol X-100 (2 mM) present, the potencies of nimesulide, ibuprofen, flufenamic acid, niflumic acid and naproxen were increased over 100-fold against Cox-2 and titration curve shapes changed, so that maximal inhibition now approached 100%.	Naproxen	124-132	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	170-175
14655004-5	2003	The clinical efficacy of the marketed COX-2 inhibitors has been proved in large phase III clinical trials in comparison to both placebo and classical NSAIDs (e.g. diclofenac, naproxen).	Naproxen	175-183	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	38-43
12842341-2	2003	Therefore, zinc complex of naproxen was prepared by adding zinc sulfate to an aqueous solution of sodium naproxen and its structure was characterized by IR, 1H NMR and 13C NMR, UV, DSC, atomic absorption spectroscopy, and elemental analysis.	Naproxen	27-35	desmocollin 3	Homo sapiens	181-184
12730088-8	2003	Naproxen and aspirin significantly suppressed thrombin generation.	Naproxen	0-8	coagulation factor II, thrombin	Homo sapiens	46-54
12811683-1	2003	NO-naproxen, consisting of the NSAID naproxen linked to a nitric oxide (NO) moiety, is under development by AstraZeneca plc, under license from NicOx SA, for the potential treatment of acute/chronic pain.	Naproxen	3-11	heparan sulfate proteoglycan 2	Homo sapiens	120-123
15130760-1	2004	Studies have shown that CYP2C9.1 mediated metabolism of flurbiprofen or naproxen is activated by co-incubation with dapsone.	Naproxen	72-80	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	24-30
15130760-5	2004	In similar experiments using the substrate naproxen, dapsone increased the efficiency of naproxen demethylation 7-, 15-, 13-, and 22-fold, in CYP2C9.1, CYP2C9.2, CYP2C9.3, and CYP2C9.5, respectively.	Naproxen	43-51	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	142-148
15130760-5	2004	In similar experiments using the substrate naproxen, dapsone increased the efficiency of naproxen demethylation 7-, 15-, 13-, and 22-fold, in CYP2C9.1, CYP2C9.2, CYP2C9.3, and CYP2C9.5, respectively.	Naproxen	89-97	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	142-148
15130760-5	2004	In similar experiments using the substrate naproxen, dapsone increased the efficiency of naproxen demethylation 7-, 15-, 13-, and 22-fold, in CYP2C9.1, CYP2C9.2, CYP2C9.3, and CYP2C9.5, respectively.	Naproxen	89-97	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	152-158
15130760-5	2004	In similar experiments using the substrate naproxen, dapsone increased the efficiency of naproxen demethylation 7-, 15-, 13-, and 22-fold, in CYP2C9.1, CYP2C9.2, CYP2C9.3, and CYP2C9.5, respectively.	Naproxen	89-97	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	152-158
15130760-5	2004	In similar experiments using the substrate naproxen, dapsone increased the efficiency of naproxen demethylation 7-, 15-, 13-, and 22-fold, in CYP2C9.1, CYP2C9.2, CYP2C9.3, and CYP2C9.5, respectively.	Naproxen	89-97	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	152-158
15130760-6	2004	Also, dapsone normalized naproxen"s kinetic profile from biphasic (CYP2C9.1 and CYP2C9.2) or linear (CYP2C9.3 and CYP2C9.5) to hyperbolic for all variant forms.	Naproxen	25-33	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	67-73
15130760-6	2004	Also, dapsone normalized naproxen"s kinetic profile from biphasic (CYP2C9.1 and CYP2C9.2) or linear (CYP2C9.3 and CYP2C9.5) to hyperbolic for all variant forms.	Naproxen	25-33	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	80-86
15130760-6	2004	Also, dapsone normalized naproxen"s kinetic profile from biphasic (CYP2C9.1 and CYP2C9.2) or linear (CYP2C9.3 and CYP2C9.5) to hyperbolic for all variant forms.	Naproxen	25-33	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	80-86
15130760-6	2004	Also, dapsone normalized naproxen"s kinetic profile from biphasic (CYP2C9.1 and CYP2C9.2) or linear (CYP2C9.3 and CYP2C9.5) to hyperbolic for all variant forms.	Naproxen	25-33	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	80-86
14726152-5	2004	Naproxen did not modify 45Ca(2+) uptake by inside-out plasma membrane vesicles, but it inhibited the hexokinase/glucose-induced Ca(2+) efflux from preloaded vesicles.	Naproxen	0-8	hexokinase 1	Homo sapiens	101-111
12783912-12	2003	RESULTS: The 1-year mean (SD) change in ADAS-Cog scores in participants treated with naproxen (5.8 [8.0]) or rofecoxib (7.6 [7.7]) was not significantly different from the change in participants treated with placebo (5.7 [8.2]).	Naproxen	85-93	alkylglycerone phosphate synthase	Homo sapiens	40-44
12445672-7	2003	Ibuprofen and naproxen exhibited 59 and 95% COX-1, and 53 and 79% COX-2 inhibitory activities, respectively.	Naproxen	14-22	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	44-49
12852704-1	2003	BACKGROUND: Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac, ibuprofen, naproxen, and related agents are nonselective inhibitors of both cyclooxygenase-1 (COX-1) and COX-2, which catalyze prostaglandin synthesis.	Naproxen	101-109	prostaglandin-endoperoxide synthase 1	Homo sapiens	166-182
12852704-1	2003	BACKGROUND: Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac, ibuprofen, naproxen, and related agents are nonselective inhibitors of both cyclooxygenase-1 (COX-1) and COX-2, which catalyze prostaglandin synthesis.	Naproxen	101-109	prostaglandin-endoperoxide synthase 1	Homo sapiens	184-189
12852704-1	2003	BACKGROUND: Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac, ibuprofen, naproxen, and related agents are nonselective inhibitors of both cyclooxygenase-1 (COX-1) and COX-2, which catalyze prostaglandin synthesis.	Naproxen	101-109	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	195-200
12445672-7	2003	Ibuprofen and naproxen exhibited 59 and 95% COX-1, and 53 and 79% COX-2 inhibitory activities, respectively.	Naproxen	14-22	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	66-71
11968070-2	2002	Nine first-order kinetic rate constants for the hydrolysis and acyl migration between the beta-l-O-acyl glucuronide, its alpha/beta-2, alpha/beta-3-, alpha/beta-4-, and alpha-1-O-acyl isomers and naproxen aglycone were determined for I and II at pH 7.00, 7.40 and 8.00 at 37 degrees C by kinetic simulation.	Naproxen	196-204	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	127-178
12508788-0	2002	A selective COX-2 inhibitor, meloxicam, as a treatment option in patients with juvenile idiopathic arthritis and gastrointestinal side effects from naproxen.	Naproxen	148-156	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	12-17
12489538-3	2002	It was found that a chiral drug Naproxen (A21) was a highly efficient additive for Ti-catalyzed HDA reaction, affording 2-substituted 2,3-dihydro-4H-pyran-4-one in up to 97 % ee and >99 % yields.	Naproxen	32-40	immunoglobulin kappa variable 2-26 (pseudogene)	Homo sapiens	42-45
12427115-2	2002	Ambroxol decreased the inactivation or destruction of alpha1-antiproteinase induced by peroxynitrite (ONOO-) or hypochlorous acid (HOCl), which was similar to penicillamine and glutathione and was greater than diclofenac sodium and naproxen sodium.	Naproxen	232-247	serpin family A member 1	Homo sapiens	54-75
12234061-9	2002	Indomethacin, naproxen and tiaprofenic acid stimulated the release of PAI-1 into culture media, whereas meloxicam also induced expression of PAI-1 above IL-1 stimulated levels.	Naproxen	14-22	serpin family E member 1	Bos taurus	70-75
12190122-6	2002	The acute rabbit kidney (RK13) cell apoptosis (cell death in < 5 h) induced by apical or basal application of MDP was associated with glutamate (Glu) release, decreased gamma-glutamyltranspeptidase (GGT) and acidosis and was suppressed by Indomethacin, Naproxen and Curcumin.	Naproxen	256-264	dipeptidase 1	Homo sapiens	113-116
11755111-7	2001	On PGHS-2, the ibuprofen isomers showed no selectivity, and indomethacin, S(+)-ibuprofen, and S(+)-naproxen were 6-, 27-, and 5-fold more potent as inhibitors of PGHS-1 than PGHS-2 activity.	Naproxen	94-107	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	162-168
11901091-3	2002	To this end, the kinetic profiles of three model CYP2C9 substrates (flurbiprofen, naproxen, and piroxicam) were studied using purified CYP2C9*1 (wild-type) and variants involving active site amino acid changes, including the naturally occurring variants CYP2C9*3 (Leu359) and CYP2C9*5 (Glu360) and the man-made mutant CYP2C9 F114L.	Naproxen	82-90	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	49-55
11901091-4	2002	CYP2C9*1 (wild-type) metabolized each of the three compounds with a distinctive profile reflective of typical hyperbolic (flurbiprofen), biphasic (naproxen), and substrate inhibition (piroxicam) kinetics.	Naproxen	147-155	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
11901091-5	2002	CYP2C9*3 metabolism was again hyperbolic for flurbiprofen, of a linear form for naproxen (no saturation noted), and exhibited substrate inhibition with piroxicam.	Naproxen	80-88	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
11901091-6	2002	CYP2C9*5-mediated metabolism was hyperbolic for flurbiprofen and piroxicam but linear with respect to naproxen turnover.	Naproxen	102-110	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
11755111-7	2001	On PGHS-2, the ibuprofen isomers showed no selectivity, and indomethacin, S(+)-ibuprofen, and S(+)-naproxen were 6-, 27-, and 5-fold more potent as inhibitors of PGHS-1 than PGHS-2 activity.	Naproxen	94-107	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	174-180
11696466-2	2001	Among the randomized, controlled trials with the COX-2 inhibitor rofecoxib, one study demonstrated a significant difference between rofecoxib and its NSAID comparator (naproxen) in the risk of CV thrombotic events.	Naproxen	168-176	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	49-54
11593916-0	2001	[Effect of naproxen on serum concentrations of IL-I, IL-6, and TNF in patients with osteoarthritis].	Naproxen	11-19	tumor necrosis factor	Homo sapiens	63-66
11525777-14	2001	Plasma from nabumetone-treated subjects showed no or little selectivity towards cyclooxygenase-1 depending on the dose of drug administered, while plasma taken from subjects receiving naproxen was more active at inhibiting cyclooxygenase-1 than cyclooxygenase-2.	Naproxen	184-192	prostaglandin-endoperoxide synthase 1	Homo sapiens	223-239
11525777-14	2001	Plasma from nabumetone-treated subjects showed no or little selectivity towards cyclooxygenase-1 depending on the dose of drug administered, while plasma taken from subjects receiving naproxen was more active at inhibiting cyclooxygenase-1 than cyclooxygenase-2.	Naproxen	184-192	prostaglandin-endoperoxide synthase 2	Homo sapiens	245-261
11838318-9	2001	Nimesulide (2 mg/kg), naproxen (10 mg/kg) and rofecoxib (2 mg/kg) significantly reversed LPS-mediated despair behavior.	Naproxen	22-30	toll-like receptor 4	Mus musculus	89-92
11457482-0	2001	Localization of cyclooxygenase isozymes in cardiovascular tissues of dogs treated with naproxen.	Naproxen	87-95	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	16-30
11457482-9	2001	Animals treated with naproxen exhibited a similar pattern and intensity of cyclooxygenase-1 staining.	Naproxen	21-29	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	75-91
11593916-3	2001	Our objective was to assess the effect of naproxen on the serum levels of IL-I, IL-6 and TNF in 18 patients with osteoarthritis.	Naproxen	42-50	interleukin 6	Homo sapiens	80-84
11593916-3	2001	Our objective was to assess the effect of naproxen on the serum levels of IL-I, IL-6 and TNF in 18 patients with osteoarthritis.	Naproxen	42-50	tumor necrosis factor	Homo sapiens	89-92
11593916-7	2001	RESULTS: Serum IL-I and IL-6 levels were reduced in the group receiving naproxen, suggesting a reduction of the degenerative changes in the patients with osteoarthritis, that may prevent the progression of the disease.	Naproxen	72-80	interleukin 6	Homo sapiens	24-28
11467888-10	2001	Transcript levels of MMP-1, however, were only reduced by indomethacin, meloxicam, naproxen and dexamethasone.	Naproxen	83-91	interstitial collagenase	Bos taurus	21-26
11484831-6	2001	Naproxen, tiaprofenic acid and piroxicam caused a decrease in GST activity at therapeutic doses.	Naproxen	0-8	glutathione S-transferase kappa 1	Homo sapiens	62-65
11513245-10	2001	Covalent NAP-protein adducts in the liver increased as the dose changed from NAP to NAG to isoNAG (0.20 to 0.34 to 0.48% of the doses, respectively).	Naproxen	9-12	sodium voltage-gated channel alpha subunit 7	Rattus norvegicus	84-87
11142556-6	2000	Despite inhibiting of PGE2 generation, both nitric oxide-releasing derivatives and native aspirin and naproxen failed to affect expression of cyclooxygenase-1 mRNA but upregulated the cyclooxygenase-2 mRNA.	Naproxen	102-110	prostaglandin-endoperoxide synthase 2	Homo sapiens	184-200
11428674-2	2001	In the present study, it was aimed to prepare Naproxen Sodium (NS), (a NSAID) loaded microsphere formulation using natural Bovine Serum Albumin (BSA) and synthetic biodegradable polymers such as poly(lactide-co-glycolic acid) (PLGA) (50:50 MW 34,000 and 88,000 Da) for intra-articular administration, and to study the retention of the drug at the site of injection in the knee joint.	Naproxen	46-61	albumin	Oryctolagus cuniculus	130-143
11428674-2	2001	In the present study, it was aimed to prepare Naproxen Sodium (NS), (a NSAID) loaded microsphere formulation using natural Bovine Serum Albumin (BSA) and synthetic biodegradable polymers such as poly(lactide-co-glycolic acid) (PLGA) (50:50 MW 34,000 and 88,000 Da) for intra-articular administration, and to study the retention of the drug at the site of injection in the knee joint.	Naproxen	63-65	albumin	Oryctolagus cuniculus	130-143
11315999-8	2001	Interestingly, OA osteoblasts produced more prostaglandin E2 (PGE2) than normal osteoblasts, and using naproxen, a cyclo-oxygenase inhibitor, increased PTH-dependent cAMP formation to a level similar to normal osteoblasts.	Naproxen	103-111	parathyroid hormone	Homo sapiens	152-155
11298095-5	2001	Cultured tumour cells showed IL-6 protein synthesis, and nonsteroidal anti-inflammatory drugs such as naproxen and indomethacin directly inhibited IL-6 release.	Naproxen	102-110	interleukin 6	Homo sapiens	147-151
11298095-6	2001	These results indicate that the effects of naproxen in vivo were due, at least in part, to direct suppression of IL-6 secretion from the tumour.	Naproxen	43-51	interleukin 6	Homo sapiens	113-117
11171823-0	2001	Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen.	Naproxen	120-128	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	24-29
11171823-9	2001	Naproxen abolished platelet aggregation to arachidonic acid and suppressed serum thromboxane B(2) (TXB(2)) by 98%, indices of COX-1 activity.	Naproxen	0-8	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	126-131
11171823-11	2001	Production of prostaglandin E(2) and prostacyclin by gastric biopsies, also COX-1 dependent, was inhibited by naproxen, but not by nimesulide.	Naproxen	110-118	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	76-81
11028250-0	2000	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.	Naproxen	84-92	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	96-101
11028250-0	2000	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.	Naproxen	84-92	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	109-114
10924050-7	2000	In studies of anesthetized rats, naproxen significantly enhanced the late hypertensive response to endothelin-1 and significantly blunted the early hypotensive response.	Naproxen	33-41	endothelin 1	Rattus norvegicus	99-111
10825559-1	2000	Naproxen sodium (NS) release mechanism from proteineous matrices based on egg albumin (EA) and bovine serum albumin (BSA) was investigated by several physico-chemical methods.	Naproxen	0-15	albumin	Homo sapiens	102-115
10826459-10	2000	CONCLUSIONS: The results indicate that cyclooxygenase 2-specific inhibition in healthy elderly subjects may spare renal hemodynamic function, although the effects on sodium excretion, as well as urinary prostaglandin E2 and 6-keto-prostaglandin F1alpha excretion, appear to be similar to those of nonspecific cyclooxygenase inhibitors such as naproxen.	Naproxen	343-351	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-55
10909271-1	2000	Inhibitory effect of naproxene and its 7-methoxy isomer on constitutive COX-1 and inducible COX-2.	Naproxen	21-30	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	72-77
10909271-1	2000	Inhibitory effect of naproxene and its 7-methoxy isomer on constitutive COX-1 and inducible COX-2.	Naproxen	21-30	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	92-97
10909271-3	2000	We evaluated the ability of naproxene and its 7-methoxy isomer to abrogate constitutive COX-1 and inducible COX-2 activity in human A549 cells.	Naproxen	28-37	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	88-93
10909271-3	2000	We evaluated the ability of naproxene and its 7-methoxy isomer to abrogate constitutive COX-1 and inducible COX-2 activity in human A549 cells.	Naproxen	28-37	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	108-113
10909271-4	2000	Naproxene inhibited COX-1 (IC50 = 3.42 microM) and COX-2 (IC50 = 1.53 microM), whereas the 7-methoxy isomer had no appreciable effect on COX-1 (IC50 >> 100 microM) but also abrogated the activity of COX-2 enzyme (IC50 = 14.42 microM).	Naproxen	0-9	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	20-25
10909271-4	2000	Naproxene inhibited COX-1 (IC50 = 3.42 microM) and COX-2 (IC50 = 1.53 microM), whereas the 7-methoxy isomer had no appreciable effect on COX-1 (IC50 >> 100 microM) but also abrogated the activity of COX-2 enzyme (IC50 = 14.42 microM).	Naproxen	0-9	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	51-56
10909271-4	2000	Naproxene inhibited COX-1 (IC50 = 3.42 microM) and COX-2 (IC50 = 1.53 microM), whereas the 7-methoxy isomer had no appreciable effect on COX-1 (IC50 >> 100 microM) but also abrogated the activity of COX-2 enzyme (IC50 = 14.42 microM).	Naproxen	0-9	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	205-210
10903982-22	2000	In addition, NO-naproxen reduced both IL-1beta and TNFalpha plasma levels whilst naproxen reduced IL-1beta levels only.	Naproxen	16-24	interleukin 1 beta	Rattus norvegicus	38-46
10903982-22	2000	In addition, NO-naproxen reduced both IL-1beta and TNFalpha plasma levels whilst naproxen reduced IL-1beta levels only.	Naproxen	16-24	tumor necrosis factor	Rattus norvegicus	51-59
18967730-1	1999	A simple, selective and sensitive heavy atom-induced room temperature phosphorimetric method (HAI-RTP) is described for the determination of naproxen (NAP) in pharmaceutical preparations.	Naproxen	141-149	MORN repeat containing 4	Homo sapiens	98-101
10682387-4	2000	The binding percentages of the ALB-binding drugs decreased in low-ALB plasma, resulting in a large increase in unbound drug, particularly for naproxen (a 13-fold increase).	Naproxen	142-150	albumin	Canis lupus familiaris	31-34
10682387-4	2000	The binding percentages of the ALB-binding drugs decreased in low-ALB plasma, resulting in a large increase in unbound drug, particularly for naproxen (a 13-fold increase).	Naproxen	142-150	albumin	Canis lupus familiaris	66-69
10584064-6	1999	The CYP2C9 model was then used to characterize explicit enzyme complexes with three structurally and chemically diverse substrates: (S)-naproxen, phenytoin, and progesterone.	Naproxen	132-144	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	4-10
18967730-1	1999	A simple, selective and sensitive heavy atom-induced room temperature phosphorimetric method (HAI-RTP) is described for the determination of naproxen (NAP) in pharmaceutical preparations.	Naproxen	151-154	MORN repeat containing 4	Homo sapiens	98-101
18967730-3	1999	These variables selection constitute the basis of a HAI-RTP method for the determination of naproxen (detection limit 17.6 ng ml(-1); 1.71% relative standard deviation at 250 ng ml(-1)).	Naproxen	92-100	MORN repeat containing 4	Homo sapiens	56-59
10425885-0	1999	[Effect of naproxen sodium on serum concentrations of IL-1, IL-6, and TNF in patients with acute, purulent pharyngo-tonsillitis].	Naproxen	11-26	interleukin 1 beta	Homo sapiens	54-58
10425885-0	1999	[Effect of naproxen sodium on serum concentrations of IL-1, IL-6, and TNF in patients with acute, purulent pharyngo-tonsillitis].	Naproxen	11-26	interleukin 6	Homo sapiens	60-64
10425885-0	1999	[Effect of naproxen sodium on serum concentrations of IL-1, IL-6, and TNF in patients with acute, purulent pharyngo-tonsillitis].	Naproxen	11-26	tumor necrosis factor	Homo sapiens	70-73
10425885-3	1999	OBJECTIVE: Assess the effect of sodium naproxen on the serum concentration of IL-1, IL-6 and TNF in acute infectious process.	Naproxen	32-47	interleukin 1 beta	Homo sapiens	78-82
10425885-3	1999	OBJECTIVE: Assess the effect of sodium naproxen on the serum concentration of IL-1, IL-6 and TNF in acute infectious process.	Naproxen	32-47	interleukin 6	Homo sapiens	84-88
10425885-3	1999	OBJECTIVE: Assess the effect of sodium naproxen on the serum concentration of IL-1, IL-6 and TNF in acute infectious process.	Naproxen	32-47	tumor necrosis factor	Homo sapiens	93-96
10425885-9	1999	DISCUSSION: Patients receiving treatment with sodium naproxen had a statistically significant reduction of the serum concentration of IL-1b as compared to basal and 72 h measurements; there were also statistically significant differences with respect to patients receiving placebo.	Naproxen	46-61	interleukin 1 beta	Homo sapiens	134-139
10425885-11	1999	These results show that serum IL-1b levels dropped in both groups with a more striking reduction in the group receiving sodium naproxen , that also showed a faster improvement of the symptoms.	Naproxen	120-135	interleukin 1 beta	Homo sapiens	30-35
10102977-12	1999	Exposure to TNFalpha resulted in a time- and concentration-dependent HUVEC apoptosis, an effect that was prevented by pretreating the cells with NCX-4016, NO-naproxen, NO-flurbiprofen, SNP or Z-VAD.FMK, a pan-caspase inhibitor.	Naproxen	158-166	tumor necrosis factor	Homo sapiens	12-20
9920026-2	1999	METHODS: HSF were incubated with NIM (0.3, 3, and 30 microg/ml), NAP (15, 30, and 90 microg/ml), and dexamethasone (DEX; 0.01, 0.1, and 1 microM) on a time- and dose-dependent basis.	Naproxen	65-68	interleukin 6	Homo sapiens	9-12
10369402-5	1999	During the treatment period, both nimesulide and naproxen significantly inhibited COX-2-dependent PGE2 synthesis in the whole blood; however, naproxen had a lesser effect than nimesulide.	Naproxen	49-57	prostaglandin-endoperoxide synthase 2	Homo sapiens	82-87
9754723-0	1998	Role of acid and salivary epidermal growth factor in gastric mucosal adaptation to naproxen in man.	Naproxen	83-91	epidermal growth factor	Homo sapiens	26-49
9858439-11	1998	Naproxen, however, showed only a slight inhibition of IL-1beta induced NO production at the highest dose used, 90 microg/ml.	Naproxen	0-8	interleukin 1 beta	Homo sapiens	54-62
9874702-0	1999	In vitro regioselective stability of beta-1-O- and 2-O-acyl glucuronides of naproxen and their covalent binding to human serum albumin.	Naproxen	76-84	albumin	Homo sapiens	121-134
9754723-3	1998	We therefore wanted to assess the effect of acid suppression and salivary EGF output during naproxen-induced acute gastric injury and subsequent adaptation.	Naproxen	92-100	epidermal growth factor	Homo sapiens	74-77
9886235-7	1998	The feasibility of targeting naproxen to the chronically diseased liver could be clearly demonstrated: 15 min after administration of the conjugate 46% and 55% of the administered dose was found in the liver of CTR and BDL rats, whereas after injection of free naproxen only 5% and 12% of the dose was detected in liver tissue, respectively.	Naproxen	29-37	calcitonin receptor	Rattus norvegicus	211-214
9667024-8	1998	Generally, the binding affinity of HSA decreased, perhaps due to a conformational change or steric hindrance (except naproxen) when further glycosylation occurred.	Naproxen	117-125	albumin	Homo sapiens	35-38
9616184-8	1998	Drugs containing a carboxylic acid moiety, such as nonsteroidal anti-inflammatory agents (e.g. naproxen and ibuprofen) and fibrates (e.g. ciprofibrate), were substrates for human UGT1A3.	Naproxen	95-103	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	179-185
9588014-6	1998	It has been successfully applied to the assessment of the total NAP content within liver and kidney tissues of male Sprague Dawley rats that have been treated with NAP conjugated to human serum albumin (the drug targeting carrier) and free NAP.	Naproxen	164-167	albumin	Rattus norvegicus	188-201
9588014-6	1998	It has been successfully applied to the assessment of the total NAP content within liver and kidney tissues of male Sprague Dawley rats that have been treated with NAP conjugated to human serum albumin (the drug targeting carrier) and free NAP.	Naproxen	164-167	albumin	Rattus norvegicus	188-201
9521735-4	1998	Naphthalene metabolism by CYP3A4 and naproxen metabolism by CYP2C9 demonstrated nonhyperbolic enzyme kinetics suggestive of a low Km, low Vmax component for the first substrate molecule and a high Km, high Vmax component for the second substrate molecule.	Naproxen	37-45	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	60-66
9521735-5	1998	7, 8-Benzoflavone activation of phenanthrene metabolism by CYP3A4 and dapsone activation of flurbiprofen and naproxen metabolism by CYP2C9 were also observed.	Naproxen	109-117	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	132-138
9830168-3	1998	With the integrated chemiluminescence intensity for 15 s after CeIV injection as a quantitative parameter, naproxen can be determined over the concentration range 100-1000 ng ml-1 with a detection limit of 15 ng ml-1 and with RSDs (n = 10) of 0.9% and 1.5% at levels of 1000 and 100 ng ml-1, respectively.	Naproxen	107-115	interleukin 17F	Homo sapiens	175-179
9830168-3	1998	With the integrated chemiluminescence intensity for 15 s after CeIV injection as a quantitative parameter, naproxen can be determined over the concentration range 100-1000 ng ml-1 with a detection limit of 15 ng ml-1 and with RSDs (n = 10) of 0.9% and 1.5% at levels of 1000 and 100 ng ml-1, respectively.	Naproxen	107-115	interleukin 17F	Homo sapiens	212-216
9830168-3	1998	With the integrated chemiluminescence intensity for 15 s after CeIV injection as a quantitative parameter, naproxen can be determined over the concentration range 100-1000 ng ml-1 with a detection limit of 15 ng ml-1 and with RSDs (n = 10) of 0.9% and 1.5% at levels of 1000 and 100 ng ml-1, respectively.	Naproxen	107-115	interleukin 17F	Homo sapiens	212-216
9725465-4	1998	The phase diagram of the naproxen-PEG 4000 system produced by DSC and hot stage microscopy is reported.	Naproxen	25-33	desmocollin 3	Homo sapiens	62-65
9397997-3	1997	We argued that administration of naproxen (NAP) linked to human serum albumin (HSA), which results in specific delivery of NAP to endothelial cells (EC) and Kupffer cells (KC) and exhibited hepatoprotective effects against lipopolysaccharide (LPS) in vitro, could protect cirrhotic rats from LPS toxicity while preserving renal function.	Naproxen	33-41	albumin	Rattus norvegicus	64-77
9728323-16	1998	The relaxation by naproxen, phenylbutazone, piroxicam and tolmetin is presumably produced by increasing cAMP because the effects of these are antagonized with Rp-cAMPS and H-7, and by pertussis-toxin-sensitive mechanisms.	Naproxen	18-26	calmodulin 2, pseudogene 1	Rattus norvegicus	162-167
9728323-16	1998	The relaxation by naproxen, phenylbutazone, piroxicam and tolmetin is presumably produced by increasing cAMP because the effects of these are antagonized with Rp-cAMPS and H-7, and by pertussis-toxin-sensitive mechanisms.	Naproxen	18-26	solute carrier family 9 member A2	Rattus norvegicus	172-175
9728323-8	1998	The relaxant effects of naproxen, phenylbutazone, piroxicam and tolmetin were significantly antagonized with pertussis toxin (50 ng ml-1), Rp-cAMPS (100 microM) and H-7 (1 microM).	Naproxen	24-32	calmodulin 2, pseudogene 1	Rattus norvegicus	142-147
9728323-8	1998	The relaxant effects of naproxen, phenylbutazone, piroxicam and tolmetin were significantly antagonized with pertussis toxin (50 ng ml-1), Rp-cAMPS (100 microM) and H-7 (1 microM).	Naproxen	24-32	solute carrier family 9 member A2	Rattus norvegicus	165-168
9397997-3	1997	We argued that administration of naproxen (NAP) linked to human serum albumin (HSA), which results in specific delivery of NAP to endothelial cells (EC) and Kupffer cells (KC) and exhibited hepatoprotective effects against lipopolysaccharide (LPS) in vitro, could protect cirrhotic rats from LPS toxicity while preserving renal function.	Naproxen	43-46	albumin	Rattus norvegicus	64-77
9397997-3	1997	We argued that administration of naproxen (NAP) linked to human serum albumin (HSA), which results in specific delivery of NAP to endothelial cells (EC) and Kupffer cells (KC) and exhibited hepatoprotective effects against lipopolysaccharide (LPS) in vitro, could protect cirrhotic rats from LPS toxicity while preserving renal function.	Naproxen	123-126	albumin	Rattus norvegicus	64-77
9057869-1	1997	Representative nonsteroidal anti-inflammatory drug (NSAID) cyclooxygenase inhibitors such as ibuprofen, naproxen, and indomethacin were used as orally bioavailable scaffolds to design selective 5-lipoxygenase (5-LO) inhibitors.	Naproxen	104-112	arachidonate 5-lipoxygenase	Homo sapiens	194-208
9263136-3	1997	RESULTS: Tenidap, ibuprofen, and naproxen, at therapeutically attainable concentrations, significantly inhibited the proliferative response of T cells to IL-2.	Naproxen	33-41	interleukin 2	Homo sapiens	154-158
9263136-6	1997	Both ibuprofen and naproxen interfered with the binding of IL-2 to T cells.	Naproxen	19-27	interleukin 2	Homo sapiens	59-63
9272300-0	1997	Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts.	Naproxen	27-35	interleukin 6	Homo sapiens	79-83
9272300-0	1997	Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts.	Naproxen	27-35	serpin family E member 1	Homo sapiens	101-106
9272300-1	1997	OBJECTIVES: To evaluate the effect of therapeutic and pharmacologic concentrations of two non-steroidal anti-inflammatory drugs (NSAIDs), nimesulide and naproxen, on the synthesis of urokinase (uPA), plasminogen activator inhibitor (PAI-1) and interleukin-6 (IL-6) in human synovial fibroblasts isolated from osteoarthritis (OA) patients.	Naproxen	153-161	proline rich acidic protein 1	Homo sapiens	194-197
9272300-3	1997	RESULTS: Nimesulide and naproxen induced a dose-dependent decrease in uPA synthesis.	Naproxen	24-32	proline rich acidic protein 1	Homo sapiens	70-73
9150857-2	1997	The S-naproxen betainate sodium salt monohydrate (naproxen-betaNa, CAS 104124-26-7, Aprenin) was synthesized to improve bioavailability and tolerability of naproxen.	Naproxen	6-14	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	67-70
9129911-0	1997	Left ventricular myxoma presenting with constitutional symptoms and raised serum interleukin-6 both suppressed by naproxen.	Naproxen	114-122	interleukin 6	Homo sapiens	81-94
9042976-6	1997	RESULTS: NO-naproxen was found to produce significantly less gastric damage despite inducing similar increases in plasma TNF alpha to naproxen.	Naproxen	12-20	tumor necrosis factor	Homo sapiens	121-130
8825200-12	1996	It is concluded that the O-demethylation of naproxen (< or = 0.4 mM) is catalyzed by CYP2C subfamily members (CYP2C9/10) and CYP1A2 in human liver microsomes.	Naproxen	44-52	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	88-93
9061203-1	1997	Representative examples of NSAID cyclooxygenase inhibitors such as naproxen, ibufenac, ibuprofen, and butibufen have been transformed into 5-lipoxygenase inhibitors by replacement of the carboxylic acid moiety with a 4-hydroxythiazole group.	Naproxen	67-75	arachidonate 5-lipoxygenase	Homo sapiens	139-153
8817534-4	1996	Tenidap, naproxen and meloxicam inhibited the IL-1 beta-induced synthesis of IL-6, whereas ibuprofen, piroxicam, diclofenac and indomethacin had no effect.	Naproxen	9-17	interleukin 1 beta	Homo sapiens	46-55
8817534-4	1996	Tenidap, naproxen and meloxicam inhibited the IL-1 beta-induced synthesis of IL-6, whereas ibuprofen, piroxicam, diclofenac and indomethacin had no effect.	Naproxen	9-17	interleukin 6	Homo sapiens	77-81
8866821-1	1996	A preliminary report implicated cytochrome P450 (CYP) 2C9 in the human liver microsomal O-demethylation of S-naproxen, suggesting that this pathway may be suitable for investigation of human hepatic CYP2C9 in vitro.	Naproxen	107-117	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	32-57
8866821-1	1996	A preliminary report implicated cytochrome P450 (CYP) 2C9 in the human liver microsomal O-demethylation of S-naproxen, suggesting that this pathway may be suitable for investigation of human hepatic CYP2C9 in vitro.	Naproxen	107-117	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	199-205
8891757-5	1996	Four non-steroidal antiinflammatory drugs, indomethacin, flurbiprofen, naproxen and meclofenamic acid, inhibited basal, IL-1 beta- and TNF-alpha-stimulated PGE2 formation in the MG-63 cells without affecting IL-1 beta- or TNF-alpha-induced inhibition of osteocalcin and type I collagen formation.	Naproxen	71-79	interleukin 1 beta	Homo sapiens	120-129
8891757-5	1996	Four non-steroidal antiinflammatory drugs, indomethacin, flurbiprofen, naproxen and meclofenamic acid, inhibited basal, IL-1 beta- and TNF-alpha-stimulated PGE2 formation in the MG-63 cells without affecting IL-1 beta- or TNF-alpha-induced inhibition of osteocalcin and type I collagen formation.	Naproxen	71-79	tumor necrosis factor	Homo sapiens	135-144
8891757-5	1996	Four non-steroidal antiinflammatory drugs, indomethacin, flurbiprofen, naproxen and meclofenamic acid, inhibited basal, IL-1 beta- and TNF-alpha-stimulated PGE2 formation in the MG-63 cells without affecting IL-1 beta- or TNF-alpha-induced inhibition of osteocalcin and type I collagen formation.	Naproxen	71-79	interleukin 1 beta	Homo sapiens	208-217
8891757-5	1996	Four non-steroidal antiinflammatory drugs, indomethacin, flurbiprofen, naproxen and meclofenamic acid, inhibited basal, IL-1 beta- and TNF-alpha-stimulated PGE2 formation in the MG-63 cells without affecting IL-1 beta- or TNF-alpha-induced inhibition of osteocalcin and type I collagen formation.	Naproxen	71-79	tumor necrosis factor	Homo sapiens	222-231
8757923-4	1996	The range of application is 0-14 mg l-1 for naproxen and 0-13 mg l-1 for salicylic acid.	Naproxen	44-52	immunoglobulin kappa variable 1-16	Homo sapiens	36-39
8757923-5	1996	The detection limits for naproxen and salicylic acid are 0.003 and 0.01 mg l-1, respectively.	Naproxen	25-33	immunoglobulin kappa variable 1-16	Homo sapiens	75-78
8667229-4	1996	Other cyclooxygenase inhibitors such as naproxen and ibuprofen also enhanced TPA-stimulated PAF production in accordance with inhibition of PGE2 production.	Naproxen	40-48	PCNA clamp associated factor	Rattus norvegicus	92-95
8737748-8	1996	Diclofenac, naproxen and flufenamic acid were equipotent or slightly selective for PGHS-2.	Naproxen	12-20	prostaglandin-endoperoxide synthase 2	Homo sapiens	83-89
8730734-4	1996	LPS-induced nitrite production was markedly attenuated by the nitroxybutylester derivatives of flurbiprofen (FNBE), aspirin, ketoprofen, naproxen, diclofenac and ketorolac, with each compound reducing accumulated nitrite levels by > 40% at the maximum concentrations (100 micrograms ml-1) used.	Naproxen	137-145	toll-like receptor 4	Mus musculus	0-3
8825200-12	1996	It is concluded that the O-demethylation of naproxen (< or = 0.4 mM) is catalyzed by CYP2C subfamily members (CYP2C9/10) and CYP1A2 in human liver microsomes.	Naproxen	44-52	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	113-122
8825200-12	1996	It is concluded that the O-demethylation of naproxen (< or = 0.4 mM) is catalyzed by CYP2C subfamily members (CYP2C9/10) and CYP1A2 in human liver microsomes.	Naproxen	44-52	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	128-134
8838503-1	1996	OBJECTIVE: To compare the effects of tenidap, a new antirheumatic drug, with a nonsteroidal anti-inflammatory drug, naproxen, on the synthesis and expression of interleukin-1 beta (IL-1 beta), tumor necrosis factor (TNF-alpha), and interleukin-6 (IL-6) in rheumatoid synovium.	Naproxen	116-124	interleukin 1 beta	Homo sapiens	161-179
11859381-7	1996	Naproxen and indomethacin, but not tiaprofenic acid, at therapeutic concentrations, significantly reduced the level of GR in synovial cells.	Naproxen	0-8	nuclear receptor subfamily 3 group C member 1	Homo sapiens	119-121
8607507-5	1996	Naproxen caused a 46% (p = 0.008) increase in the rate of luminal mucin release, an 18% increase (p = 0.510) in protein release, and a 61% decrease (p = 0.001) in hydrophobicity.	Naproxen	0-8	LOC100508689	Homo sapiens	66-71
8607507-10	1996	The initial mucin of subjects who developed endoscopic mucosal changes after naproxen was 53% higher than in subjects without damage.	Naproxen	77-85	LOC100508689	Homo sapiens	12-17
8838503-1	1996	OBJECTIVE: To compare the effects of tenidap, a new antirheumatic drug, with a nonsteroidal anti-inflammatory drug, naproxen, on the synthesis and expression of interleukin-1 beta (IL-1 beta), tumor necrosis factor (TNF-alpha), and interleukin-6 (IL-6) in rheumatoid synovium.	Naproxen	116-124	interleukin 1 beta	Homo sapiens	181-190
8838503-6	1996	Under LPS stimulation, IL-1 beta synthesis was inhibited by tenidap at all concentrations tested (p < 0.01) and by naproxen at only 90 micrograms/ml (p < 0.01).	Naproxen	118-126	interleukin 1 beta	Homo sapiens	23-32
8838503-9	1996	Naproxen, at 90 micrograms/ml, reduced TNF-alpha synthesis by about 40% (p < 0.03) and values were similar to those with subtherapeutic concentrations (5 micrograms/ml) of tenidap.	Naproxen	0-8	tumor necrosis factor	Homo sapiens	39-48
8838503-12	1996	Naproxen only slightly reduced the LPS induced expression of IL-6, while enhancing the IL-1 beta expression.	Naproxen	0-8	interleukin 6	Homo sapiens	61-65
8668670-0	1996	The effect of octanoic acid on the binding of the enantiomers of ibuprofen and naproxen to human serum albumin: a chromatographic implication.	Naproxen	79-87	albumin	Homo sapiens	97-110
7791168-6	1995	Adjusted rates of discontinuation were significantly higher for ibuprofen (RR 1.43, 95% CI 1.22 to 1.69) and for naproxen (RR 1.40, 95% CI 1.19 to 1.65) when compared to piroxicam.	Naproxen	113-121	ribonucleotide reductase catalytic subunit M1	Homo sapiens	123-127
7612058-1	1995	The relationship between the plasma concentration and the anti-inflammatory effect of naproxen (CAS 22204-53-1) after oral administration of a 6 mg.kg-1 dose was studied in rats with galactosamine-induced acute hepatitis and under control conditions.	Naproxen	86-94	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	96-99
8838503-12	1996	Naproxen only slightly reduced the LPS induced expression of IL-6, while enhancing the IL-1 beta expression.	Naproxen	0-8	interleukin 1 beta	Homo sapiens	87-96
8597883-1	1995	We performed an open, between patients, placebo controlled study in order to evaluate the effect of the treatment with the non steroidal anti inflammatory drugs indomethacin, diclofenac and naproxen on the concentrations of the cytokines IL-1 beta and IL-6 and of the neuropeptide substance P in plasma and synovial fluid of 24 rheumatoid arthritis patients.	Naproxen	190-198	interleukin 1 beta	Homo sapiens	238-247
8597883-1	1995	We performed an open, between patients, placebo controlled study in order to evaluate the effect of the treatment with the non steroidal anti inflammatory drugs indomethacin, diclofenac and naproxen on the concentrations of the cytokines IL-1 beta and IL-6 and of the neuropeptide substance P in plasma and synovial fluid of 24 rheumatoid arthritis patients.	Naproxen	190-198	interleukin 6	Homo sapiens	252-256
8597883-1	1995	We performed an open, between patients, placebo controlled study in order to evaluate the effect of the treatment with the non steroidal anti inflammatory drugs indomethacin, diclofenac and naproxen on the concentrations of the cytokines IL-1 beta and IL-6 and of the neuropeptide substance P in plasma and synovial fluid of 24 rheumatoid arthritis patients.	Naproxen	190-198	tachykinin precursor 1	Homo sapiens	281-292
7983601-1	1994	The binding of naproxen, ketoprofen, phenylbutazone, salicylic acid, azapropazone, and indobufen to bovine serum albumin was studied by applying the potentiometric ion probe technique.	Naproxen	15-23	albumin	Homo sapiens	107-120
7564880-5	1995	However, indomethacin, diclofenac, phenylbutazone, mefenamic acid, naproxen, piroxicam, aspirin and W-7 inhibit, in a concentration-dependent way, the calmodulin-stimulated activity of phosphodiesterase.	Naproxen	67-75	calmodulin 1	Rattus norvegicus	151-161
7879699-5	1994	The ability of the cyclooxygenase inhibitors indomethacin and naproxen to decrease the response to bradykinin by approximately 68% indicates the effect is mediated, at least partially, through the generation of prostaglandins.	Naproxen	62-70	kininogen 1	Homo sapiens	99-109
7855040-3	1994	Simulations from non-mixed co-compressates of naproxen and phenytoin indicated that dissolution rates are proportional to bL2/3, as reported for pure compounds in the laminar dissolution apparatus by Shah and Nelson.	Naproxen	46-54	cell adhesion molecule 1	Homo sapiens	122-127
8620667-0	1995	The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.	Naproxen	133-141	arachidonate 5-lipoxygenase	Homo sapiens	65-79
7799361-5	1994	RESULTS: Naproxen and indomethacin but not tiaprofenic acid, at therapeutic concentrations, significantly reduced the level of GR in synovial cells.	Naproxen	9-17	nuclear receptor subfamily 3 group C member 1	Homo sapiens	127-129
7525383-10	1994	The NSAID naproxen (30 micrograms/ml) induced the expression of PAI-1 mRNA over basal levels and super-induced the inhibitor"s expression above rhIL-1 beta stimulated levels.	Naproxen	10-18	serpin family E member 1	Homo sapiens	64-69
8240429-9	1993	In OA chondrocytes, the effect of indomethacin and naproxen on the IL-1R level was greatly reduced, whereas tenidap still had a marked effect (IC50 22.5 micrograms/ml).	Naproxen	51-59	interleukin 1 receptor type 1	Homo sapiens	67-72
8265610-8	1993	Diclofenac, BW 755C, acetaminophen, and naproxen were approximately equipotent inhibitors of COX-1 and COX-2 in intact cells.	Naproxen	40-48	cytochrome c oxidase subunit I	Ovis aries	93-98
8265610-8	1993	Diclofenac, BW 755C, acetaminophen, and naproxen were approximately equipotent inhibitors of COX-1 and COX-2 in intact cells.	Naproxen	40-48	cytochrome c oxidase subunit II	Ovis aries	103-108
8216382-1	1993	Recombinant rat phenol UDP-glucuronosyltransferase (UGT1A1) conjugates (R)-naproxen at a much higher rate (> 17-fold) than its (S)-enantiomer, substantiating previous findings on stereoselective glucuronidation of racemic naproxen.	Naproxen	75-83	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	52-58
8216382-3	1993	In line with high constitutive expression of UGT1A1 in extrahepatic tissues, a high R/S ratio of naproxen glucuronidation was found in rat testes, intestine, lung and kidney.	Naproxen	97-105	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	45-51
8214591-3	1993	The technique was validated for each of the seven substrates tested by reversed-phase HPLC, and was then applied successfully to the determination of optimal conditions for the activation of the carboxylic acid-UGT, and the estimation of kinetic constants for the glucuronidation of clofibric acid, 2-naphthylacetic acid, naproxen, and 4,4,4-triphenylbutanoic acid in rat liver microsomes.	Naproxen	322-330	UDP glycosyltransferase 2 family, polypeptide B	Rattus norvegicus	211-214
8352821-3	1993	One day after intoxication the liver was considerably damaged; cytochrome P450, the main enzymatic system for naproxen metabolism, was decreased in 90%.	Naproxen	110-118	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	63-78
18965666-4	1993	The study was extended to examine the interactions of bilirubin and two anionic drugs, warfarin and naproxen, with HSA and the three fragments.	Naproxen	100-108	albumin	Homo sapiens	115-118
7685226-6	1993	CRP concentrations in naproxen-treated and placebo patients were essentially unchanged.	Naproxen	22-30	C-reactive protein	Homo sapiens	0-3
8440758-8	1993	The effect of naproxen sodium on the IL-1-stimulated release was to suppress, but not totally overcome, the increased release of proteoglycan and neutral metalloproteinase activity.	Naproxen	14-29	interleukin 1 alpha	Homo sapiens	37-41
8466542-1	1993	The anti-inflammatory agent naproxen (Nap) was covalently coupled to human serum albumin (HSA) and to the neoglycoproteins, galactose and mannose terminated HSA, to deliver this drug selectively to different cell types of the liver.	Naproxen	28-36	albumin	Homo sapiens	90-93
8466542-1	1993	The anti-inflammatory agent naproxen (Nap) was covalently coupled to human serum albumin (HSA) and to the neoglycoproteins, galactose and mannose terminated HSA, to deliver this drug selectively to different cell types of the liver.	Naproxen	28-36	albumin	Homo sapiens	157-160
8466542-1	1993	The anti-inflammatory agent naproxen (Nap) was covalently coupled to human serum albumin (HSA) and to the neoglycoproteins, galactose and mannose terminated HSA, to deliver this drug selectively to different cell types of the liver.	Naproxen	38-41	albumin	Homo sapiens	90-93
8466542-1	1993	The anti-inflammatory agent naproxen (Nap) was covalently coupled to human serum albumin (HSA) and to the neoglycoproteins, galactose and mannose terminated HSA, to deliver this drug selectively to different cell types of the liver.	Naproxen	38-41	albumin	Homo sapiens	157-160
8466542-13	1993	Studies in the intact organ and in purified liver lysosomal lysates indicate that after internalization of Nap20-HSA the conjugate is proteolytically degraded leading to the formation of the lysine conjugate of Nap.	Naproxen	107-110	albumin	Homo sapiens	113-116
8466542-16	1993	Coupling of Nap to Lact27-HSA and Man10-HSA resulted in a major shift in intrahepatic distribution from endothelial cells to the hepatocytes and Kupffer cells, respectively.	Naproxen	12-15	albumin	Homo sapiens	26-29
8466542-16	1993	Coupling of Nap to Lact27-HSA and Man10-HSA resulted in a major shift in intrahepatic distribution from endothelial cells to the hepatocytes and Kupffer cells, respectively.	Naproxen	12-15	albumin	Homo sapiens	40-43
8466542-17	1993	We conclude that conjugation of Nap to HSA itself results in a selective delivery to endothelial cells and that the local proteolysis of the conjugate produces an active catabolite.	Naproxen	32-35	albumin	Homo sapiens	39-42
8440758-9	1993	In summary, these in vitro studies of cartilage metabolism indicate that naproxen sodium has the potential to suppress catabolic activities in articular cartilage, including those that are motivated by IL-1.	Naproxen	73-88	interleukin 1 alpha	Homo sapiens	202-206
8423545-4	1993	Additionally, the stereoselectivity of ketoprofen, naproxen (S/R ratio approximately unity) and ibuprofen (S/R ratio 1.62) glucuronidation by the UGT2B7 variant was shown to differ.	Naproxen	51-59	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	146-152
1468903-6	1992	Due to the possible involvement of endothelin in headache disorders, the objective of this study was to verify the effects of lithium and cyclooxygenase inhibitors (indomethacin, acetylsalicylic acid and naproxen) on endothelin-1 (ET-1)-induced contractions in isolated human temporal arteries and porcine ophthalmic arteries.	Naproxen	204-212	endothelin 1	Homo sapiens	217-229
1468903-6	1992	Due to the possible involvement of endothelin in headache disorders, the objective of this study was to verify the effects of lithium and cyclooxygenase inhibitors (indomethacin, acetylsalicylic acid and naproxen) on endothelin-1 (ET-1)-induced contractions in isolated human temporal arteries and porcine ophthalmic arteries.	Naproxen	204-212	endothelin 1	Homo sapiens	231-235
1907931-0	1991	Naproxen: an aldose reductase inhibitor and potential anti-cataract agent.	Naproxen	0-8	aldo-keto reductase family 1 member B	Homo sapiens	13-29
8013267-4	1993	The results corroborated the stimulation of TNF alpha production by NSAIDs (indomethacin, naproxen, ibuprofen) and indicated that the stimulation rank-ordered with the potency of inhibition of PGHS-1.	Naproxen	90-98	tumor necrosis factor	Mus musculus	44-53
1729367-5	1992	Indeed, an increase in IL-6 production was observed after exposure to naproxen.	Naproxen	70-78	interleukin 6	Homo sapiens	23-27
33812973-3	2021	Therefore, in the present study, we developed four L-type amino acid transporter 1 (LAT1)-utilizing prodrugs of flurbiprofen, ibuprofen, naproxen, and ketoprofen, since LAT1 is expressed on both, the BBB endothelial cells as well as parenchymal cells.	Naproxen	137-145	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5	Mus musculus	51-82
1982151-2	1990	At a concentration approaching that achieved in synovial fluid of patients treated with the drug (i.e. 30 micrograms mL-1) naproxen sodium had no significant effect on net synthesis of either glycosaminoglycans or protein in organ cultures of femoral condylar cartilage, nor did it increase the proportion of newly synthesized glycosaminoglycans recovered from the culture medium, suggesting that it had no direct effect on the integrity of the extracellular matrix.	Naproxen	123-138	L1 cell adhesion molecule	Mus musculus	117-121
33812973-3	2021	Therefore, in the present study, we developed four L-type amino acid transporter 1 (LAT1)-utilizing prodrugs of flurbiprofen, ibuprofen, naproxen, and ketoprofen, since LAT1 is expressed on both, the BBB endothelial cells as well as parenchymal cells.	Naproxen	137-145	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5	Mus musculus	84-88
33812973-3	2021	Therefore, in the present study, we developed four L-type amino acid transporter 1 (LAT1)-utilizing prodrugs of flurbiprofen, ibuprofen, naproxen, and ketoprofen, since LAT1 is expressed on both, the BBB endothelial cells as well as parenchymal cells.	Naproxen	137-145	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5	Mus musculus	169-173
34769120-4	2021	The present study was designed to determine, for the first time, the changes in pituitary adenylate cyclase-activating polypeptide (PACAP), substance P (SP) and galanin (GAL) expression in porcine jejunum after long-term treatment with aspirin, indomethacin and naproxen.	Naproxen	262-270	adenylate cyclase activating polypeptide 1	Sus scrofa	132-137
34182020-5	2021	Thus, the relative COX-2 selectivity of traditional NSAIDs correlates with their cardiovascular risk profile, being more favorable for non-selective NSAIDs, such as naproxen and low-dose ibuprofen, and less favorable for more COX-2 selective agents, such as diclofenac.	Naproxen	165-173	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	19-24
33806467-3	2021	This work studies the interaction of human serum albumin (HSA) with four non-steroidal anti-inflammatory drugs (NSAIDs)-ibuprofen, flurbiprofen, naproxen, and diflunisal-by monitoring the fluorescence quenching when the drug-albumin complex is formed.	Naproxen	145-153	albumin	Homo sapiens	43-56
33806467-3	2021	This work studies the interaction of human serum albumin (HSA) with four non-steroidal anti-inflammatory drugs (NSAIDs)-ibuprofen, flurbiprofen, naproxen, and diflunisal-by monitoring the fluorescence quenching when the drug-albumin complex is formed.	Naproxen	145-153	albumin	Homo sapiens	49-56
34427537-0	2021	The protective effects of naproxen against interleukin-1beta (IL-1beta)- induced damage in human umbilical vein endothelial cells (HUVECs).	Naproxen	26-34	interleukin 1 beta	Homo sapiens	43-60
34427537-0	2021	The protective effects of naproxen against interleukin-1beta (IL-1beta)- induced damage in human umbilical vein endothelial cells (HUVECs).	Naproxen	26-34	interleukin 1 alpha	Homo sapiens	62-70
34427537-2	2021	Naproxen is an NSAID with relatively low selectivity for cyclooxygenase-2 (COX-2), thereby having decreased risk for cardiovascular (CV) events.	Naproxen	0-8	prostaglandin-endoperoxide synthase 2	Homo sapiens	57-73
34427537-2	2021	Naproxen is an NSAID with relatively low selectivity for cyclooxygenase-2 (COX-2), thereby having decreased risk for cardiovascular (CV) events.	Naproxen	0-8	prostaglandin-endoperoxide synthase 2	Homo sapiens	75-80
34427537-5	2021	Our findings indicate that naproxen could protect against IL-1beta-induced damage by improving cell viability and preventing cell death.	Naproxen	27-35	interleukin 1 alpha	Homo sapiens	58-66
34427537-6	2021	Additionally, naproxen suppressed the expression of the cytokines IL-6, IL-12, and tumor necrosis factor-alpha (TNF-alpha), and downregulated the expression of vascular endothelial growth factor (VEGF) and tissue factor (TF) induced by IL-1beta.	Naproxen	14-22	interleukin 6	Homo sapiens	66-70
34427537-6	2021	Additionally, naproxen suppressed the expression of the cytokines IL-6, IL-12, and tumor necrosis factor-alpha (TNF-alpha), and downregulated the expression of vascular endothelial growth factor (VEGF) and tissue factor (TF) induced by IL-1beta.	Naproxen	14-22	tumor necrosis factor	Homo sapiens	83-110
34427537-6	2021	Additionally, naproxen suppressed the expression of the cytokines IL-6, IL-12, and tumor necrosis factor-alpha (TNF-alpha), and downregulated the expression of vascular endothelial growth factor (VEGF) and tissue factor (TF) induced by IL-1beta.	Naproxen	14-22	tumor necrosis factor	Homo sapiens	112-121
34427537-6	2021	Additionally, naproxen suppressed the expression of the cytokines IL-6, IL-12, and tumor necrosis factor-alpha (TNF-alpha), and downregulated the expression of vascular endothelial growth factor (VEGF) and tissue factor (TF) induced by IL-1beta.	Naproxen	14-22	vascular endothelial growth factor A	Homo sapiens	160-194
34427537-6	2021	Additionally, naproxen suppressed the expression of the cytokines IL-6, IL-12, and tumor necrosis factor-alpha (TNF-alpha), and downregulated the expression of vascular endothelial growth factor (VEGF) and tissue factor (TF) induced by IL-1beta.	Naproxen	14-22	vascular endothelial growth factor A	Homo sapiens	196-200
34427537-6	2021	Additionally, naproxen suppressed the expression of the cytokines IL-6, IL-12, and tumor necrosis factor-alpha (TNF-alpha), and downregulated the expression of vascular endothelial growth factor (VEGF) and tissue factor (TF) induced by IL-1beta.	Naproxen	14-22	coagulation factor III, tissue factor	Homo sapiens	206-219
34427537-6	2021	Additionally, naproxen suppressed the expression of the cytokines IL-6, IL-12, and tumor necrosis factor-alpha (TNF-alpha), and downregulated the expression of vascular endothelial growth factor (VEGF) and tissue factor (TF) induced by IL-1beta.	Naproxen	14-22	interleukin 1 alpha	Homo sapiens	236-244
34427537-7	2021	Importantly, naproxen also inhibited the attachment of monocytes to endothelial cells, which was achieved through Kruppel-like factor 6 (KLF6)-mediated reduced expression of intracellular adhesion molecule-1 (ICAM-1) and E-selectin.	Naproxen	13-21	Kruppel like factor 6	Homo sapiens	114-135
34427537-7	2021	Importantly, naproxen also inhibited the attachment of monocytes to endothelial cells, which was achieved through Kruppel-like factor 6 (KLF6)-mediated reduced expression of intracellular adhesion molecule-1 (ICAM-1) and E-selectin.	Naproxen	13-21	Kruppel like factor 6	Homo sapiens	137-141
34427537-7	2021	Importantly, naproxen also inhibited the attachment of monocytes to endothelial cells, which was achieved through Kruppel-like factor 6 (KLF6)-mediated reduced expression of intracellular adhesion molecule-1 (ICAM-1) and E-selectin.	Naproxen	13-21	intercellular adhesion molecule 1	Homo sapiens	174-207
34427537-7	2021	Importantly, naproxen also inhibited the attachment of monocytes to endothelial cells, which was achieved through Kruppel-like factor 6 (KLF6)-mediated reduced expression of intracellular adhesion molecule-1 (ICAM-1) and E-selectin.	Naproxen	13-21	intercellular adhesion molecule 1	Homo sapiens	209-215
34427537-7	2021	Importantly, naproxen also inhibited the attachment of monocytes to endothelial cells, which was achieved through Kruppel-like factor 6 (KLF6)-mediated reduced expression of intracellular adhesion molecule-1 (ICAM-1) and E-selectin.	Naproxen	13-21	selectin E	Homo sapiens	221-231
34374961-2	2021	Recent rodent and human brain imaging studies suggest involvement of sexually dimorphic, dopaminergic-motivational, mesolimbic circuits in the transition to chronic pain (tCBP), and hint that the combination of carbidopa/levodopa and naproxen (LDP + NPX) may block tCBP.	Naproxen	234-242	histidine triad nucleotide binding protein 1	Homo sapiens	182-186
34374961-2	2021	Recent rodent and human brain imaging studies suggest involvement of sexually dimorphic, dopaminergic-motivational, mesolimbic circuits in the transition to chronic pain (tCBP), and hint that the combination of carbidopa/levodopa and naproxen (LDP + NPX) may block tCBP.	Naproxen	234-242	carboxypeptidase Q	Homo sapiens	244-247
34374961-2	2021	Recent rodent and human brain imaging studies suggest involvement of sexually dimorphic, dopaminergic-motivational, mesolimbic circuits in the transition to chronic pain (tCBP), and hint that the combination of carbidopa/levodopa and naproxen (LDP + NPX) may block tCBP.	Naproxen	234-242	TIA1 cytotoxic granule associated RNA binding protein like 1	Homo sapiens	265-269
34769120-4	2021	The present study was designed to determine, for the first time, the changes in pituitary adenylate cyclase-activating polypeptide (PACAP), substance P (SP) and galanin (GAL) expression in porcine jejunum after long-term treatment with aspirin, indomethacin and naproxen.	Naproxen	262-270	galanin and GMAP prepropeptide	Sus scrofa	170-173
34091121-10	2021	Biomarker analysis showed significantly reduced inflammation (COX-2, IL-10), reduced tumor cell proliferation (PCNA, cyclin D1), and increased apoptosis (p21, caspase-3) in the lung tumors exposed to naproxen.	Naproxen	200-208	cytochrome c oxidase II, mitochondrial	Mus musculus	62-67
34364048-4	2021	Physicochemical characteristics of the Mn/CQD/SiO2@naproxen were investigated using FT-IR, SEM, TEM, UV-Vis and BET.	Naproxen	51-59	delta/notch like EGF repeat containing	Homo sapiens	112-115
34162101-1	2021	In this study, granular activated carbon (GAC) was examined for the removal of five of the most commonly detected pharmaceuticals (naproxen, carbamazepine, acetaminophen, ibuprofen and metronidazole) from a nitrified urine to make the urine-derived fertiliser nutrient safe for food crops.	Naproxen	131-139	glutaminase	Homo sapiens	42-45
34303168-7	2021	In the presence of Cl-, we found that Cl2 - and in particular ClO  were responsible for the enhanced degradation with increasing Cl- concentrations due to the considerable ClO  reactivity of gemfibrozil (1.93 x 109 M-1 s-1) and naproxen (9.24 x 109 M-1 s-1) and the rapid transformation of Cl2 - to ClO .	Naproxen	228-236	endogenous retrovirus group W member 5	Homo sapiens	38-41
34577570-0	2021	Naproxen Based 1,3,4-Oxadiazole Derivatives as EGFR Inhibitors: Design, Synthesis, Anticancer, and Computational Studies.	Naproxen	0-8	epidermal growth factor receptor	Homo sapiens	47-51
34577570-1	2021	A library of novel naproxen based 1,3,4-oxadiazole derivatives (8-16 and 19-26) has been synthesized and screened for cytotoxicity as EGFR inhibitors.	Naproxen	19-27	epidermal growth factor receptor	Homo sapiens	134-138
34577570-6	2021	These results demonstrated that these synthesized naproxen hybrids have EGFR inhibition effects and can be used as leads for cancer therapy.	Naproxen	50-58	epidermal growth factor receptor	Homo sapiens	72-76
34231570-3	2021	A combination of beta-cyclodextrin (beta-CD) and methylene blue (MB) was used as an enantioselective discrimination probe to develop a straightforward electrochemical chiral sensor using the drug naproxen (R-and S-NaX) as the representative enantiomers.	Naproxen	196-204	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	36-43
34091121-10	2021	Biomarker analysis showed significantly reduced inflammation (COX-2, IL-10), reduced tumor cell proliferation (PCNA, cyclin D1), and increased apoptosis (p21, caspase-3) in the lung tumors exposed to naproxen.	Naproxen	200-208	interleukin 10	Mus musculus	69-74
34091121-10	2021	Biomarker analysis showed significantly reduced inflammation (COX-2, IL-10), reduced tumor cell proliferation (PCNA, cyclin D1), and increased apoptosis (p21, caspase-3) in the lung tumors exposed to naproxen.	Naproxen	200-208	proliferating cell nuclear antigen	Mus musculus	111-115
34091121-10	2021	Biomarker analysis showed significantly reduced inflammation (COX-2, IL-10), reduced tumor cell proliferation (PCNA, cyclin D1), and increased apoptosis (p21, caspase-3) in the lung tumors exposed to naproxen.	Naproxen	200-208	cyclin D1	Mus musculus	117-126
34091121-10	2021	Biomarker analysis showed significantly reduced inflammation (COX-2, IL-10), reduced tumor cell proliferation (PCNA, cyclin D1), and increased apoptosis (p21, caspase-3) in the lung tumors exposed to naproxen.	Naproxen	200-208	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	154-157
34091121-10	2021	Biomarker analysis showed significantly reduced inflammation (COX-2, IL-10), reduced tumor cell proliferation (PCNA, cyclin D1), and increased apoptosis (p21, caspase-3) in the lung tumors exposed to naproxen.	Naproxen	200-208	caspase 3	Mus musculus	159-168
34091121-11	2021	Decreased serum levels of PGE2 and CXCR4 were observed in naproxen diet fed KrasG12V mice.	Naproxen	58-66	chemokine (C-X-C motif) receptor 4	Mus musculus	35-40
35134455-2	2022	The considered ligands are clinical drugs with different binding constants to albumin: relatively strong binders (naproxen, ibuprofen, warfarin with 105 to 107 binding constant values) and weak binders (isoniazid, ranitidine with 103 to 104 binding constant values).	Naproxen	114-122	albumin	Homo sapiens	78-85
35168147-5	2022	Flurbiprofen/naproxen and piroxicam are located in the active site and the primary binding site of CYP2C9, respectively.	Naproxen	13-21	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	99-105
35605690-5	2022	Crystallographic lattice parameters, elemental analysis, and TGA experimental results were then employed in the calculations, which revealed that NAP anions can completely neutralize the positive charge of the LDH layers: both Mg2Al and Zn2Al LDH structures could be optimized with all Cl- anions substituted by NAP.	Naproxen	146-149	T-box transcription factor 1	Homo sapiens	61-64
35585779-9	2022	Randomized trials comparing COX-2 inhibitors with NSAIDs have exaggerated their gastrointestinal benefits by using maximal NSAID doses regardless of indication, and/or hidden the cardiovascular risk by comparing with COX-2 selective diclofenac instead of low-dose ibuprofen or naproxen.	Naproxen	277-285	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	28-33
2764314-1	1989	A 52-year-old male developed cutaneous necrotizing vasculitis, renal failure, massive proteinuria, and elevated serum IgE levels following oral naproxen therapy.	Naproxen	144-152	immunoglobulin heavy constant epsilon	Homo sapiens	118-121
35408503-1	2022	The synthesis of derivatives of three nonspecific COX-1 and COX-2 inhibitors, ibuprofen, ketoprofen, naproxen is presented.	Naproxen	101-109	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	50-55
35408503-1	2022	The synthesis of derivatives of three nonspecific COX-1 and COX-2 inhibitors, ibuprofen, ketoprofen, naproxen is presented.	Naproxen	101-109	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	60-65
35424767-6	2022	The cytotoxicity evaluation also showed that the addition of naproxen increased the death of HeLa cells with a CC50 of up to 29.33 mug mL-1.	Naproxen	61-69	L1 cell adhesion molecule	Mus musculus	135-139
34987061-5	2022	The decrease in PD-L1 was associated with an influx of CD8+ T-cells into polyps (p<0.0001, celecoxib; p=0.048, naproxen) compared to lesions from untreated animals and correlated with disease control.	Naproxen	111-119	CD274 antigen	Mus musculus	16-21
34987061-6	2022	Naproxen is a nonselective inhibitor of both COX-1 and COX-2, and we questioned the role of the different cyclooxygenases in PD-L1 regulation.	Naproxen	0-8	cytochrome c oxidase I, mitochondrial	Mus musculus	45-50
34987061-6	2022	Naproxen is a nonselective inhibitor of both COX-1 and COX-2, and we questioned the role of the different cyclooxygenases in PD-L1 regulation.	Naproxen	0-8	cytochrome c oxidase II, mitochondrial	Mus musculus	55-60
35373258-1	2022	In this issue of Cancer Prevention Research, Cecil and colleagues show that nonsteroidal anti-inflammatory drugs (NSAID), celecoxib and naproxen, decrease the expression of programmed death-ligand 1 (PD-L1) and increase the influx of Type I tumor-infiltrating lymphocytes in colonic tumors.	Naproxen	136-144	CD274 molecule	Homo sapiens	173-198
35373258-1	2022	In this issue of Cancer Prevention Research, Cecil and colleagues show that nonsteroidal anti-inflammatory drugs (NSAID), celecoxib and naproxen, decrease the expression of programmed death-ligand 1 (PD-L1) and increase the influx of Type I tumor-infiltrating lymphocytes in colonic tumors.	Naproxen	136-144	CD274 molecule	Homo sapiens	200-205
35085730-7	2022	The ATR-FTIR and MD simulation revealed H-bonding between the alginate and naproxen sodium at 3500-3200 cm-1 with a RMSD of ~2.8 A and binding free energy DeltaGpred (GB) = -10.93 kcal/mol.	Naproxen	75-90	ATR serine/threonine kinase	Rattus norvegicus	4-7
2711919-4	1989	On naproxen, ERPF and renal blood flow decreased by 10% and 9%, respectively (-32 ml/min/1.73 m2; p = 0.05 and -49 ml/min/1.73 m2; p less than 0.01).	Naproxen	3-11	CD59 molecule (CD59 blood group)	Homo sapiens	85-90
2662368-6	1989	Thus, in vitro experiments have shown that naproxen reduces the PGE2-dependent inhibitory effect exerted by IL1 on the biosynthesis of collagen and proteoglycans and suggest that this NSAIA may be of use in degenerative osteoarticular disease.	Naproxen	43-51	interleukin 1 alpha	Homo sapiens	108-111
2711919-4	1989	On naproxen, ERPF and renal blood flow decreased by 10% and 9%, respectively (-32 ml/min/1.73 m2; p = 0.05 and -49 ml/min/1.73 m2; p less than 0.01).	Naproxen	3-11	CD59 molecule (CD59 blood group)	Homo sapiens	118-123
2579598-1	1985	The hypothesis of cyclooxygenase derivates of arachidonic acid as putative mediators of late phase skin reactions (LPR) was evaluated by studying the effect of indomethacin and naproxen on anti-IgE elicited skin reactions in healthy volunteers.	Naproxen	177-185	immunoglobulin heavy constant epsilon	Homo sapiens	194-197
2478241-1	1989	Monensin, a highly selective sodium ionophore, inhibits vasopressin-stimulated water flow in toad urinary bladder pretreated with naproxen, an inhibitor of prostaglandin synthesis.	Naproxen	130-138	arginine vasopressin	Homo sapiens	56-67
2688082-9	1989	Alterations in plasma protein binding, with an increased free fraction of the drug subsequent to changes in serum albumin concentrations were reported with naproxen and salicylates in the aged population.	Naproxen	156-164	albumin	Homo sapiens	108-121
2847761-3	1988	Treatment of the cells with dibutyryl cAMP or prostaglandin E2 enhanced both spontaneous and rIL-1 beta-induced 3H-AA release; treatment with indomethacin or naproxen inhibited the response.	Naproxen	158-166	interleukin 1 beta	Rattus norvegicus	93-103
3177653-4	1988	Furthermore, histidine was additive to naproxen in increasing the hydrosmotic effect of vasopressin, without causing a further decrease in PGE2 production.	Naproxen	39-47	arginine vasopressin	Homo sapiens	88-99
3134688-10	1988	It was demonstrated that naproxen (Naprosyne 500) seems to antagonize the inhibiting action of IL1 on the production of collagen, the main component of cartilage.	Naproxen	25-33	interleukin 1 alpha	Homo sapiens	95-98
3134688-10	1988	It was demonstrated that naproxen (Naprosyne 500) seems to antagonize the inhibiting action of IL1 on the production of collagen, the main component of cartilage.	Naproxen	35-44	interleukin 1 alpha	Homo sapiens	95-98
3126818-9	1988	The prostaglandin synthetase inhibitors indomethacin, meclofenamic acid and naproxen and 5,8,11,14-eicosatetraynoic acid reduced 45Ca release from thrombin-stimulated calvaria.	Naproxen	76-84	coagulation factor II	Mus musculus	147-155
3593436-4	1987	Bradykinin-stimulated resorption was inhibited by calcitonin, an increased concentration of phosphate in the culture medium, hydrocortisone, dexamethasone, indomethacin, meclofenamic acid, naproxen, and 5, 8, 11, 14-eicosatetraenoic acid.	Naproxen	189-197	kininogen 1	Bos taurus	0-10
3548982-2	1986	Treatment was begun with 500 mg BID of diflunisal or 375 mg BID of naproxen.	Naproxen	67-75	BH3 interacting domain death agonist	Homo sapiens	60-63
2939907-5	1985	Using this technique, I found that the effect of the prostaglandin inhibitor Naproxen to increase vasopressin-stimulated water flow is due to increased luminal membrane permeability.	Naproxen	77-85	arginine vasopressin	Homo sapiens	98-109
6408711-2	1983	It was found that the best inhibitors of lipoxygenase were naproxen, BW 755C, indomethacin and isoxicam.	Naproxen	59-67	linoleate 9S-lipoxygenase-4	Glycine max	41-53
3011158-9	1985	Furthermore, the inhibition of prostaglandin biosynthesis by hydrocortisone (a phospholipase inhibitor) or by indomethacin and naproxen (agents that inhibit arachidonic acid oxygenase) results in augmented vasopressin-stimulated water flow and prevents the inhibitory effect of the ionophore.	Naproxen	127-135	arginine vasopressin	Homo sapiens	206-217
2997891-3	1985	This inhibitory effect of TFP on the ADH-stimulated osmotic water flow persisted in the presence of naproxen (10(-5) M), a known inhibitor of prostaglandin synthesis.	Naproxen	100-108	arginine vasopressin	Homo sapiens	37-40
6394759-0	1984	The renal excretion of prostaglandins and changes in plasma renin during treatment with either sulindac or naproxen in patients with rheumatoid arthritis and thiazide treated heart failure.	Naproxen	107-115	renin	Homo sapiens	60-65
6829384-2	1983	Tolmetin and naproxen appear to be more effective in HLA-B27 positive males with pauciarticular disease.	Naproxen	13-21	major histocompatibility complex, class I, B	Homo sapiens	53-60
6807110-5	1982	In rats fed regular laboratory chow the renal vasoconstrictor response to ANG II was potentiated after the administration of either indomethacin or naproxen (5 mg/kg iv).	Naproxen	148-156	angiotensinogen	Rattus norvegicus	74-80
6405453-2	1983	We further compared the effects of acetylsalicylic acid, indomethacin, naproxen sodium and diclofenac sodium on platelet TxA2 production in response to thrombin-induced aggregation during spontaneous clotting, and on prostacyclin (PGI2) production by umbilical arteries in a superfusion system by measuring the 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) concentration in the superfusate.	Naproxen	71-86	coagulation factor II, thrombin	Homo sapiens	152-160
6291348-11	1982	Salicylates and arylacetic acid derivatives, such as naproxen, also decreased MPO-CL.	Naproxen	53-61	myeloperoxidase	Homo sapiens	78-81
229574-3	1979	Non-steroidal anti-inflammatory drugs (naproxen, indomethacin and flufenamic acid) showed a significant inhibitory effect on myeloperoxidase-catalysed iodination at concentrations of 10(-4)M and higher.	Naproxen	39-47	myeloperoxidase	Homo sapiens	125-140
7246192-1	1981	V. Effects of various drugs on the binding of naproxen to bovine serum albumin.	Naproxen	46-54	albumin	Homo sapiens	65-78
7003449-5	1980	A small, but significant, increase in renal excretion of beta-n-acetyl glucosaminidase occurred during treatment with both naproxen and flurbiprofen.	Naproxen	123-131	O-GlcNAcase	Homo sapiens	57-86
7460481-1	1981	The purpose of our investigation was to determine kinetics of naproxen [(+)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid] relative to its inhibition of PGF 2 alpha release during thrombin-induced platelet aggregation in man after a single oral dose of 250 or 500 mg. Naproxen and its metabolite 6-hydroxy-alpha-methyl-2-naphthaleneacetic acid were measured by high-performance, reversed-phase liquid chromatography with fluorimetric detection.	Naproxen	62-70	coagulation factor II, thrombin	Homo sapiens	182-190
7460481-8	1981	With no exception, there was a marked decrease in the PGF 2 alpha concentration in thrombin-stimulated PRP during therapy, and concentration was inversely correlated to the total plasma naproxen concentration.	Naproxen	186-194	coagulation factor II, thrombin	Homo sapiens	83-91
6777397-9	1980	Naproxen and acetaminophen inhibited prostaglandin synthesis and enhanced water flow in response to AVP and DDAVP (44-54%).	Naproxen	0-8	arginine vasopressin	Homo sapiens	100-103
6777397-11	1980	Because agents such as acetaminophen and naproxen inhibit prostaglandin synthesis and enhance vasopressin- and DDAVP-stimulated water flow, we suggest that it is the inhibitory effect of these agents on the hormone-independent rate of prostaglandin synthesis that is responsible for their enhancement of water flow.	Naproxen	41-49	arginine vasopressin	Homo sapiens	94-105
33632714-5	2021	We first confirmed the selectivity of (S)-naproxen O-demethylation by CYP2C9 using activity phenotyped human liver microsomes and selective CYP inhibitors, then developed and validated a novel LC/MS method for simultaneous quantification of (S)-naproxen, (S)-O-desmethyl naproxen, and naproxen acyl glucuronide in human urine.	Naproxen	38-50	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	70-76
89704-5	1979	The non-steroidal anti-inflammatory drugs indomethacin, flufenamic acid and naproxen were far less effective inhibitors of MPO-catalysed BSA iodination of sonicated leucocytes at concentrations expected in blood with therapeutic dose levels than was observed earlier with TPO-catalysed in vitro iodination of BSA.	Naproxen	76-84	myeloperoxidase	Homo sapiens	123-126
89704-5	1979	The non-steroidal anti-inflammatory drugs indomethacin, flufenamic acid and naproxen were far less effective inhibitors of MPO-catalysed BSA iodination of sonicated leucocytes at concentrations expected in blood with therapeutic dose levels than was observed earlier with TPO-catalysed in vitro iodination of BSA.	Naproxen	76-84	thyroid peroxidase	Homo sapiens	272-275
930756-1	1977	The anti-inflammatory agents, phenylbutazone, naproxen and niflumic acid inhibited in vitro rabbit peritoneal neutrophil chemotactic responsiveness to Escherichia coli derived chemotactic factor/s when added to cells suspended in 0.1% bovine serum albumin (BSA).	Naproxen	46-54	albumin	Oryctolagus cuniculus	242-255
33632714-9	2021	Here, we validated (S)-naproxen as a CYP2C9 probe substrate to characterize the in vivo functional activity of the CYP2C9 Leu1 variant.	Naproxen	19-31	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	115-121
33632714-5	2021	We first confirmed the selectivity of (S)-naproxen O-demethylation by CYP2C9 using activity phenotyped human liver microsomes and selective CYP inhibitors, then developed and validated a novel LC/MS method for simultaneous quantification of (S)-naproxen, (S)-O-desmethyl naproxen, and naproxen acyl glucuronide in human urine.	Naproxen	38-50	peptidylprolyl isomerase G	Homo sapiens	70-73
33632714-9	2021	Here, we validated (S)-naproxen as a CYP2C9 probe substrate to characterize the in vivo functional activity of the CYP2C9 Leu1 variant.	Naproxen	19-31	deleted in lymphocytic leukemia 1	Homo sapiens	122-126
33632714-5	2021	We first confirmed the selectivity of (S)-naproxen O-demethylation by CYP2C9 using activity phenotyped human liver microsomes and selective CYP inhibitors, then developed and validated a novel LC/MS method for simultaneous quantification of (S)-naproxen, (S)-O-desmethyl naproxen, and naproxen acyl glucuronide in human urine.	Naproxen	241-253	peptidylprolyl isomerase G	Homo sapiens	70-73
33632714-9	2021	Here, we validated (S)-naproxen as a CYP2C9 probe substrate to characterize the in vivo functional activity of the CYP2C9 Leu1 variant.	Naproxen	19-31	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	37-43
33795278-7	2021	The patient improved on treatment with naproxen and was referred to rheumatology where he was found to be HLA-B27 positive.	Naproxen	39-47	major histocompatibility complex, class I, B	Homo sapiens	106-113
33044630-12	2021	Naproxen demonstrated the lowest rate of Brooker I HO (LOR 2.82), followed by celecoxib (LOR 3.52).	Naproxen	0-8	lysyl oxidase like 2	Homo sapiens	55-60
33592689-6	2021	conditions, good sensitivity was achieved with a limit of detection between 0.006 and 0.012 ng mL-1, the linear range of 0.02-2 ng mL-1 for phenacetin, meloxicam and 0.05-5 ng mL-1 for naproxen, diclofenac sodium, carprofen (r2 >= 0.9940).	Naproxen	185-193	L1 cell adhesion molecule	Mus musculus	131-135
33592689-6	2021	conditions, good sensitivity was achieved with a limit of detection between 0.006 and 0.012 ng mL-1, the linear range of 0.02-2 ng mL-1 for phenacetin, meloxicam and 0.05-5 ng mL-1 for naproxen, diclofenac sodium, carprofen (r2 >= 0.9940).	Naproxen	185-193	L1 cell adhesion molecule	Mus musculus	131-135
32423989-6	2020	Upon reconstitution with cytochrome P450 reductase and cytochrome b5, the N218I and P279T protein variants metabolized (S)-warfarin, phenytoin, flurbiprofen and (S)-naproxen to the expected mono-hydroxylated or O-demethylated metabolites.	Naproxen	161-173	cytochrome b5 type A	Homo sapiens	55-68
32832995-7	2020	On the other hand, when the inhibitory activities of other profens were examined, naproxen also showed relatively potent NAM activity against the receptor.	Naproxen	82-90	SH3 and cysteine rich domain 3	Homo sapiens	121-124
32832995-8	2020	The results from both mutant analysis for the transmembrane domain (TMD) of T1R3 and docking simulation strongly suggest that ibuprofen and naproxen interact with T1R3-TMD, similar to lactisole and 2,4-DP.	Naproxen	140-148	taste 1 receptor member 3	Homo sapiens	76-80
32832995-8	2020	The results from both mutant analysis for the transmembrane domain (TMD) of T1R3 and docking simulation strongly suggest that ibuprofen and naproxen interact with T1R3-TMD, similar to lactisole and 2,4-DP.	Naproxen	140-148	taste 1 receptor member 3	Homo sapiens	163-167
32740982-9	2021	In addition, the involvement of the PTHrP-Ihh loop in Naproxen and MTX treated cells was shown.	Naproxen	54-62	parathyroid hormone-like peptide	Mus musculus	36-41
33216613-10	2021	However, the changes in CROM and PPT values were small and did not surpass their respective reference MCIDs except for the right lateral bending CROM for naproxen treatment.	Naproxen	154-162	CD55 molecule (Cromer blood group)	Homo sapiens	145-149
32869436-11	2020	For the acidic drugs analysis, EkE-ESI-MS, the LOQs were 3.1 microg/mL and 2.9 microg/mL for naproxen and paracetamol, respectively.	Naproxen	93-101	TARBP2 subunit of RISC loading complex	Homo sapiens	47-51
32751993-7	2020	However, the synergistic inhibition of Il12b observed in nanoparticles that combine dexamethasone and naproxen was not observed in nanoparticles that combine dexamethasone and ketoprofen, suggesting that the synergistic trans-repression of Il12b observed in the first case was not mediated by cyclooxygenase-dependent pathways.	Naproxen	102-110	interleukin 12B	Homo sapiens	39-44
32028022-2	2020	DESIGN: Using phorbol 12-myristate 13-acetate, THP-1 human monocytic cells were differentiated into mature monocyte-derived macrophages in vitro then treated with Nx pre- or post-activating an inflammatory response with lipopolysaccharide (LPS) and hyaluronan (HA) fragments (n=8/group).	Naproxen	163-165	GLI family zinc finger 2	Homo sapiens	47-52
32464520-11	2020	And in network meta-analysis, we found the best 3 treatments were ibuprofen, sumatriptan with naproxen sodium and ibuprofen suspension in achieving pain-free.	Naproxen	94-109	bestrophin 3	Homo sapiens	43-49
32421256-0	2020	Polymeric Nanoparticles that Combine Dexamethasone and Naproxen for the Synergistic Inhibition of Il12b Transcription in Macrophages.	Naproxen	55-63	interleukin 12B	Rattus norvegicus	98-103
32334069-8	2020	The deviations from the model predictions at high ligand concentrations in the cases of naproxen and ibuprofen indicate that albumin is able to bind several additional molecules of these drugs with its low-affinity sites.	Naproxen	88-96	albumin	Homo sapiens	125-132
32028022-7	2020	Low dose Nx reduced the percentage of IL-1beta producing primary monocytes and macrophages.	Naproxen	9-11	interleukin 1 alpha	Homo sapiens	38-46
32028022-9	2020	Low dose Nx both prevented and reduced inflammatory responses of a human monocytic cell line and reduced IL-1beta production by primary human SF monocytes and macrophages.	Naproxen	9-11	interleukin 1 alpha	Homo sapiens	105-113
32236281-2	2020	Here, naproxen as a potent inhibitor of both COX and MMP was combined with platinum(iv) to construct hybrids as antitumor agents.	Naproxen	6-14	matrix metallopeptidase 9	Homo sapiens	53-56
32236281-5	2020	The naproxen platinum(iv) complex could easily undergo reduction and liberate the platinum(ii) complex and naproxen as well as exert a multifunctional antitumor mechanism: (i) the liberated platinum(ii) fragment would cause serious DNA injury; (ii) naproxen would inhibit COX-2 and decrease tumor-associated inflammation; and (iii) the naproxen platinum(iv) complex exhibited remarkable MMP-9 inhibition in tumor tissues.	Naproxen	4-12	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	272-277
32236281-5	2020	The naproxen platinum(iv) complex could easily undergo reduction and liberate the platinum(ii) complex and naproxen as well as exert a multifunctional antitumor mechanism: (i) the liberated platinum(ii) fragment would cause serious DNA injury; (ii) naproxen would inhibit COX-2 and decrease tumor-associated inflammation; and (iii) the naproxen platinum(iv) complex exhibited remarkable MMP-9 inhibition in tumor tissues.	Naproxen	4-12	matrix metallopeptidase 9	Homo sapiens	387-392
32236281-5	2020	The naproxen platinum(iv) complex could easily undergo reduction and liberate the platinum(ii) complex and naproxen as well as exert a multifunctional antitumor mechanism: (i) the liberated platinum(ii) fragment would cause serious DNA injury; (ii) naproxen would inhibit COX-2 and decrease tumor-associated inflammation; and (iii) the naproxen platinum(iv) complex exhibited remarkable MMP-9 inhibition in tumor tissues.	Naproxen	107-115	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	272-277
32236281-5	2020	The naproxen platinum(iv) complex could easily undergo reduction and liberate the platinum(ii) complex and naproxen as well as exert a multifunctional antitumor mechanism: (i) the liberated platinum(ii) fragment would cause serious DNA injury; (ii) naproxen would inhibit COX-2 and decrease tumor-associated inflammation; and (iii) the naproxen platinum(iv) complex exhibited remarkable MMP-9 inhibition in tumor tissues.	Naproxen	107-115	matrix metallopeptidase 9	Homo sapiens	387-392
32236281-5	2020	The naproxen platinum(iv) complex could easily undergo reduction and liberate the platinum(ii) complex and naproxen as well as exert a multifunctional antitumor mechanism: (i) the liberated platinum(ii) fragment would cause serious DNA injury; (ii) naproxen would inhibit COX-2 and decrease tumor-associated inflammation; and (iii) the naproxen platinum(iv) complex exhibited remarkable MMP-9 inhibition in tumor tissues.	Naproxen	107-115	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	272-277
32236281-5	2020	The naproxen platinum(iv) complex could easily undergo reduction and liberate the platinum(ii) complex and naproxen as well as exert a multifunctional antitumor mechanism: (i) the liberated platinum(ii) fragment would cause serious DNA injury; (ii) naproxen would inhibit COX-2 and decrease tumor-associated inflammation; and (iii) the naproxen platinum(iv) complex exhibited remarkable MMP-9 inhibition in tumor tissues.	Naproxen	107-115	matrix metallopeptidase 9	Homo sapiens	387-392
32188962-2	2020	The hybrid nature of this material is founded on two key elements: the presence of the DAT backbone induced the formation of hydrophobic regions that allowed efficient loading of a series of drugs of increasing hydrophobicity (Metronidazole, Benzocaine, Ibuprofen, Naproxen and Imipramine), while simultaneously endowing swelling-induced pH-responsiveness to the hydrogel.	Naproxen	265-273	solute carrier family 6 member 3	Homo sapiens	87-90
31787265-6	2020	Under the optimal conditions, LOD values were found to be 25 ng mL-1 for naproxen and diclofenac and 15 ng mL-1 for mefenamic acid.	Naproxen	73-81	L1 cell adhesion molecule	Mus musculus	64-68
32252408-13	2020	The concentrations were variable and ranged from ng L-1 in some compounds like diclofenac or carbamazepine to microg L-1 in common pharmaceutical compounds such as caffeine, naproxen or ibuprofen.	Naproxen	174-182	L1 cell adhesion molecule	Homo sapiens	117-120
31905261-9	2020	Additionally, crystallographic data reveal the secondary binding sites of ketoprofen in leporine serum albumin and ibuprofen in equine serum albumin, both overlapping with previously identified naproxen binding sites: the cleft formed between subdomains IIIA and IIIB close to the fatty acid binding site 5 and the niche created between subdomains IIA and IIIA, called fatty acid site 6.	Naproxen	194-202	albumin	Equus caballus	103-110
31905261-9	2020	Additionally, crystallographic data reveal the secondary binding sites of ketoprofen in leporine serum albumin and ibuprofen in equine serum albumin, both overlapping with previously identified naproxen binding sites: the cleft formed between subdomains IIIA and IIIB close to the fatty acid binding site 5 and the niche created between subdomains IIA and IIIA, called fatty acid site 6.	Naproxen	194-202	albumin	Equus caballus	141-148
32368976-6	2020	Naproxen shows its activity by inhibiting the COX2 enzyme.	Naproxen	0-8	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	46-50
31787265-7	2020	A seven-point calibration curve was obtained in the range of 75-2000 ng mL-1 for naproxen and diclofenac and 50-2000 for mefenamic acid.	Naproxen	81-89	L1 cell adhesion molecule	Mus musculus	72-76
31999978-6	2020	Glucuronidation of 20-HETE by UGT2B7 and UGT1A9 recombinant enzymes was significantly inhibited by indomethacin, mefanemic acid, diclofenac, ibuprofen, naproxen, and celecoxib (P < 0.001).	Naproxen	152-160	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	30-36
31999978-6	2020	Glucuronidation of 20-HETE by UGT2B7 and UGT1A9 recombinant enzymes was significantly inhibited by indomethacin, mefanemic acid, diclofenac, ibuprofen, naproxen, and celecoxib (P < 0.001).	Naproxen	152-160	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	41-47
31983907-5	2020	As a possible mechanism of eryptosis, oxidative stress induced by naproxen sodium was determined by catalase, glutathione peroxidase, and superoxide dismutase activities.	Naproxen	66-81	catalase	Homo sapiens	100-108
31983907-7	2020	Results of our study illustrated that the therapeutic doses (10-25 microM) of naproxen sodium induce oxidative stress, confirmed by significant decrease in superoxide dismutase, catalase, and glutathione peroxidase activities that lead to the triggering of cell death by eryptosis and hemolysis.	Naproxen	78-93	catalase	Homo sapiens	178-186
31349507-5	2019	The results showed that under optimal process conditions (temperature 25  C, pH 5 and 3 for naproxen and diclofenac respectively), even from a solution at a concentration of 1 mg L-1, over 90% of both pharmaceuticals was removed by encapsulated laccase in batch mode.	Naproxen	92-100	immunoglobulin kappa variable 1-16	Homo sapiens	179-182
31994643-0	2019	The effect of naproxen patches on relieving orthodontic pain by evaluation of VAS and IL-1beta inflammatory factor: a split-mouth study.	Naproxen	14-22	interleukin 1 alpha	Homo sapiens	86-94
31994643-2	2019	Objective: The present study aimed to compare the efficacy of naproxen patches in pain control during orthodontic tooth separation, by means of visual analogue scale (VAS) and interleukin 1beta (IL-1beta) levels in gingival crevicular fluid (GCF).	Naproxen	62-70	interleukin 1 beta	Homo sapiens	176-193
31994643-2	2019	Objective: The present study aimed to compare the efficacy of naproxen patches in pain control during orthodontic tooth separation, by means of visual analogue scale (VAS) and interleukin 1beta (IL-1beta) levels in gingival crevicular fluid (GCF).	Naproxen	62-70	interleukin 1 alpha	Homo sapiens	195-203
31994643-8	2019	Significant differences were found in pain scores (p&lt; 0.0001) and IL-1beta levels (p= 0.047) between naproxen and placebo groups.	Naproxen	104-112	interleukin 1 alpha	Homo sapiens	69-77
31994643-10	2019	IL-1beta levels were lower for the patients using naproxen patches only 1 hour after separation (p= 0.047).	Naproxen	50-58	interleukin 1 alpha	Homo sapiens	0-8
31994643-12	2019	CONCLUSION: In the light of VAS scores and IL-1beta levels, naproxen patches reduced the pain caused by separator placement.	Naproxen	60-68	interleukin 1 alpha	Homo sapiens	43-51
31969306-1	2019	Adsorption behavior of pure enantiomers and racemic mixtures of nonsteroidal anti-inflammatory drugs (ibuprofen and naproxen) on human serum albumin (HSA) was evaluated.	Naproxen	116-124	albumin	Homo sapiens	135-148
31125226-4	2019	The new naproxen analogue had significant potency against cyclooxygenase 1 and 2 (IC50 = 31.0 and 66.1 muM, respectively).	Naproxen	8-16	prostaglandin-endoperoxide synthase 1	Homo sapiens	58-80
31463587-6	2019	Graphical abstract Schematic presentation of simultaneous electrochemical sensing of acetaminophen (AMP), naproxen (NPX), and theophylline (TPH) in real sample analysis using poly(acrylic acid) nanogel covalently grafted onto a carbon black/La2O3 composite (CB-g-PAA/La2O3/GCE).	Naproxen	116-119	glucosylceramidase beta 3 (gene/pseudogene)	Homo sapiens	258-262
30548602-9	2019	After treatment with naproxen, the expression of PTGS1 sharply decreased in the OA group.	Naproxen	21-29	prostaglandin-endoperoxide synthase 1	Mus musculus	49-54
30548602-12	2019	Naproxen could also influence the expression level of six OA-related genes: LUBRICIN, matrix metalloproteinase 13 (MMP-13), cyclooxygenase-2 (COX-2), ACAN, COL2A1, and COL1A1.	Naproxen	0-8	proteoglycan 4 (megakaryocyte stimulating factor, articular superficial zone protein)	Mus musculus	76-84
30548602-12	2019	Naproxen could also influence the expression level of six OA-related genes: LUBRICIN, matrix metalloproteinase 13 (MMP-13), cyclooxygenase-2 (COX-2), ACAN, COL2A1, and COL1A1.	Naproxen	0-8	matrix metallopeptidase 13	Mus musculus	86-113
30548602-12	2019	Naproxen could also influence the expression level of six OA-related genes: LUBRICIN, matrix metalloproteinase 13 (MMP-13), cyclooxygenase-2 (COX-2), ACAN, COL2A1, and COL1A1.	Naproxen	0-8	matrix metallopeptidase 13	Mus musculus	115-121
30548602-12	2019	Naproxen could also influence the expression level of six OA-related genes: LUBRICIN, matrix metalloproteinase 13 (MMP-13), cyclooxygenase-2 (COX-2), ACAN, COL2A1, and COL1A1.	Naproxen	0-8	prostaglandin-endoperoxide synthase 2	Mus musculus	124-140
30548602-12	2019	Naproxen could also influence the expression level of six OA-related genes: LUBRICIN, matrix metalloproteinase 13 (MMP-13), cyclooxygenase-2 (COX-2), ACAN, COL2A1, and COL1A1.	Naproxen	0-8	prostaglandin-endoperoxide synthase 2	Mus musculus	142-147
30548602-12	2019	Naproxen could also influence the expression level of six OA-related genes: LUBRICIN, matrix metalloproteinase 13 (MMP-13), cyclooxygenase-2 (COX-2), ACAN, COL2A1, and COL1A1.	Naproxen	0-8	aggrecan	Mus musculus	150-154
30548602-12	2019	Naproxen could also influence the expression level of six OA-related genes: LUBRICIN, matrix metalloproteinase 13 (MMP-13), cyclooxygenase-2 (COX-2), ACAN, COL2A1, and COL1A1.	Naproxen	0-8	collagen, type II, alpha 1	Mus musculus	156-162
30548602-12	2019	Naproxen could also influence the expression level of six OA-related genes: LUBRICIN, matrix metalloproteinase 13 (MMP-13), cyclooxygenase-2 (COX-2), ACAN, COL2A1, and COL1A1.	Naproxen	0-8	collagen, type I, alpha 1	Mus musculus	168-174
30548602-13	2019	CONCLUSION: We validated that naproxen could suppress the expression of PTGS1 in synovial cells.	Naproxen	30-38	prostaglandin-endoperoxide synthase 1	Mus musculus	72-77
31318093-2	2019	Two well-known targeting peptide sequences, RGD and NGR, were conjugated with naproxen and ibuprofen.	Naproxen	78-86	reticulon 4 receptor	Homo sapiens	52-55
31318093-6	2019	The NGR conjugate forms of both ibuprofen and naproxen showed better activity against the SKOV-3 tumor cell line.	Naproxen	46-54	reticulon 4 receptor	Homo sapiens	4-7
33405631-3	2019	In this study, we prepared naproxen nanoparticles that were loaded with chitosan hydrogel (CS/Nap hydrogel) to prevent postoperative adhesions.	Naproxen	27-35	catenin beta like 1	Homo sapiens	94-97
31067470-4	2019	Furthermore, the NP of influenza B virus (BNP) has a higher binding affinity to naproxen than influenza A virus NP (ANP).	Naproxen	80-88	natriuretic peptide B	Homo sapiens	42-45
31067470-5	2019	Specifically, naproxen targets the NP at residues F209 (BNP) and Y148 (ANP).	Naproxen	14-22	natriuretic peptide B	Homo sapiens	56-59
30878890-0	2019	Novel aryl carboximidamide and 3-aryl-1,2,4-oxadiazole analogues of naproxen as dual selective COX-2/15-LOX inhibitors: Design, synthesis and docking studies.	Naproxen	68-76	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	95-100
33405631-8	2019	We showed that a drug delivery system based on CS/Nap hydrogel has the potential not only to prevent postoperative abdominal adhesions and relieve pain but also to contribute to the administration of the hydrophobic drug naproxen.	Naproxen	221-229	catenin beta like 1	Homo sapiens	50-53
30391698-6	2019	For compound 25, it showed about 340 and 198 times more potent than celecoxib and naproxen respectively as COX-1 inhibitor (IC50 value 0.044 vs. 15.000 and 8.700 microM), and 10 and 115 times more potent than the same drugs as COX-2 inhibitor (IC50 value 4.52 vs. 40.00 and 520.00 nM).	Naproxen	82-90	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	107-112
30391698-6	2019	For compound 25, it showed about 340 and 198 times more potent than celecoxib and naproxen respectively as COX-1 inhibitor (IC50 value 0.044 vs. 15.000 and 8.700 microM), and 10 and 115 times more potent than the same drugs as COX-2 inhibitor (IC50 value 4.52 vs. 40.00 and 520.00 nM).	Naproxen	82-90	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	227-232
30452246-3	2018	Specifically, integrating a short peptide with naproxen (a nonsteroidal anti-inflammatory drug (NSAID) and a ligand of cyclooxygenase-2 (COX-2)) generates an enzymatic substrate that acts as a precursor for instructed assembly.	Naproxen	47-55	prostaglandin-endoperoxide synthase 2	Homo sapiens	119-135
30800067-5	2019	Cell culture studies demonstrated that naproxen-HBTA induced caspase 3-mediated apoptosis and inhibited motility, invasiveness, and focus formation.	Naproxen	39-47	caspase 3	Mus musculus	61-70
30710016-5	2019	For example, naproxen directly and completely inhibits COX-1 by binding Ecat but indirectly and incompletely inhibits COX-2 by binding Eallo.	Naproxen	13-21	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	55-60
30710016-5	2019	For example, naproxen directly and completely inhibits COX-1 by binding Ecat but indirectly and incompletely inhibits COX-2 by binding Eallo.	Naproxen	13-21	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	118-123
30585484-3	2019	In this study, we developed a solid-phase microextraction (SPME) method based on C18-coated fibers to quantify the partitioning of diclofenac, 2,4-dichlorophenoxyacetic acid (2,4-D), ibuprofen, naproxen, torasemide, warfarin, and genistein to bovine serum albumin (BSA), phospholipid liposomes, fetal bovine serum (FBS), and cells.	Naproxen	194-202	Bardet-Biedl syndrome 9	Homo sapiens	81-84
30472018-8	2019	The catabolic factor IL-6 also had a significant decline from baseline (77% decrease in median, P &lt; .05) after 1 week of naproxen use.	Naproxen	124-132	interleukin 6	Homo sapiens	21-25
30472018-10	2019	CONCLUSIONS: Naproxen use diminished several biological factors in LR-PRP; however, a 1-week washout period was sufficient for the recovery of PDGF-AA, PDGF-AB, and IL-6 to return to baseline levels.	Naproxen	13-21	complement component 4 binding protein alpha	Homo sapiens	70-73
30472018-10	2019	CONCLUSIONS: Naproxen use diminished several biological factors in LR-PRP; however, a 1-week washout period was sufficient for the recovery of PDGF-AA, PDGF-AB, and IL-6 to return to baseline levels.	Naproxen	13-21	interleukin 6	Homo sapiens	165-169
30878890-0	2019	Novel aryl carboximidamide and 3-aryl-1,2,4-oxadiazole analogues of naproxen as dual selective COX-2/15-LOX inhibitors: Design, synthesis and docking studies.	Naproxen	68-76	arachidonate 15-lipoxygenase	Homo sapiens	101-107
30878890-1	2019	A series of novel naproxen analogues containing 3-aryl-1,2,4-oxadiazoles moiety (4b-g) and their reaction intermediates aryl carboximidamides moiety (3b-g) was synthesized and evaluated in vitro as dual COXs/15-LOX inhibitors.	Naproxen	18-26	arachidonate 15-lipoxygenase	Homo sapiens	208-214
30842737-13	2019	Conclusion: The study shows that naproxen partially prevents POI, probably through its inhibitory effect on COX-2 activity.	Naproxen	33-41	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	108-113
30737317-9	2019	Nonsteroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, and naproxen) block PG synthesis by inhibiting COX-1 and COX-2.	Naproxen	67-75	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	110-115
30737317-9	2019	Nonsteroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, and naproxen) block PG synthesis by inhibiting COX-1 and COX-2.	Naproxen	67-75	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	120-125
30452246-3	2018	Specifically, integrating a short peptide with naproxen (a nonsteroidal anti-inflammatory drug (NSAID) and a ligand of cyclooxygenase-2 (COX-2)) generates an enzymatic substrate that acts as a precursor for instructed assembly.	Naproxen	47-55	prostaglandin-endoperoxide synthase 2	Homo sapiens	137-142
30216848-0	2018	Structural alterations based on naproxen scaffold: Synthesis, evaluation of antitumor activity and COX-2 inhibition, and molecular docking.	Naproxen	32-40	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	99-104
29618298-2	2018	We showed that inhibition of PGHS-1 from sheep vesicular glands by naproxen (a representative of NSAIDs) demonstrates a non-competitive character with respect to arachidonic acid and cannot be described within a framework of the commonly used kinetic schemes.	Naproxen	67-75	prostaglandin G/H synthase 1	Ovis aries	29-35
30028133-2	2018	We previously identified by in silico screening naproxen being a dual inhibitor of NP and cyclooxygenase COX2, thus combining antiviral and anti-inflammatory effects.	Naproxen	48-56	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	105-109
29655108-5	2018	The chronic no observed effect concentrations (NOECs) of naproxen for reproduction were determined to be 10 mg L-1 in D. magna and 0.3 mg L-1 in M. macrocopa.	Naproxen	57-65	L1 cell adhesion molecule	Homo sapiens	111-114
29655108-5	2018	The chronic no observed effect concentrations (NOECs) of naproxen for reproduction were determined to be 10 mg L-1 in D. magna and 0.3 mg L-1 in M. macrocopa.	Naproxen	57-65	L1 cell adhesion molecule	Homo sapiens	138-141
29655108-7	2018	Concentration of 17beta-estradiol (E2) and the ratio of E2 and testosterone were significantly increased in H295R cells at 10 mg L-1, suggesting that naproxen could modulate sex hormone production.	Naproxen	150-158	L1 cell adhesion molecule	Homo sapiens	129-132
29182950-0	2018	Design, synthesis, anti-inflammatory antitumor activities, molecular modeling and molecular dynamics simulations of potential naprosyn  analogs as COX-1 and/or COX-2 inhibitors.	Naproxen	126-134	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	147-152
29182950-0	2018	Design, synthesis, anti-inflammatory antitumor activities, molecular modeling and molecular dynamics simulations of potential naprosyn  analogs as COX-1 and/or COX-2 inhibitors.	Naproxen	126-134	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	160-165
29182950-4	2018	In this study, novel and successfully synthesized naproxen-derivatives indicated powerful anti-inflammatory properties as potent of COX-1 and/or COX-2 inhibitors are reported.	Naproxen	50-58	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	132-137
29182950-4	2018	In this study, novel and successfully synthesized naproxen-derivatives indicated powerful anti-inflammatory properties as potent of COX-1 and/or COX-2 inhibitors are reported.	Naproxen	50-58	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	145-150
29514128-7	2018	Our data demonstrate that compounds GUF-1, GUF-2, and GUF-5 possesses antinociceptive and antiinflammatory activities resembling and improving those known for the traditional NSAIDs, paracetamol, naproxen and ibuprofen.	Naproxen	196-204	GTP binding elongation factor GUF1	Rattus norvegicus	36-41
29618298-3	2018	However, it can be described by taking into account the negative cooperativity of naproxen binding to the cyclooxygenase active sites of the PGHS-1 homodimer (the first naproxen molecule forms a more stable complex (K1 = 0.1 microM) with the enzyme than the second naproxen molecule (K2 = 9.2 microM)).	Naproxen	82-90	prostaglandin G/H synthase 1	Ovis aries	141-147
29618298-3	2018	However, it can be described by taking into account the negative cooperativity of naproxen binding to the cyclooxygenase active sites of the PGHS-1 homodimer (the first naproxen molecule forms a more stable complex (K1 = 0.1 microM) with the enzyme than the second naproxen molecule (K2 = 9.2 microM)).	Naproxen	169-177	prostaglandin G/H synthase 1	Ovis aries	141-147
29618298-3	2018	However, it can be described by taking into account the negative cooperativity of naproxen binding to the cyclooxygenase active sites of the PGHS-1 homodimer (the first naproxen molecule forms a more stable complex (K1 = 0.1 microM) with the enzyme than the second naproxen molecule (K2 = 9.2 microM)).	Naproxen	169-177	prostaglandin G/H synthase 1	Ovis aries	141-147
29618298-4	2018	An apparent non-competitive interaction of PGHS-1 with naproxen is due to slow dissociation of the enzyme-inhibitor complexes.	Naproxen	55-63	prostaglandin G/H synthase 1	Ovis aries	43-49
29235601-7	2018	Molecular docking studies with COX-2 reveal that complexes 1 and 2 having naproxen and diclofenac ligands exhibit stronger interactions with COX-2 than their respective free NSAIDs and these results are in good agreement with their relative experimentally observed COX inhibition as well as anti-proliferative activities.	Naproxen	74-82	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	31-36
28277163-8	2018	The addition of ALB significantly influenced the liver kinetics of BPA and NAP either administered alone or in binary mixtures, which was reflected in the Michaelis-Menten constants.	Naproxen	75-78	albumin	Rattus norvegicus	16-19
28277163-12	2018	Our findings support the notion that high binding to ALB reduces the biotransformation of BPA and NAP when administered alone or in mixtures in the IPRL system.	Naproxen	98-101	albumin	Rattus norvegicus	53-56
29235601-7	2018	Molecular docking studies with COX-2 reveal that complexes 1 and 2 having naproxen and diclofenac ligands exhibit stronger interactions with COX-2 than their respective free NSAIDs and these results are in good agreement with their relative experimentally observed COX inhibition as well as anti-proliferative activities.	Naproxen	74-82	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	141-146
28276722-7	2017	A correlation between the dose of naproxen and an increase in SBP of 7 mm Hg was found.	Naproxen	34-42	selenium binding protein 1	Homo sapiens	62-65
28823493-10	2017	Moreover, the results of a docking study of compound 5n into the COX-2 binding site revealed that its mechanism was possibly similar to that of naproxen, a COX-2 inhibitor.	Naproxen	144-152	cytochrome c oxidase II, mitochondrial	Mus musculus	65-70
28823493-10	2017	Moreover, the results of a docking study of compound 5n into the COX-2 binding site revealed that its mechanism was possibly similar to that of naproxen, a COX-2 inhibitor.	Naproxen	144-152	cytochrome c oxidase II, mitochondrial	Mus musculus	156-161
28823401-4	2017	We reported that the extrapolations of hepatic CL of BPA, NAP, and the binary mixtures between 2 ALB concentrations did not follow the free drug hypothesis; however, potential ALB-facilitated hepatic uptake mechanism(s) were highly suspected.	Naproxen	58-61	albumin	Rattus norvegicus	176-179
28549294-2	2017	The method was based on quenching of the fluorescence intensity of bovine serum albumin-stabilized gold nanoclusters in the presence of naproxen enantiomers.	Naproxen	136-144	albumin	Homo sapiens	74-87
28549294-4	2017	The chiral recognition occurred due to steric effect between bovine serum albumin conformation and naproxen enantiomers.	Naproxen	99-107	albumin	Homo sapiens	68-81
29375050-10	2017	Naproxen significantly increased gastric mucosal protein expression of CSE, Nrf-2 and HIF-1alpha as compared with vehicle (p &lt; 0.05), but failed to affect CBS, 3-MST and HO-1.	Naproxen	0-8	cystathionine gamma-lyase	Homo sapiens	71-74
29375050-10	2017	Naproxen significantly increased gastric mucosal protein expression of CSE, Nrf-2 and HIF-1alpha as compared with vehicle (p &lt; 0.05), but failed to affect CBS, 3-MST and HO-1.	Naproxen	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	76-81
29375050-10	2017	Naproxen significantly increased gastric mucosal protein expression of CSE, Nrf-2 and HIF-1alpha as compared with vehicle (p &lt; 0.05), but failed to affect CBS, 3-MST and HO-1.	Naproxen	0-8	hypoxia inducible factor 1 subunit alpha	Homo sapiens	86-96
28620994-1	2017	OBJECTIVES: Naproxen, a nonsteroid anti-inflammatory drug studied for Alzheimer"s disease, was conjugated with lipoamino acids (LAA) directly or through a diethylamine (EDA) spacer to improve the drug lipophilicity and the interaction with phospholipid bilayers.	Naproxen	12-20	ectodysplasin A	Homo sapiens	169-172
28678269-2	2017	This work reports the encapsulation of the lead metallodrug of ibuprofen (HIbp), [Ru2(Ibp)4Cl] or RuIbp, and also of the new analogue of naproxen (HNpx), [Ru2(Npx)4Cl] or RuNpx, in novel intravenously (i.v.)	Naproxen	137-145	doublecortin domain containing 2	Homo sapiens	155-158
28276722-10	2017	In intermediate and frequent users of NSAID there was a dose response relation with naproxen and SBP which was not found in diclofenac and ibuprofen.	Naproxen	84-92	selenium binding protein 1	Homo sapiens	97-100
28329421-6	2017	As expected, inflammation-related iNOS, COX-2 and nuclear NFkappaBp65 were also diminished by naproxen treatment.	Naproxen	94-102	nitric oxide synthase 2, inducible	Mus musculus	34-38
28732024-2	2017	We have identified a novel group of small molecule compounds with a 4-nitrophenylsulfonamide (NPS) backbone in common that dramatically decrease mortality from the hematopoietic acute radiation syndrome (hARS).	Naproxen	94-97	RIEG2	Homo sapiens	204-208
28329421-6	2017	As expected, inflammation-related iNOS, COX-2 and nuclear NFkappaBp65 were also diminished by naproxen treatment.	Naproxen	94-102	cytochrome c oxidase II, mitochondrial	Mus musculus	40-45
28329421-7	2017	Residual tumors excised from naproxen-treated animal were less invasive and showed reduced expression of epithelial-mesenchymal transition (EMT) markers N-cadherin, Vimentin, Snail and Twist with increased expression of E-cadherin.	Naproxen	29-37	cadherin 2	Mus musculus	153-163
28329421-7	2017	Residual tumors excised from naproxen-treated animal were less invasive and showed reduced expression of epithelial-mesenchymal transition (EMT) markers N-cadherin, Vimentin, Snail and Twist with increased expression of E-cadherin.	Naproxen	29-37	vimentin	Mus musculus	165-173
28329421-7	2017	Residual tumors excised from naproxen-treated animal were less invasive and showed reduced expression of epithelial-mesenchymal transition (EMT) markers N-cadherin, Vimentin, Snail and Twist with increased expression of E-cadherin.	Naproxen	29-37	snail family zinc finger 1	Mus musculus	175-180
28329421-7	2017	Residual tumors excised from naproxen-treated animal were less invasive and showed reduced expression of epithelial-mesenchymal transition (EMT) markers N-cadherin, Vimentin, Snail and Twist with increased expression of E-cadherin.	Naproxen	29-37	cadherin 1	Mus musculus	220-230
28329421-8	2017	In BCC and SCC cells, naproxen-induced apoptosis and activated unfolded protein response (UPR) signaling with increased expression of ATF4, p-eIF2alpha and CHOP.	Naproxen	22-30	activating transcription factor 4	Mus musculus	134-138
28329421-8	2017	In BCC and SCC cells, naproxen-induced apoptosis and activated unfolded protein response (UPR) signaling with increased expression of ATF4, p-eIF2alpha and CHOP.	Naproxen	22-30	DNA-damage inducible transcript 3	Mus musculus	156-160
28329421-9	2017	Employing iRNA-based approaches, we found that naproxen-induced apoptosis was regulated by CHOP as sensitivity of these cutaneous neoplastic cells for apoptosis was significantly diminished by ablating CHOP.	Naproxen	47-55	DNA-damage inducible transcript 3	Mus musculus	91-95
28329421-9	2017	Employing iRNA-based approaches, we found that naproxen-induced apoptosis was regulated by CHOP as sensitivity of these cutaneous neoplastic cells for apoptosis was significantly diminished by ablating CHOP.	Naproxen	47-55	DNA-damage inducible transcript 3	Mus musculus	202-206
26141932-7	2016	DAMI cells treated with celecoxib, diclofenac, and naproxen showed a significant increase in MRP4-mRNA expression compared to the mock culture.	Naproxen	51-59	ATP binding cassette subfamily C member 4	Homo sapiens	93-97
28977822-6	2017	EIS Regimen uses the antifungal drug itraconazole to block Hedgehog signaling, the antidiabetes drug metformin to block AMP kinase (AMPK), the analgesic drug naproxen to block Rac1, the anti-fibrosis drug pirfenidone to block transforming growth factor-beta (TGF-beta), the psychiatric drug quetiapine to block receptor activator NFkB ligand (RANKL) and the antibiotic rifampin to block Wnt- all by their previously established ancillary attributes.	Naproxen	158-166	Rac family small GTPase 1	Homo sapiens	176-180
27826802-3	2017	The balance of evidence suggests that cardiovascular risk correlates with cyclooxygenase (COX)-2 selectivity, and the low COX-2 selectivity of naproxen results in a lower cardiovascular risk than that of other NSAIDs.	Naproxen	143-151	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	122-127
27793394-4	2016	By combining C18-MPSBSE with HPLC-UV, a method was proposed for the direct determination of two common non-steroidal anti-inflammatory drugs, Ketoprofen (KEP) and Naproxen (NAP) in complex water samples.	Naproxen	163-171	Bardet-Biedl syndrome 9	Homo sapiens	13-16
27793394-4	2016	By combining C18-MPSBSE with HPLC-UV, a method was proposed for the direct determination of two common non-steroidal anti-inflammatory drugs, Ketoprofen (KEP) and Naproxen (NAP) in complex water samples.	Naproxen	173-176	Bardet-Biedl syndrome 9	Homo sapiens	13-16
27288817-8	2016	The peaks of prominent functional groups of naproxen were found in the FT-IR spectra of naproxen-SLN, which confirmed the entrapment of naproxen in the lipid matrix.	Naproxen	44-52	sarcolipin	Homo sapiens	97-100
27288817-8	2016	The peaks of prominent functional groups of naproxen were found in the FT-IR spectra of naproxen-SLN, which confirmed the entrapment of naproxen in the lipid matrix.	Naproxen	88-96	sarcolipin	Homo sapiens	97-100
27428449-1	2016	A new design of hyperbranched polyglycerol/graphene oxide nanocomposite reinforced hollow fiber solid/liquid phase microextraction (HBP/GO -HF-SLPME) coupled with high performance liquid chromatography used for extraction and determination of ibuprofen and naproxen in hair and waste water samples.	Naproxen	257-265	heme binding protein 1	Homo sapiens	132-135
27015283-1	2016	OBJECTIVE: To investigate the course of active inflammatory and fatty lesions seen on magnetic resonance imaging (MRI) in patients with early axial spondyloarthritis (SpA) treated with the tumor necrosis factor (TNF) inhibitor infliximab added to naproxen as compared to those treated with naproxen alone.	Naproxen	247-255	tumor necrosis factor	Homo sapiens	212-215
27015283-1	2016	OBJECTIVE: To investigate the course of active inflammatory and fatty lesions seen on magnetic resonance imaging (MRI) in patients with early axial spondyloarthritis (SpA) treated with the tumor necrosis factor (TNF) inhibitor infliximab added to naproxen as compared to those treated with naproxen alone.	Naproxen	290-298	tumor necrosis factor	Homo sapiens	212-215
26525846-10	2016	Incorporating OTC naproxen rather than ibuprofen added 0.01 QALYs and increased costs by $300, resulting in an ICER of $54,800/QALY.	Naproxen	18-26	cAMP responsive element modulator	Homo sapiens	111-115
26525846-11	2016	Using prescription naproxen with OTC PPIs led to an ICER of $76,700/QALY, while use of prescription naproxen with prescription PPIs resulted in an ICER of $252,300/QALY.	Naproxen	100-108	cAMP responsive element modulator	Homo sapiens	147-151
27849643-8	2017	The overall incidence of PEP was 8.6%, which occurred in five of the 124 (4%) patients who received diclofenac, seven of the 122 (5.8%) patients who received indomethacin, and 20 of the 126 (15.9%) patients who received naproxen.	Naproxen	220-228	prolyl endopeptidase	Homo sapiens	25-28
27756840-3	2016	We report here that movement of helical residues 120-122 and loop residues 123-129 of Eallo underlies the allosteric effects of FAs and allosteric COX-2 inhibitors, including naproxen and flurbiprofen.	Naproxen	175-183	prostaglandin-endoperoxide synthase 2	Homo sapiens	147-152
27275104-1	2016	AIM: To determine the efficacy of rectally administered naproxen for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP).	Naproxen	56-64	progestagen associated endometrial protein	Homo sapiens	160-163
27275104-8	2016	RESULTS: PEP occurred in 12% (40/324) of participants, and was significantly more frequent in the placebo group compared to the naproxen group (P &lt; 0.01).	Naproxen	128-136	progestagen associated endometrial protein	Homo sapiens	9-12
27275104-13	2016	Naproxen reduced the PEP in patients with &gt;= 3 pancreatic cannulations (P &lt; 0.01, RRR = 25%, AR = 0.1, 95%CI: 0.1-0.4) and an ERCP duration &gt; 40 min (P &lt; 0.01, RRR = 20%, AR = 0.9, 95%CI: 0.4-1.2).	Naproxen	0-8	progestagen associated endometrial protein	Homo sapiens	21-24
27275104-14	2016	CONCLUSION: Single dose of suppository naproxen administered immediately before ERCP reduces the incidence of PEP.	Naproxen	39-47	progestagen associated endometrial protein	Homo sapiens	110-113
26767575-1	2016	The present study investigated the protective effect of naturally purified 4-(3,4- dihydroxyphenyl)-3-buten-2-one (DHP) from Phellinus linteus against naproxen-induced gastric antral ulcers in rats.	Naproxen	151-159	dihydropyrimidinase	Rattus norvegicus	115-118
26767575-3	2016	DHP prevented naproxen-induced gastric antral ulcers in a dose-dependent manner.	Naproxen	14-22	dihydropyrimidinase	Rattus norvegicus	0-3
26767575-4	2016	In particular, 10 mug/kg DHP showed the best protective effect against naproxen-induced gastric antral ulcers.	Naproxen	71-79	dihydropyrimidinase	Rattus norvegicus	25-28
26767575-5	2016	Moreover, DHP significantly attenuated the naproxen-induced lipid peroxide level in gastric mucosa and increased the activities of radical scavenging enzymes, such as superoxide dismutase, catalase, and glutathione peroxidase, in a dose-dependent manner.	Naproxen	43-51	dihydropyrimidinase	Rattus norvegicus	10-13
26767575-6	2016	A histological examination clearly demonstrated that the gastric antral ulcer induced by naproxen nearly disappeared after the pretreatment of DHP.	Naproxen	89-97	dihydropyrimidinase	Rattus norvegicus	143-146
26767575-7	2016	These results suggest that DHP can inhibit naproxen-induced gastric antral ulcers through prevention of lipid peroxidation and activation of radical scavenging enzymes.	Naproxen	43-51	dihydropyrimidinase	Rattus norvegicus	27-30
26934120-12	2016	Then, five compounds including rutin, isoquercitrin, salvianolic acid A, naproxen, and felodipline were identified to be PRMT1 inhibitors.	Naproxen	73-81	protein arginine methyltransferase 1	Homo sapiens	121-126
26652101-0	2016	Structural Insights into the Competitive Binding of Diclofenac and Naproxen by Equine Serum Albumin.	Naproxen	67-75	albumin	Homo sapiens	86-99
26652101-1	2016	The binding modes to equine serum albumin (ESA) of two nonsteroidal anti-inflammatory drugs (NSAIDs), diclofenac (Dic) and naproxen (Nps), were studied by X-ray crystallography and isothermal titration calorimetry.	Naproxen	123-131	albumin	Homo sapiens	28-41
27324742-3	2016	METHODS: A series of 3-arylidene-5-(naphthalene-2-yl)-furan-2(3H)-ones (2a-j) were synthesized by incorporating pharmacophore of COX-2 inhibitor rofecoxib and naphthyl ring of naproxen as potential non steroidal anti-inflammatory agents.	Naproxen	176-184	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	129-134
26634864-8	2016	Naproxen sodium significantly decreased PGE2 secretion (p &lt; 0.01) and COX-2 mRNA expression (p &lt; 0.01).	Naproxen	0-15	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	73-78
26634864-9	2016	TNF-alpha induced PGE2 release was reduced in presence of naproxen sodium (p &lt; 0.05), in association with decreased COX-2 and increased HPDG mRNAs expression.	Naproxen	58-73	tumor necrosis factor	Homo sapiens	0-9
26634864-9	2016	TNF-alpha induced PGE2 release was reduced in presence of naproxen sodium (p &lt; 0.05), in association with decreased COX-2 and increased HPDG mRNAs expression.	Naproxen	58-73	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	119-124
26634864-10	2016	Naproxen sodium decreases endometrial PGE2 release induced by inflammatory stimulus acting on endometrial COX-2 and HPDG expression, suggesting endometrial synthesis of prostaglandins as a possible target for reduction of uterine inflammatory mechanism in dysmenorrhea.	Naproxen	0-15	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	106-111
26903770-8	2016	Our optimized matrix-mini-tablets-filled-capsule formulation F18 releases Naproxen after a lag time of 2.45 +- 0.97 h and 27.30 +- 0.86%, 92.59 +- 0.47%, 99.38 +- 0.69% at the end of 5, 8, 12 h respectively.	Naproxen	74-82	mastermind like domain containing 1	Homo sapiens	61-64
26558612-2	2015	Based on high throughput screening of the Prestwick Chemical Library  and cheminformatics we identified the R-enantiomers of two approved drugs (naproxen and ketorolac) as inhibitors of Rac1 and Cdc42.	Naproxen	145-153	Rac family small GTPase 1	Homo sapiens	186-190
26558612-2	2015	Based on high throughput screening of the Prestwick Chemical Library  and cheminformatics we identified the R-enantiomers of two approved drugs (naproxen and ketorolac) as inhibitors of Rac1 and Cdc42.	Naproxen	145-153	cell division cycle 42	Homo sapiens	195-200
26126188-5	2015	The n-pi electron donor-acceptor (n-pi EDA) interaction between diaromatic ring of naproxen (pi-electron acceptors) and the siloxane oxygens (n-donors) of kaolinite is the dominant sorption mechanism.	Naproxen	83-91	ectodysplasin A	Homo sapiens	39-42
25636639-0	2015	Naproxen-induced Ca2+ movement and death in MDCK canine renal tubular cells.	Naproxen	0-8	carbonic anhydrase 2	Canis lupus familiaris	17-20
26292179-6	2015	VA694, Naproxcinod and Naproxen, at both concentrations analyzed, significantly counteracted the negative effects induced by IL-1beta.	Naproxen	23-31	interleukin 1 beta	Homo sapiens	125-133
26292179-7	2015	VA694, Naproxcinod and Naproxen pre-treatment were able to inhibit IL-1beta-induced NF-kappaB activation, when measured as its nuclear translocation (p50 and p65 subunits).	Naproxen	23-31	interleukin 1 beta	Homo sapiens	67-75
26292179-7	2015	VA694, Naproxcinod and Naproxen pre-treatment were able to inhibit IL-1beta-induced NF-kappaB activation, when measured as its nuclear translocation (p50 and p65 subunits).	Naproxen	23-31	nuclear factor kappa B subunit 1	Homo sapiens	150-153
26292179-7	2015	VA694, Naproxcinod and Naproxen pre-treatment were able to inhibit IL-1beta-induced NF-kappaB activation, when measured as its nuclear translocation (p50 and p65 subunits).	Naproxen	23-31	RELA proto-oncogene, NF-kB subunit	Homo sapiens	158-161
26346117-0	2015	Hydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-kappaB signaling.	Naproxen	27-35	nuclear factor kappa B subunit 1	Homo sapiens	85-94
25873236-5	2015	We recently found that naproxen (Npx), but not other nonsteroidal anti-inflammatory drugs, can induce collagen type X alpha 1 (COL10A1) gene expression in bone marrow-derived MSCs from healthy and OA donors.	Naproxen	23-31	collagen type X alpha 1 chain	Homo sapiens	102-125
25873236-5	2015	We recently found that naproxen (Npx), but not other nonsteroidal anti-inflammatory drugs, can induce collagen type X alpha 1 (COL10A1) gene expression in bone marrow-derived MSCs from healthy and OA donors.	Naproxen	23-31	collagen type X alpha 1 chain	Homo sapiens	127-134
25873236-5	2015	We recently found that naproxen (Npx), but not other nonsteroidal anti-inflammatory drugs, can induce collagen type X alpha 1 (COL10A1) gene expression in bone marrow-derived MSCs from healthy and OA donors.	Naproxen	33-36	collagen type X alpha 1 chain	Homo sapiens	102-125
25873236-5	2015	We recently found that naproxen (Npx), but not other nonsteroidal anti-inflammatory drugs, can induce collagen type X alpha 1 (COL10A1) gene expression in bone marrow-derived MSCs from healthy and OA donors.	Naproxen	33-36	collagen type X alpha 1 chain	Homo sapiens	127-134